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ABSTRACT 
The overall goal of our research was to design a vector for efficient delivery of 
therapeutic genes/drugs to brain. Specifically, this research work was focused on designing 
PEGylated liposomes surface modified with the receptor targeting protein, transferrin and cell 
penetrating peptides (CPPs) for targeting and improving the delivery of desired therapeutic agent 
to brain. Various CPPs including poly-L-arginine, TAT, Penetratin and Mastoparan were 
investigated for their influence on transport of transferrin receptor targeted liposomes across 
brain endothelial cells. The dual-modified liposomes were synthesized using thin film hydration 
and post-insertion technique. The biocompatibility of the liposomes was evaluated at increasing 
concentrations to obtain an optimum value for safe and effective delivery of drugs or genes. The 
liposomes showed excellent cellular, blood and tissue compatibility at the optimized 
concentration. In addition, the combination of targeting ligand transferrin and CPPs resulted in 
considerable translocation of the therapeutic agent across cellular and brain endothelial barriers 
both in vitro and in vivo. 
Among different Tf-CPP liposomes, the Tf-Penetratin liposomes showed maximum 
translocation of the drug across the brain endothelial barrier (approximately 15% across in vitro 
and 4% across in vivo BBB) and efficient cellular transport of the encapsulated drug 
(approximately 90-98%) in various cell lines. In addition, Tf-poly-L-arginine and Tf-Penetratin 
liposomes showed improved transfection efficiencies in various cell lines. The Tf-Penetratin and 
Tf-TAT liposomes demonstrated excellent cellular biocompatibility and no hemolytic activity 
upto 200nM phospholipid concentration. In vivo efficacy of the liposomes was evaluated by 
performing biodistribution studies in in adult Sprague Dawley rats. The liposomes were intended 
for delivery of small molecule drug, doxorubicin and pDNA to brain. The dual modified 
iv 
 
liposomes showed significantly (p<0.05) higher transport of encapsulated agents in rat brain as 
compared to single ligand (Tf) or plain liposomes. Histological examination of the tissues, from 
various organs, did not show any signs of toxicity including necrosis, inflammation, fibrosis etc. 
The study underlines the potential of bifunctional liposomes as high-efficiency and low-toxicity 
gene delivery system for the treatment of central nervous system disorders. 
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CHAPTER I. INTRODUCTION 
Over the recent years, there has been a considerable progress in the field of neuroscience 
leading to an improved understanding of disorders of central nervous system (CNS). In contrast, 
the development of successful strategies for treating these disorders is limited due to the 
protective function of blood brain barrier (BBB).The concept of BBB originated in late 19
th
 and 
early 20
th
 centuries, when Paul Ehrlich and his colleagues discovered that some dyes could stain 
the brain cells after direct injection into brain, but were not able to penetrate the brain after 
peripheral administration (Bradbury et al. 1979). A parallel study revealed that bile salts induced 
seizures after direct injection into brain but did not show any related symptoms after peripheral 
administration (Roth et al. 1961; Banks et al. 2012). Since then, there have been comprehensive 
efforts to provide a scientific definition of BBB and to elucidate the mechanisms of transport of 
different molecules across this barrier (Davson et al. 1969; Cserr et al. 1992; Knopf et al. 1995; 
Chen et al. 2012). More restrictively, BBB is defined as the microvasculature of brain that is 
composed of endothelial cells having tight intracellular junctions and absence of any fenestrea 
(Davson et al. 1969). However, the vascular BBB does not explain all facets of conceptual BBB. 
The choroid plexus with cerebrospinal fluid, referred to as the cerebrospinal fluid barrier 
(CSFB), is another important gateway to reach brain parenchyma (Johanson et al. 2008, 
Townsend et al. 2007). The entry of any molecule into brain, after parenteral administration, is 
largely controlled by BBB and CSFB (Chen et al. 2012). However, the CSFB faces a ventricle 
that flushes the drug, injected in the back of the ventricle, back into the blood (Rip et al. 2009; 
Pathan et al. 2009). Moreover, there are about 100 billion capillaries with a surface area of 20m
2
 
that contribute to the formation of BBB (Pardridge et al. 2003).  Therefore, BBB is universally 
2 
 
considered the most important barrier in restricting the transport of molecules into brain 
(Hawkins et al. 2008).  
BBB is a highly regulated and tightly controlled barrier that provides a safe asylum to the 
brain. It plays a vital role in maintaining brain homeostasis and allows selective transport of 
essential nutrient molecules into brain (Chen et al. 2012). However, the high impermeability and 
selectivity of this barrier prevents the transport of many drugs and other therapeutic molecules 
into brain (Serwer et al. 2012; Scherrmann et al. 2002). The delivery of therapeutic agents across 
BBB has engendered substantial interest over past decades (Kohane et al. 2002; Qin et al. 
2011;Townsend et al. 2007). BBB possesses unique biological characteristics that contribute to 
restricting the movement of molecules to brain: 
1) Brain endothelial cells lack fenestrations and have very few pinocytotic vesicles and 
larger number of mitochondria (Stewart et al. 2000; Abbott et al. 2005; Oldendorf et al. 
1997). 
2) Occurrence of an intricate complex of transmembrane proteins (e.g. occludins, claudins), 
forming intimate intracellular connections, called tight junctions (TJ). 
3) The expression of different transport proteins on brain endothelial cells like p-
glycoproteins (efflux transporters) and multidrug resistance proteins (MRPs) (Rip et al. 
2009; Abbott et al. 2006). 
4) Synergistic influence of astrocytes, pericytes, astrocytic perivascular end feet, 
macrophages and neurons on BBB functions (Ramsauer et al. 1998; Ramsauer et al. 
2002; Dohgu et al. 2005). 
5) The immune barrier of brain is formed by tightly packed endothelial cells, perivascular 
macrophages and mast cells and is further reinforced by the macroglial cells. This barrier 
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limits the passage of external immune cells, especially lymphocytes across BBB 
(Wekerle et al. 2002; Daneman et al. 2009; Williams  et al. 2001; Streit et al. 2005; Levin 
et al. 1980). 
This unique environment of CNS presents a formidable barrier to the delivery of a wide 
number of therapeutic molecules to brain. With the exception of small lipophilic drug molecules 
having molecular mass of less than 400-600 Da, most of the drugs in circulation do not penetrate 
the BBB (Levin et al. 1980; Pardridge et al. 1998). More than 98% percent of the drugs are 
halted mid-development due to poor brain permeability (Terasaki et al. 2003). Also, recent 
statistics from National Cancer Institute show about 22,910 new cases of brain tumor leading to 
13,700 deaths, each year.  In addition, neuro-degenerative diseases like Alzheimer’s disease have 
become the most common cause of dementia among the elderly and have been reported to affect 
about 5% of Americans over age of 65, and 20% over the age of 80 years (Roney et al. 2005). 
These factors have triggered extensive efforts, by scientists across the globe, in developing safe 
and efficient vectors for delivery of therapeutics to brain.  Viruses are equipped with different 
molecular mechanisms to overcome these hurdles and can therefore, serve as efficient delivery 
vectors (Foust et al. 2009). Yet, the potential application of viruses as delivery agents and their 
further investigation in clinical research is impeded by the associated immune response and 
cytotoxicity thereby, accentuating the need for synthesis of safe and efficient non-viral delivery 
vectors. Multidisciplinary approaches involving biology, nanotechnology and biophysics need to 
be considered to accomplish the goal of improving the delivery of therapeutic drugs and genes 
across BBB (Chen et al. 2012).  
 
 
4 
 
1.1. Strategies for delivery of therapeutics to brain 
1.1.1. Modulation of tight junction barrier 
Various chemical and biological substances and physical stimuli have been reported to 
cause temporary opening of the BBB by modulating the TJ (Hynynen et al. 2008; Stam et al. 
2010). It has been previously reported that cyclodextrins extract cholesterol from brain capillary 
endothelial cell membrane and allow the penetration of water soluble drugs across the in vitro 
brain endothelial monolayer (Tilloy et al. 2006). Also, chemicals like poloxamers are co-
administered with Digoxin to increase the brain permeability via inhibition of P-gp and MRP 
efflux transporters (Batrakova et al. 2001).  Apart from this, biological viruses like adeno-
associated virus cause up regulation of chemokines thereby increasing the permeability of BBB 
(Kuang et al. 2009; Kaplitt et al. 2007). Bradykinin agonist, Cereport (RMP-7), has been widely 
employed to increase the CNS delivery of carboplatin, loperamide and cyclosporine A. Physical 
agents like ultrasound also increase the delivery of therapeutic molecules like gene, antibodies or 
water soluble chemotherapeutic agents by causing partial opening of the TJ (Williams et al. 
1984; Yang et al. 2007; Liu et al. 2010). Electromagnetic field causes opening of TJ via protein 
kinase C signaling and translocation of TJ proteins whereas, microwave increases the brain 
permeability by thermal effects (Moriyama et al. 1991; Qiu et al. 2010; Kuo et al. 2008). The 
rationale for opening the TJ barrier is based on the fact that most of the disease states are 
associated with leakage of BBB or TJ opening. In addition, partial opening of BBB can lead to 
improved passage of small water soluble drugs as well as macromolecules like liposomes, 
nucleic acids and antibodies (Chen et al. 2012). However, the strategy of modulating the BBB by 
partial opening of BBB is a dual-edged sword. On one hand it improves the permeability of 
water soluble molecules, antibodies, proteins, liposomes and nanoparticles without the need for 
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chemical modification of the drug molecule. On the other hand, temporary opening of TJ can 
also increase the permeability of unwanted molecules like pathogens and toxins thereby 
necessitating the control of the duration of TJ modulation.  
1.1.2.  Utilization of brain transporter systems 
BBB expresses a wide variety of transporters for the movement of essential nutrients like 
glucose, amino acids or peptides (Tsuji et al. 1999). Therapeutic molecules mimicking the 
endogenous nutrients are easily transported via these transporter proteins. Levodopa is a lipid 
insoluble precursor of dopamine used for the treatment of Parkinson’s disease. It contains 
carboxyl and -amino groups that facilitate its transport via large neutral amino acid carrier 
(Wade et al. 1975). Although, these endogenous transport systems can be used as efficient 
portals for delivery of drugs, however, there practical application is limited to the peptide drugs. 
Also, this approach is less favored as it competes with the transport of essential nutrients to 
brain. 
1.1.3.  Inhibition of efflux pumps  
    Various efflux pumps on the surface of BBB like P-gp and MRP transporters inhibit the 
transport of drug molecules into brain (Fromm et al. 2000). Miller et al., initiated the concept of 
inhibiting the P-gp efflux pumps using Pluronic® P85 (poloxamer) copolymers. The study 
compared the accumulation of Rhodamine 123, a selective substrate of P-gp, in brain 
microvessel endothelial cells. Poloxamer block co polymers consist of hydrophilic ethylene 
oxide (EO) and hydrophobic proplylene oxide (PO) arranged in the triblock fashion thereby, 
imparting an amphiphilic character to the polymer. Due to the amphiphilic character of these co 
polymers they exhibit surfactant properties. Previous studies suggest that the inhibition of P-gp 
involves 1) Interaction of the copolymer with cellular membrane to increase membrane 
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fluidization 2) Inhibition of P-gp ATPase activity and depletion of cellular ATP (Kabanov et al. 
2003). These copolymers have been reported to enhance the permeability of a wide range of 
drugs, including doxorubicin, etoposide, taxol, 3'-azido-3'-deoxythymidine, valproic acid and 
loperamide, in the bovine brain microvessel endothelial cell monolayer (Batrakova et al. 1999). 
It has been reported earlier that both the HLB value and PO block length are important in 
determining the P-gp inhibition activity of Pluronic co polymers (Batrakova et al. 2003). Even 
though these block co polymers have a significant potential in increasing the transport of many 
drug molecules across the BBB, however their direct interaction with the cell membrane and 
inhibition of ATP activity has raised concerns about the toxicity associated with their chronic 
use. Nevertheless, short term application has shown transient depletion of ATP and restoration of 
BBB integrity (Batrakova et al. 2001; Batrakova et al. 1999). 
1.1.4.  Adsorptive mediated transcytosis (AMT) 
The growing evidence indicating the success of transport of therapeutic molecules into 
brain via cationic proteins and cell penetrating peptides (CPPs) has conveyed significant 
importance to AMT as route for delivery of molecules across BBB. CPPs are short cationic 
peptides (less than 30 amino acids) that have the ability to transport extracellular molecular cargo 
into the cells. These peptides are capable of entering the cells without producing cytolytic 
effects. In addition, they effectively by pass P-gp in the BBB and are therefore used as vectors 
for delivery of drugs that are substrates for P-gp (Rousselle et al. 2000). Table 1 illustrates 
commonly used CPPs with their features. Despite the variation in length and sequence of amino 
acids, these peptides share some common features like their amphipathic nature, net positive 
charge, theoretical hydrophobicity and helical moment, the ability to interact with lipidic 
membranes, and to adopt a distinct secondary structure upon association with lipids (Deshayes et 
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al. 2005). The CPPs are primarily considered to be transported via receptor and energy 
dependent pathways but the exact mechanism is not yet fully understood. While for some CPPs 
endocytosis is the exclusive mechanism of uptake however for others it is an alternative 
mechanism (Drin et al. 2003).The use of CPPs is based on the fact that these peptides can be 
linked to the therapeutically active molecules and can transported across the cell membrane. This 
linkage can either be covalent or non-covalent. Various cargo molecules and delivery agents 
have been delivered into the cells using CPPs e.g. proteins, small drug molecules, nucleic acids, 
liposomes and nanoparticles. Adenot et al., have previously reported an increase in the 
penetration of various chemotherapeutic agents across BBB in situ and in vitro cell based model, 
after conjugation with SynB3 CPP (Adenot et al. 2007). They reported an increase in brain 
delivery of doxorubicin by factor of 30, benzylpenicillin by factor of 7, paclitaxel by factor of 
22, dalargin by factor of 18 and morphine 6-glucoronide by factor of 50 without disrupting the 
function of BBB. Another study reported a significant increase in the uptake of dalargin after 
conjugation with SynB on intravenous injection into mice (Rousselle et al. 2003).  
In addition TAT conjugated nanoparticles and liposomes have been used for deliveryof 
therapeutic agents across BBB. Qin et al., reported enhanced penetration of Choletrol-PEG2000-
TAT into brain as compared to Cholesterol-PEG
2000
 and conventional cholesterol liposomes (Qin 
et al. 2011). Sharma et al., reported enhanced penetration of CPP-transferrin-liposomes into 
brains of adult Sprague Dawley rats as compared to transferrin conjugated and conventional 
plain liposomes (Sharma et al. 2012; Sharma et al. 2013). A recent study demonstrated 
significantly (p<0.001) higher accumulation of Penetratin functionalized PEG-PLA (poly lactic 
acid) nanoparticles in rats as compared to the low molecular weight protamine nanoparticles (Xia 
et al. 2012). 
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Apart from the CPPs, cationic proteins have also been employed to increase the 
penetration of therapeutic agents across BBB via adsorptive-mediated mechanism. Poduslo and 
Curran demonstrated that polyamine modification of proteins (albumin, insulin and IgG) 
dramatically increased their penetration across BBB. The permeability of insulin increased by 
1.7-2.0 fold, albumin increased by 54-165 fold and IgG increased by 111-349 fold (Poduslo et al. 
1996). A previous study compared cationic bovine serum albumin conjugated PEG-PLA 
nanoparticles (CBSA-NP) with the native bovine serum albumin conjugated NP (BSA-NP) and 
unconjugated nanoparticles (NP) for brain delivery in mice (Lu et al. 2007). The results 
demonstrated that the penetration of CBSA-NP increased by 2.3 fold as compared to NP. 
Although cationic proteins have shown considerable improvement in delivery of molecules or 
delivery vectors across BBB, however the toxicity or immunogenicity associated with this 
chemical modification cannot be ruled out (Roney et al. 2005).  
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Table 1. Properties of some naturally occurring cell penetrating peptides 
CPP Amino acid Sequence 
Net 
charge 
Cell 
Lysis 
activity 
MAP KLALKLALKALKAALKLA  +5 Yes 
pAntp43-
68(Penetratin) 
RQIKIWFQNRRMKWKK  +8 No 
SynB1 RGGRLSYSRRFSTSTGR  +6 Yes 
SBP 
MGLGLHLLVAAALQGAWSPKKKR
KV  
+6 No 
SynB3 RRLSYSRRRF  +6 - 
Transportan 
GWTLNSAGYLLGKINLKALAALAK
KIL  
+4 No 
FBP 
GALFLGWLGAAGSTMGAWSQPKK
KRKV  
+6 - 
TAT 48-60 GRKKRRQRRRPPQ  +8 No 
 
(Batrakova et al. 2003; Zorkoet al. 2005; Rousselle et al. 2000; Deshayes et al. 2005) 
 
The delivery of small molecules, vectors and other protein and nucleic acid drugs that are 
associated with poor brain penetration can be efficiently transported across BBB via AMT. 
However, the non-specific uptake of the CPP or cationic proteins can result in higher 
accumulations in blood vessels and peripheral organs. In addition, the toxicity and 
immunogenicity associated with chemical modifications of proteins can pose a challenge to 
practical application of these agents in improving brain delivery. Previous studies have reported 
membrane toxicity and tissue inflammation using CPPs and cationic albumin nanoparticles 
(Drin, et al. 2003; Lu et al. 2007). A recent report has indicated that is non-toxic up to a 
concentration of 100µM however after peptide bound TAT demonstrated significant and chain 
length dependent toxicity irrespective of the sequence of peptide (Cardozo et al. 2007). A study 
indicated toxicity associated with a very high dose of TAT46–60 peptide (Sabatier et al. 1991).  
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1.1.5. Receptor mediated transcytosis (RMT) 
RMT overcomes the limitation of non-specific uptake by peripheral tissues and blood 
vessels thus reducing the side effects associated with AMT. Up regulation of certain receptor 
types in a diseased condition further enhance the opportunity for active targeting of therapeutic 
molecules to specific sites and tissues e.g. transferrin receptors are over expressed on brain 
endothelium and the receptor expression is significantly up regulated in tumor conditions 
(Huwyler et al. 1996; Oba et al. 2007). Cargo molecules like proteins, peptides, delivery vectors 
can be linked with an active targeting ligand and transported across BBB via RMT. Therefore, 
this approach is also called as Trojan horse approach (Pardridge et al. 2002; Pardridge et al. 
2003). Increased understanding of BBB biology and genomics has led to the discovery of a large 
number of transporters and receptors that can be used for delivery of molecules across BBB. In 
general there are three steps involved in RMT (Pardridge et al. 2002; Pardridge et al. 2003): 
a) Endocytosis of the molecules on the luminal(blood) side after binding of the ligand to 
the targeted receptor. 
b) Movement of the molecules across the endothelial cytoplasm 
c) Exocytosis of the drug/ ligand-attached drug or delivery vector on the abluminal 
(brain) side. 
The second step sometimes leads endosomal/lysosomal degradation of the drug 
molecules or cargo. This fate is overcome by using pH sensitive liposomes or cationic 
peptides/molecules (Bartsch et al. 2005; Shir et al. 2006). Certain targeting ligands like 
diphtheria toxin have endosomal escaping ability (Boer et al. 2007).  Advantageously, 
lysosomal/endosomal escaping phenomenon is not required for brain delivery and successful 
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transport of small drug molecules, liposomes, nanoparticles and polymeric complexes to brain 
(Gabathuler et al. 2010; Boer et al. 2007).  
Various receptors involved in RMT for delivery of molecules across BBB are listed 
below: 
a) Insulin receptors: Insulin receptor is a heterotetramer protein of molecular weight 
300kDa and consists of two extracellular alpha and two transmemberane beta subunits (Boer et 
al. 2007). This receptor has been widely evaluated for RMT and is used for transporting drugs 
into brain. Pardridge and colleagues extensively investigated this receptor system and 
successfully developed a radiolabelled amyloid-β-peptide, 125I-Abeta1–40 conjugated to 83–14 
monoclonal antibody(mAb) that was used to target human insulin receptor and was used as a 
diagnostic probe for Alzheimer’s disease (AD) (Pardridge  et al. 1985; Pardridge et al. 1995; 
Zhang et al. 2003; Xia et al. 2009; Wu et al. 1997; Frolich et al. 1998). The same group also 
investigated human insulin receptor monoclonal antibody in adult Rhesus monkey and observed 
wide distribution of the antibody in all parts of the primate brain and thus confirmed the potential 
of the antibody in delivering therapeutic molecules across BBB. Insulin receptors on BBB are 
involved in transport of glucose to brain and therefore, these receptors play an important role 
diabetes and obesity. Frolich et al., reported that the expression of insulin receptors is altered in 
AD (Frolich et al. 1998). A previous study also reported that amyloid-β peptide, an important 
mediator of AD, can compete with the endogenous insulin and interfere insulin metabolism 
thereby leading to impaired glucose utilization in the brain of AD patients (Recht et al. 1990). 
These results suggested the profound implications of using insulin receptor of transporting 
receptor targeted therapeutic molecules or delivery vectors across BBB. The approach is likely to 
affect the most important pathway for glucose utilization. 
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b) Transferrin receptors (TfR):  Transferrin receptors are the widely studied systems for 
RMT of delivery vectors and therapeutic agents across BBB. The receptor is a transmembrane 
glycoprotein with two subunits of 90kDa that are linked by disulfide bridge and each of these 
subunits can bind to one molecule of transferrin (Moos et al. 2000). In addition to the BBB, this 
TfR is also expressed on hepatocytes, monocytes, erythrocytes, intestinal cells, epithelial cells of 
choroid plexus and neurons. TfRs on BBB mediate the transport of iron bound to transferrin into 
the brain. Nanoparticles, liposomes, therapeutic drug molecules can be conjugated to either 
transferrin protein or transferrin monoclonal antibody (OX-26). The TfR targeted monoclonal 
antibody binds to a different site as compared to transferrin protein and therefore, is less likely to 
interfere with the endogenous transferrin in circulation. A recent study reported an improvement 
in the expression of luciferase gene in C6 glioma cells, primary hippocampal neurons and 
primary cortical neurons on transfection with transferrin modified cationic liposomes as 
compared to conventional plain liposomes. However, the transfection levels were low with the 
conjugation of transferrin protein. There low transfection levels with transferrin conjugated 
delivery vector were attributed to the high concentration of transferrin protein in circulation 
which competes with the transferrin on the nanoparticle system (Cruz et al. 2004). Another 
limitation of using transferrin as a delivery system is that exogenously supplied transferrin can 
lead to overdose of iron transport into brain. In order to avoid the limitations of using transferrin 
as a delivery system, transferrin receptor targeted antibodies have been used that bind to a 
receptor binding site different as compared to the transferrin protein. Different antibodies that 
have been evaluated include OX26 (anti-rat TfR monoclonal antibody), R17-217 and 8D3 (anti 
mouse TfR monoclonal antibody) were all examined. Comparison of the brain uptake of R17-
217 and 8D3 revealed a higher uptake of 8D3 (3.1% injected dose/gram of tissue) as compared 
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to R17-217 (1.7% injected dose/gram of the tissue) (Lee et al. 2000). Ulbrich et al., investigated 
the distribution and brain targeting properties of human serum albumin nanoparticles conjugated 
to transferrin protein or transferrin monolclonal antibodies (OX26 or R17-217) for delivery of 
loperamide (does not cross BBB) (Ulbrich et al. 2009). The results demonstrated significant anti-
nociceptive effects with loperamine loaded HAS nanoparticles after covalent modification with 
transferrin or antibodies (OX-26 or R17-217). The study also showed enhanced transport of 
transferrin monoclonal antibody modified nanoparticles across BBB as compared to the IgG2a 
antibody or transferrin modified nanoparticles thus further confirming the efficacy of 
monoclonal antibodies over transferrin protein for delivery of therapeutic agents to brain 
(Ulbrich et al. 2009). A recent report showed a comparison of different targeting ligands in 
improving the transport of molecules to brain. Five different targeting ligands were compared for 
their ability to target brain both in vitro and in vivo: transferrin, R17-217 (against TfR), COG 133 
(against low density lipoprotein receptor -LDLR and lipoprotein receptor protein-LRP), 
Angioprep-2 (against LRP) and cross reacting material (CRM)197(against diphtheria toxin 
receptor-DTR). The in vitro results showed that only R17-217 and CRM197 were observed to be 
associated with human endothelial cells and only R17-217 showed enhanced brain uptake of 
liposomes in Balb/c mice at all time-points after intravenous injection (Rooy et al. 2011). The 
authors studied the distribution of 
3
H-labelled liposomes in brain capillaries using capillary 
depletion method and observed that the distribution of R17-217 liposomes was 10 times more 
than the untargeted liposomes. In addition, R17-217 liposomes were the only ones whose 
concentration was maintained in the brain over a period of 6h and was 0.18% of the injected 
dose/gram of tissue after 12h. The authors also suggested that the higher accumulation of this 
antibody in comparison to the other groups could be due the higher molecular weight and higher 
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affinity of the antibody to the receptors leading to stronger brain targeting ability and lower rate 
of elimination (Rooy et al. 2011). Although targeting ligand has a significant contribution in 
improving the delivery of molecules to brain, there are other parameters like matrix material, 
particle size, surface properties, the density and conformation of targeting ligand that also play 
an important role in brain delivery. A recent study performed by Sharma et al., also showed 
higher accumulation of transferrin-CPP modified liposomes in rat brain after 24h of intravenous 
administration (Sharma et al. 2013). The authors proposed a dual mechanism for improved and 
targeted delivery of transferrin modified liposomes. The conjugation of CPP with transferrin-
liposomes enhanced the penetration of transferrin liposomes into brain by overcoming receptor 
saturation versus the transferrin conjugated or untargeted liposomes. Transferrin has been 
evaluated to be an important target for delivery to brain. However, more studies need to be 
conducted in order to fully understand the function and performance of targeting ligands. The 
expression of TfR on brain endothelial cells was observed to decrease in brain ischemia (Moos et 
al. 2004). In contrast, the expression was observed to be decreased in the hippocampus of 
patients with AD as compared to normal humans (Morris et al. 2004; Kalaria et al. 1992).  
However, there was a marked increase in the expression of transferrin receptors during brain 
injury and after intra cerebral hemorrhage (Wu et al. 2003). An immunohistochemical evaluation 
of normal brain tissue and tumor biopsy revealed a differential staining pattern for TfRs on brain 
endothelial cells of normal and tumor tissue indicating a higher level of expression in tumor 
associated brain endothelial cells (Recht et al. 1990). 
c) Low-density lipoprotein receptor related proteins 1 and 2 (LRP1 and LRP2) receptors: 
These are multi-ligand, multifunctional scavengers and signaling receptors. They can interact 
with a diverse range of molecules and/or mediators like ApoE, tissue plasminogen 
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activator(tPA), plasminogen activator inhibitor 1 (PAI-1), amyloid precursorprotein (APP), 
lactoferrin, melanotransferrin, α2 macroglobulin(α2 M), receptor associated protein (RAP), HIV-
1 TAT protein, Heparin, cofactor II, heat shock protein 96 (HSP-96) and engineered angiopeps 
(Gabathuler et al. 2010; Boer et al. 2007). Recently, a wide number of investigations have 
revealed the application of LRP1 and LRP 2 in targeting drugs to brain in a manner similar to the 
transferrin or insulin receptors. Schroder et al., first investigated the distribution of polysorbate-
80 coated poly(butylcyanoacrylate-PBCA) nanoparticles in vivo and observed increased 
transport of hexapeptidedalargin after intravenous injection of the nanoparticles (Schröder et al. 
1996). Similar study also indicated improved brain transport of drugs that do not cross BBB e.g. 
tubocurarine, loperamide, 8-chloro-4-hydroxy-1-oxol, 2-dihydropyridazino, quinoline-5-oxide 
choline salt (MRZ 2/576),and doxorubicin, after incorporation into polysorbate 80 coated 
nanoparticles. The enhanced transport across BBB was attributed to the adsorption of Apo E or B 
on the nanoparticles followed by LDL receptor mediated transcytosis (Blasi et al. 2007). A 
recent study reported enhanced uptake and intracellular localization of PEGylated albumin 
nanoparticles, covalently bound to ApoE, into mouse brain microvascular endothelial cells 
(Zensi et al. 2009).  Furthermore, in vivo evaluation of ApoE modified albumin nanoparticles in 
SV129 mice showed transcytosis of the nanoparticles into brain parenchyma and transport into 
neurons 30 min after administration into juglar vein (Yuan et al. 2006).  
Lactoferrin is another ligand that can be targeted to brain via LRP mediated transcytosis 
(Fillebeenet al. 1999). A group of scientists also confirmed the expression of lactoferrin 
receptors on mouse brain capillary endothelial cells (Huang et al. 2007). It is an iron binding 
glycoprotein that belongs to transferrin family. It has been implicated in a number of 
pathological conditions of brain.  This cationic glycoprotein is found to be associated with 
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normal ageing and to be increased in people with AD, Pick’s disease and Down Syndrome 
(Leveugle et al. 1994). Ji et al., demonstrated greater transport of lactoferrin into rat brain as 
compared to transferrin and OX26 (Ji et al. 2006). Another group of researchers showed a 3fold 
increase in the brain transport of PEG-PLA nanoparticles after conjugation with lactoferrin, in 
intravenously injected mice (Hu et al. 2009). Later the same group evaluated the biodistribution 
of Lactoferrin conjugated PEG-PLA nanoparticles loaded with coumarin-6 in mice and the 
therapeutic efficacy of the same nanoparticles loaded with urocortin in Parkinson’s disease rat 
model (Hu e al. 2011). The data demonstrated an increase in the AUC by 2.5 times using 
lactoferrin conjugated nanoparticles as compared to the unmodified nanoparticles, 24h post 
administration. Despite the low drug loading levels of lactoferrin nanoparticles, these were 
successfully taken up by brain and resulted in enhanced attenuation of lesions in striatum (Hu et 
al. 2011). This suggests that lactoferin modified nanoparticles can serve as efficient delivery 
vectors for treatment of brain diseases like Parkinson’s disease.  
Melanotransferrin is another targeting molecule that has been evaluated to undergo 
transcytosisvia LRP1 receptor. It has been previously reported that recombinant human 
melanotransferrin was easily taken up by mouse brain after intravenous injection and in situ 
perfusion of brain (Demeule et al. 2002). This transcytosis across bovine brain capillary 
endothelial cells was atleast 14 fold higher as compared to transferrin and showed minimum 
intra-endothelial degradation. A previous report indicated higher efficacy of P97- adrimaycin 
conjugates against intracranial rat C6 glioma and human ZR-75-1 mammary tumors in athymic 
mice in comparison to the adriamycin alone (Gabathuler et al. 2005). The technology involving 
application of melanotransferrin as targeting molecule is now patented and a related product 
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(NeroTransTM transporter platform) is the proprietary property of Raptor Pharmaceutical Corp 
(Novato, CA). 
Angiopeps is a group of targeting ligands that are reported to be highly effective in 
targeting BBB. Angiopeps have a high affinity for LRP receptors and belong to a family of 
peptides derived from Kunitz domains of aprotinin and other human proteins (Demeule et al. 
2008). Angiopep2 (TFFYGGSRGKRNNFKTEEY, molecular weight 2.4 kDa) is a group of 
angiopeps that has demonstrated higher transcytosis and accumulation in brain parenchyma as 
compared to transferrin, lactoferrin and avidin (Demeule et al. 2008). Some recent studies have 
highlighted the efficiency of angiopep 2 conjugated dendrimers and amphotericin B loaded 
polymeric micelles in transporting across BBB (Ke et al. 2009; Shao et al. 2010). Thomas et al., 
reported 86 fold increase in transport of paclitaxel (3 molecules) conjugated with angiopep 2 
(ANG1005) across BBB, using in situ rat brain perfusion model, as compared to free drug. The 
transport of angiopep conjugated drug also increased 4-54 fold as compared to free drug, after 
intravenous administration (Thomas et al. 2009).The therapeutic efficiency of ANG1005 was 
confirmed by increased survival rates of mice with implanted tumor cells (Regina et al. 2008).  A 
recent study reported the use of dual modified PLGA naoparticles in improving the delivery of 
drugs or molecules into brain. The nanoparticles were surface modified with a brain penetrating 
peptide (similipoid, g7) and sialic acid residue for targeting receptors on brain tissue (Tosi et al. 
2010).  The dual modified nanoparticles showed an accumulation of ~6% of the injected 
dose/gram of tissue in the CNS over a period of 24h. In contrast, the single modified 
nanoparticles with only g7 modification showed a brain uptake of about 14%injected dose/gram 
of tissue at 1.5h after injection, however, they demonstrated a much shorter opioid effect (5h). 
Sialic acid conjugation with g7 modified nanoparticles increased the CNS activity of drug to 24h 
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(Tosi et al. 2010). The results established the significance of sialic acid g7 modified 
nanoparticles in improving the delivery of therapeutic agents to brain. The researchers confirmed 
the significance of sialic acid in retaining the nanoparticles in brain by slowing their clearance 
from brain parenchyma. The increased clearance without sialic acid was attributed more to the 
physical translocation rather than enzymatic degradation. 
d) Diphtheria toxin receptor (DTR): This is commonly referred to as transmembrane 
Heparin binding Epidermal Growth factor (HB-EGF). This receptor forms a well characterized 
internalizing transporter on BBB and neuronal and glial cells that facilitated the transport of 
molecules via RMT (Mishima et al. 1996). The advantage of using DTR for RMT is that there 
are no endogenous ligands that can compete for transport across BBB (Gaillard et al. 2005). In 
addition, upregulation of this receptor is observed in various inflammatory condition associated 
with brain diseases (Opanashuk et al. 1999; Kawahara et al. 1999, Jin et al. 2004). However, a 
major disadvantage of using this receptor for targeting is that Diphtheria toxin (DT) is very toxic 
and not suitable for in vivo administration (Giannini et al. 1984).  A mutated form of DT that has 
been used for targeting DTR is cross reacting material (CRM 197). It does not retain the toxicity 
associated with the enzymatic activity of DT but has the ability to bind with the DTR (Kaefer et 
al. 2000). CRM 197 has demonstrated efficient brain targeting both in vitro and in vivo. The 
safety and efficacy of CRM 197 as a carrier protein has been tested in clinical trials and has been 
recommended for use in human vaccines (Anderson et al. 1983; Buzzi et al. 2004). The 
upregulation of DTR in seizures and inflammatory brain conditions provides an opportunity for 
targeting in brain disease conditions and helps in maximizing the therapeutic efficacy of the 
conjugated therapeutic or diagnostic cargo across BBB. 
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1.2. Nanocarriers for delivery across blood brain barrier (BBB) 
These are nanoscale carriers for delivery of therapeutic drugs or other molecules and 
consist of particles in the size range of 100-1000µm (Kreuter et al. 2005). These nanocarrier 
systems consist of polymeric nanoparticles and lipid based particles e.g. liposomes and solid 
lipid nanoparticles. This emerging class of delivery systems can be easily customized to transport 
desired therapeutic agents to specific tissues in the body. Rapid development in polymer 
chemistry and nanotechnology coupled with an increased understanding of the molecular biology 
of brain and various receptor systems that can be used to target brain, the development of 
nanocarriers for delivery to brain has gained increasing attention of scientists across the world. 
They can be surface modified for targeting specific receptors, can carry the therapeutic drugs and 
molecules in sufficient amounts and provide a controlled/ targeted release of the therapeutic 
agent. Ideal nanocarriers should have the following properties for delivery of drugs/therapeutic 
agents across BBB (Koo et al. 2006; Bhaskar et al. 2010): 
a) They should be biodegradable, non-toxic and biocompatible, 
b) Preferably a size of less than 200 nm 
c) They should not aggregate/ dissociate in blood; should be stable in circulation 
d) They should be non-immunogenic 
e) Should have a targeting moiety coupled for delivery across BBB via 
receptor/adsorptive transcytosis or monocytes and macrophages. 
f) The drug (small molecules, peptides, proteins, nucleic acids) carried should be stable 
and the drug release should be tunable 
A large variety of nanocarriers have been developed so far, however only polymeric 
nanoparticles and amphiphilic lipids forming liposomes have been extensively exploited as 
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delivery of therapeutic agents to brain (Garcia et al. 2005). Several polymeric and liposomal 
delivery systems for treatment of brain disorders have reached clinical trials. The University of 
Regensburg in collaboration with Essex Pharma (Schering-Plough) has successfully completed 
phase 2 of clinical trials for pegylated liposomal doxorubicin and prolonged temozolamide in 
combination with radiotherapy in treatment of glioblastoma (ClinicalTrials.gov, 2011; Chen et 
al. 2012). Another pegylated doxorubicin formulation surface modified with glutathione is 
currently in Phase I/II of clinical trials in the Antoni van Leeuwenhoek hospital, the Netherlands. 
Non-amphiphilic colloidal drug carriers like dendrimers and micro emulsions are still at 
relatively early stage of development.   
Amphiphilic molecules have been increasing investigated for development of nanocarrier 
systems. An amphiphilic molecule has a polar head group and a non-polar or hydrophobic tail. 
These agents interact with water or hydrophobic solution to orient their hydrophilic heads 
towards the aqueous phase and the hydrophobic tails away. At low concentrations, the 
amphiphilic molecules accumulate at the surface of water. The polar head of the amphiphile 
orients towards water while the hydrophobic tails orients towards the air. At higher 
concentrations above a critical concentration these amphiphilic molecules aggregate in the bulk 
of the aqueous phase to various structures like micelles, rods, vesicles etc (Chen et al. 2012).  
Vesicles are hollow bilayer spherical structures having a hydrophilic core and the 
lipophilic walls. The size range of these vesicles for brain delivery varies from 20-200µm while 
the thickness of the membranes is approximately 3.5 nm (Chen et al. 2012).  Liposomes are 
phospholipid bilayer vesicles that can encapsulate the hydrophilic drugs in the aqueous core and 
incorporate the lipophilic drugs in the membrane (Chen et al. 2011; Kateb et al. 2011). Niosomes 
are non-phospholipid polymeric/micellar vesicles with similar structure and function as that of 
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liposomes (Dufes et al. 2000, Arunothayanun et al. 2000).  Xie et al., evaluated brain targeted 
nerve growth factor (NGF) encapsulated liposomes for delivery across BBB.  The PEGylated 
liposomes were surface modified with RMP-7 for targeting the B2 receptors on brain endothelial 
cells.  The results demonstrated protection of NGF from enzymatic degradation in vivo and 
increased permeability into brain after encapsulation into targeted liposomes (Xie et al. 2005). 
As discussed earlier, transferrin has been studied to possess significant potential for targeting the 
transferrin receptors on BBB. A recent study reported considerable improvement in tumor 
growth inhibition and increased survival rate of C6 glioma bearing rats using transferrin 
conjugated liposomes, with epirubicin in the hydrophilic core and tamoxifen in the lipid bilayer, 
as compared to the control groups administered with unconjugated liposomes or free drug (Tian 
et al. 2010). Another group of researchers reported that the phagocytic cells of the innate 
immune system, mainly neutrophils and monocytes, can be exploited as transporters of drugs to 
the brain. They synthesized negatively charged liposomes, encapsulating serotonin in the 
hydrophilic core, to target the circulating mononuclear phagocytic cells. The drug serotonin was 
selected as a brain impermeable neurological drug. The results indicated significantly higher 
uptake of liposomal serotonin after 4h and 24 of intravenous administration as compared to 
serotonin in solution (Afergan et al. 2008). Another very recent report illustrated the influence of 
incorporating a cell penetrating peptide on transferrin conjugated liposomes for improving their 
delivery to brain. The results showed an accumulation of ~3.8% of injected dose/gram in rat 
brain following 24h of intravenous injection of the transferrin-CPP modified liposomes. The 
accumulation was significantly greater as compared to transferrin liposomes or plain 
unconjugated liposomes (Sharma et al. 2012; Sharma et al. 2013).   
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Micelles form another group of spherical aggregates formed by the amphiphilic 
molecules. Micellar aggregates are formed by the amphiphilic molecules above a certain 
concentration called the critical micellar concentration (CMC). The most commonly known 
structures are the ones with their hydrophilic heads oriented towards the outer aqueous phase and 
the hydrophobic lipid tails directed inside. The amphiphilic molecules in the micelles are in 
continuous dynamic equilibrium and are in constant exchange with the outer bulk liquid (Chen et 
al. 2012). Polymeric micelles also known as polymersomes are self-assembled polymer shells 
composed of amphiphilic block co-polymers e.g. polyethylene glycol-polylactic acid and PEG-
polycaprolactone (Discher et al. 2006). Block co-polymers that form the micelles have the same 
amphiphilic property as the lipids and differ in the fact that the block co-polymers have two 
distinct polymer groups that are covalently linked (Discher et al. 2006). Polymeric micelles 
differ from nanoparticles as the latter are either more solid (nanospheres) or contain oily/aqueous 
cores surrounded by the polymer shell (nanocapsules).  Amphilic block co-polymers micelles 
have emerged as promising brain delivery vectors over the recent years. The advantage of using 
these polymeric micelles is that they are more stable and their molecular weights are controllable 
as compared to amphiphilic lipid micelle systems (Chen et al. 2012). In addition, the diversity of 
polymers and their block lengths provides flexibility in designing the most stable and desirable 
delivery systems. Some examples of hydrophobic core forming polymers include poly propylene 
glycol, poly caprolactone and poly D, L-lactide. Cholesterol is often employed as a hydrophobic 
group as it is biocompatible and possesses the potential of interacting with the cholesterol 
receptors on cell surface (Liu et al. 2004). 
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1.2.1. Surface modification of nanocarriers  
1.2.1.1. PEGylation of nanocarriers  
The most commonly used nanocarriers for delivery of therapeutic agents to brain include 
liposomes, polymer nanoparticles and polymeric micelles. These systems not only provide an 
advantage of protecting the encapsulated therapeutic agent from enzymatic, biological or 
chemical degradation in circulation they can also be manipulated as per desired application. 
pegylation of these agents has been reported to increase the circulation time of the nanocarriers 
(Maruyama et al. 2011; Sadzuka et al. 2002; Klibanov et al. 1990). Nanocarriers especially 
liposomes have very short half lives in circulation due to their interaction with various blood 
components and opsonins their elimination by the macrophage system of the body. Specifically, 
liposomes have a tendency to exchange their lipids with the cell membrane and are taken up by 
phagocytes in the body (Woodle et al. 1995). Incorporation of highly flexible and hydrophilic 
PEG chain on the surface of liposomes imparts the latter with steric stabilization and resistance 
to opsonins (Hatakeyama et al. 2007).Thus PEGylation of liposomes has become a standard 
platform for designing various tissue/receptor targeting nanocarrier systems (Hatakeyama et al. 
2007; Li et al. 2009; Markoutsa et al. 2011). Furthermore, incorporation of PEG in block co-
polymers also provides a hydrophilic head group to the polymers. PEG containing surfactants 
like poly oxyethylene-poly oxypropylene block co-polymers (Poloxamer 338 and Poloxamine 
908) have been reported to effectively prolong the circulation life time of nanoparticles (Stolnik 
et al. 1995; Coombes et al. 1994). Gref et al., first reported the conjugation of PEG chains to 
poly (lactic acid) nanoparticles (Gref et al. 1994). Later PEG chains were also coupled to poly 
(hexadecyl cyanoacrylate) PHDCA nanoparticles (Perachhia et al. 1997). PEGylation resulted in 
an increased circulation time and decreased liver uptake of both PLA and PHDCA nanoparticles. 
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Another study indicated the distribution of fluorescently labeled PEG-PHDCA nanoparticles in 
the epithelial cells of piamater, ventricles, spinal cord surface and the ependymal cells of choroid 
plexus after intravenous administration in rats and mice. Also, the PEGylated nanoparticles were 
transported into brain at 4-8 fold higher concentration than the non-PEGylated nanoparticles 
(Calvo et al. 2001). 
1.2.1.2. Surface modification with functional ligands  
Selection and synthesis of an appropriate targeting ligand is a crucial step in formulating 
nanocarriers for drug delivery. Appropriate functionalization of nanocarriers is itself a challenge 
and requires a thorough understanding of the target organ/tissue and the transport mechanisms 
available for targeting. Some transport systems may get up regulated or down regulated during a 
diseased condition. PEG is the most common agent for surface Functionalization of nanocarriers 
(Woodle et al. 1995). It provides steric stabilization to the delivery vector and therefore prolongs 
its circulation in vivo. The Functionalization is s usually achieved via covalent linking of the 
functional groups like amines, carboxylic acid, succinimidyl ester, thiol etc. (Sharma et al. 2012; 
Sharma et al. 2013, Chen et al. 2004). Following are the two major concerns for surface 
modification of the nanocarriers: 
1) Active targeting ligands like antibody, protein, peptide, sugar moiety, folate or 
carbohydrate attached to the surface of the delivery vector can decrease the stability of 
the carrier in circulation and increase the rate of elimination uptake of the vector by liver 
and spleen. 
However, the presence of the PEG protecting polymer may compensate for this effect. 
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2) Prolonged circulation of the PEGylated ligand-bearing nanocarriers may result in the 
increased accumulation of the carrier in target organs even with low blood flow or with 
low concentration of the receptor antigens. 
1.2.2. Solid lipid nanoparticles (SLNs) 
SLNs are solid nanoparticles with a spherical lipid core matrix that can solubilize various 
lipophilic drugs. Various lipids have been used in the past including triglycerides, fatty acids 
(steric acids), waxes (bees wax, carnauba wax), cetyl alcohol and steroids (cholesterol).(Loxley 
et al. 2009) These lipids are stabilized in the aqueous environment by emulsifiers like soybean 
lecithin, poloxamers, polysorbates, Phosphatidylcholine, sodium cholate, sodium glycocholate, 
butanol, butyric acid etc. The SLNs are usually composed of 0.1% to 30% (w/w) of the solid 
lipids dispersed in an aqueous medium stabilized with 0.5% to 5% (w/w) emulsifier. The melted 
lipids containing the active ingredients are emulsified using different techniques like hot 
homogenization, cold homogenization, ultrasound and high shear homogenization (Mehnert et 
al. 2001). The application of SLNs for brain drug delivery started in late 90’s when two 
independent groups of researchers showed increased accumulation of the anticancer drugs 
camptothecin and doxorubicin after oral and intravenous administration of drug loaded SLNs 
(Yang et al. 1999, Zara et al. 1999). With increasing investigation of these lipid nanoparticles as 
drug delivery systems, another group of scientists demonstrated prolonged release of the drugs 
tetracaine, etomidate and prednisolone using SLNs synthesized with Compritol 888 ATO and 
Dynasan112 as matrix material (Muhlen et al. 1998). In a recent study Martin et al., showed 
increased levels of the antitumor drug, campothecin, in brain after intravenous administration of 
camptothecin loaded SLNs in rats (Martins et al. 2012).  The advantage of using these carriers is 
that they provide a controlled release of the encapsulated material and the lipids used are 
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biodegradable and have low systemic toxicity (Weyhers et al. 1995).  They can be surface 
modified to increase their steric stabilization or targeting efficiency (Blasi et al. 2005). Despite 
their efficacy and utility, at present there are no SLN formulations for parenteral administration 
in the market. Certain limitations associated with SLNs include particle growth, unpredictable 
gelation tendency and change in lipid polymorphic state causing drug leakage (Ekambaram et al. 
2012; Mehnart et al. 2001;Liet al. 2009). In addition, the toxicity associated with the surfactants 
used in formulating SLNs limits the in vivo applications. A previous report indicated toxic 
effects of SLN formulations composed of cetylpalmitate or Compritol® on liver and spleen of 
mice after intravenous administration (Weyhers et al. 1995). 
1.2.3. Polymeric nanoparticles 
 Increased progress in understanding of the mechanism of nanoparticle transport across 
BBB has resulted in greater application of the polymeric nanoparticles for delivery of therapeutic 
agents to brain. Various nanoparticles surface modified with targeting ligands, surfactants or 
steric stabilizers have been used in the recent past to accomplish the formidable task of 
transporting hydrophilic drug molecules to brain (Wohlfart et al. 2012). Lu et al., demonstrated 
improved accumulation of cationized albumin conjugated pegylated nanoparticles in the glioma 
tumor implanted in rat brain, 1hr post intravenous administration (Lu et al. 2007). In another 
study, Wen et al., showed that conjugation of PEG-PLGA nanoparticles with odorranalectin 
resulted in increased brain delivery of the nanoparticles and improved therapeutic effect of 
urocortin peptide loaded nanoparticles in rat with Parkinson’s disease (Wen et al. 2011). 
Recently, gold nanoparticles have been employed in combination with magnetic resonance 
imaging guided ultrasound for increasing the permeability of BBB (Etame et al. 2012). The 
uptake of nanoparticles into brain is now considered to be majorly regulated via receptor 
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mediated endocytosis followed by transcytosis across the endothelial barrier (Gabathuler et al. 
2010).  
 Various receptors like lipoprotein and scavenger receptors and the transferrin and insulin 
receptors have been utilized for transport of nanoparticles to brain. One of the major prerequisite 
for nanoparticulate delivery of therapeutics to brain is the biodegradability and safety of the 
nanoparticles, both in vitro and in vivo. Non-biodegradable particles like carbon nanotubes, 
quantum dots and fullerenes are associated with hazardous effects and therefore, are not 
considered safe for in vivo administration. Moreover, the drug loaded into the nanoparticles is 
exposed to macrophages and serum proteins in circulation and is thus, often associated with the 
risk of in vivo degradation (Wohlfart et al. 2012). 
1.2.4. Liposomes 
Liposomes are lipid vesicles that have an inner aqueous core surrounded by the 
phospholipid bilayer.  The pulsating development of targeted nanoparticulate systems has 
allowed efficient delivery of therapeutic agents to brain (Cheng et al. 2007; Jong et al. 
2008).Various nano-constructs like liposomes, dendrimers, lipid-polymeric nanoparticle systems 
and nanocapsules have been evaluated in the recent past for the delivery of desired cargo to the 
target site (Allen et al. 2004; Carlmark et al. 2009; Szoka et al. 1980; Muller et al. 2000;  
Vauthier et al. 2009).The versatility of liposomes, their ability to efficiently protect the 
encapsulated therapeutic agent in circulation, and the simplicity of surface engineering, provide 
substantial advantage to the liposomal delivery vectors over other nanoparticle systems (Maeda 
et al. 2000; Vasir et al. 2005).These liposomes can be conjugated to proteins for targeting 
specific receptors. Furthermore, sterically stabilized liposomes, surface modified with 
polyethylene glycol (PEG), show a reduction in clearance by the reticuloendothelial system and 
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immunogenic response of the targeting proteins (Shek et al. 1986; Harasyma et al. 1998). Low 
elimination by the liver and spleen increases the circulation time of liposomes and improves the 
bioavailability of encapsulated molecules for therapeutic action (Klibanov et al. 1990; Woodle et 
al. 1994).  
These liposomes have traditionally been used for delivery of poorly water soluble drugs 
by parenteral administration. Conventional liposomes, composed of cholesterol and 
phospholipids suffer from high plasma clearance and low transport across BBB. These liposomes 
can be surface modified with different ligands like proteins, peptides and antibodies for targeting 
specific receptors (Schnyder et al. 2005).  
Furthermore, surface functionalization with steric stabilizers like poly-ethylene glycol 
can increase the circulation time and decrease non-specific interactions and plasma clearance of 
liposomes (Klibanov et al. 1990, Sadzuka et al. 2002). However, the proportion of 
PEGmolecules on the surface needs to be circumspectly optimized as the incorporation of 
hydrophilic polymers can reduce the cellular uptake of liposomes. This can be attributed to the 
hydrophobicity of the cell membrane that establishes an effectual barrier for many hydrophilic 
molecules. Xiang et al., showed increased tumor transport of chlorotoxin modified PEGylated 
liposomes loaded with doxorubicin and greater inhibition of the tumor growth as compared to the 
unmodified liposomes (Xiang et al. 2011). In another study, Ying et al., evaluated dual-targeting 
liposomes surface functionalized with p-aminophenyl-α-D-mannopyranoside and transferrin for 
crossing the BBB. The dual-modified liposomes showed enhanced transport across in vitro BBB 
model and significantly decreased the C6 glioma tumor volume in rat models (Ying et al. 2010). 
A recent report showed the comparison of five different targeting ligands (transferrin, RI7217, 
COG133, angiopep-2, and CRM197) in improving the brain delivery of liposomes (Rooy et al. 
29 
 
2011).  RI7217 is the antibody targeted to mouse transferrin receptors, COG133 is an apo-E 
mimetic peptide targeted to the low density lipoprotein receptors (LDLR) on the surface of BBB, 
angiopep-2 can bind to the LDLR-related protein on the brain endothelial cells and CRM197 can 
bind to the Diphtheria toxin receptor (DTR). The results indicated that only CRM197 was able to 
bind to the brain endothelial receptors in vitro while RI7217 showed maximum uptake into brain 
in vivo.  
Liposomes can be functionalized with one or more ligands for improving the delivery of 
the encapsulated drug or plasmid to specific cells. Conjugating to multiple ligands can help 
perform multiple functions, e.g. one vector can facilitate brain tissue targeting and another ligand 
can induce cellular uptake and/or intracellular translocation to specific cell compartments like 
nucleus for delivery of pDNA (Tan et al. 2003).  
1.3. Cell penetrating peptides (CPPs) 
Cell-penetrating peptides (CPPs) are short cationic or amphipathic peptides that have the 
ability to transport the associated molecular cargo (e.g., peptides, proteins, oligonucleotides, 
liposomes, nanoparticles, bacteriophages, etc.) inside the cells (Sharma et al. 2012). Biological 
evolution has conferred certain proteins with an ability to penetrate the cell membrane due to the 
presence of specific peptide sequences called protein transduction domains (Schmidt et al. 2010). 
The peptide sequences constituting these domains carry basic amino acids and possess cell 
penetrating properties, thus, these peptides are referred to as cell penetrating peptides (CPPs). 
Over the past decade, there has been a vibrant increase in the application of these CPPs for the 
delivery of cargo molecules inside the cells (Snyder et al. 2004).These peptide sequences have 
been utilized for the delivery of various molecules like proteins, nucleic acids, liposomes, and 
nanoparticles across the cell membrane (Lewin  et al. 2000; Torchilin  et al. 2001; Torchilin  et 
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al. 2003; Huwyler  et al. 1996). The profound interest evoked by the CPPs among the scientists is 
not only attributed to their ability of crossing the cell membrane via receptor and energy-
independent processes but also their capacity to efficiently internalize the associated 
biomolecules without compromising with the biocompatibility (Trabulo et al. 2010). Various 
CPPs such as poly-L-arginine (PR), transactivator of transcription peptide (TAT), and penetratin 
have been conjugated to the delivery vectors to improve the delivery of therapeutic molecules 
(Kibria et al. 2011; Cheng et al. 2007). 
1.3.1. Poly-L-arginine 
Polyarginine is a synthetic cationic peptide consisting of 8 or more arginine residues and 
has been used to facilitate intracellular translocation of a wide variety of molecular cargo 
(Sharma et al. 2012; Sharma et al. 2013). This cell penetrating peptide has been used for delivery 
of cargo such as liposomes, nucleic acids, nanoparticles etc. into the cells. Kibria et al., (Kibria et 
al. 2011) showed that dual modification of liposomes with polyarginine and cyclic RGD (Arg-
Gly-Asp) peptide significantly increased the transfection efficiency of liposomes in Integrin 
α(v)β(3) expressing cells. Later, Opanasopit et al., (Opanasopit et al. 2011) demonstrated 
considerable improvement in transfection efficiency of liposomes after coating with poly-L-
arginine.  A previous report, provided a deeper insight into the interaction of cationic peptides 
with the phospholipid bilayer during the surface adsorption of positively charges amino acids 
onto the liposomal surface (Disalvo et al. 2012). The results showed that the adsorption of 
cationic amino acids, like arginine was not only driven by electrostatic interactions but also by 
polarization forces and caused  surface rearrangements in the phospholipid membrane. Zhang et 
al., (Zhang et al. 2006) showed that siRNA containing octarginine modified liposomes efficiently 
inhibited the targeted gene and significantly reduced the tumor cell proliferation. 
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1.3.2. HIV-1 trans-activator of transcription (TAT) peptide 
TAT is a protein encoded by the TAT gene of HIV-1. TAT was discovered with the 
emergence of various CPPs of natural (AntP/Penetratin) and synthetic origin (Mastoparan/ 
transportan) that have been alternatively termed as protein transduction domains (PTDs) (Mae et 
al. 2009; Ziegler et al. 2005).  Over the recent years, TAT peptide has gained significant 
attention in the field of nucleic acids and drug delivery. A previous study compared the 
transfection efficiencies of SLN gene delivery vector and polyethylenimine (PEI), in vitro and in 
vivo. The presence of TAT significantly enhanced the gene expression of SLNs in different cell 
lines as compared to the PEI nanoparticles (Rudolph et al. 2004). Another group of scientists 
reported efficient gene delivery using TAT peptide functionalized polymeric nanoparticle 
complexes into undifferentiated and differentiated SH-SY5Y cells (Suk et al. 2006).  TAT 
peptide modified liposomes showed considerable improvement in the delivery of plasmid 
encoding green fluorescent protein (pGFP) to human brain tumor U-87 cells in vitro and 
intracranial tumor mice model (Gupta et al. 2007). TAT modified liposomes synthesized with 
small quantities of the cationic lipid DOTAP showed substantially higher gene expression levels 
in mouse fibroblast NIH3T3 and cardiac myocytes H9C2 cells and lower cytotoxic potential as 
compared to the commercially available transfecting reagent Lipofectin® (Torchilin et al. 
2003;Wallje et al. 2005). Despite the large area of application of the TAT peptide, the exact 
mechanism of their cellular internalization still appears controversial. Variable results illustrating 
different mechanisms of uptake can result from variation in different experimental factors like 
wide range of the sequences of TAT peptide used, variable cell lines and different protocols for 
investigation of the mechanism of entry which can influence the mechanism of internalization of 
TAT peptide. 
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1.3.3. Penetratin 
 Penetratin is a 16-amino acid basic cationic CPP, derived from Antennapedia 
homeodomain, which is capable of inducing the cell uptake of a large variety of molecular cargo 
(Wallje et al. 2005). The peptide is translocated across the cell membranes by the third -helix 
of the homeodomain of Antennapedia, known as penetratin. Previous biophysical studies have 
shown that even though the entry of this peptide requires initial binding to the cell membrane, 
binding and translocation are differentially affected by the amphiphilic nature and net charge of 
the peptide. Also, the internalization of penetratin is affected by the lipid composition of the 
plasma membrane (Drin et al. 2001; Scheller et al. 2000). A group of researchers showed that the 
presence of negatively charged lipids in the membrane promote the transfer of penetratin from 
hydrophilic to hydrophobic environment likely via charge neutralization. They showed that the 
transfer of penetratin can also occur in the absence of the negatively charged lipid by adding 
DNA oligonucleotides, by the same mechanism. Their findings further confirmed that charge 
neutralization and phase transfer represented only the initial step of internalization while further 
uptake required the presence of tryptophan at position 6 of the peptide (Dom et al. 2003). 
Previous study showed enhanced accumulation of penetratin functionalized PEG-PLA 
nanoparticles in rat brain and low uptake by non-specific organs as compared to the protamine 
conjugated nanoparticles (Xia et al. 2012). Another group of researchers showed improved 
transfection efficiency of penetratin conjugated polymethacrylates as compared to PEI-
polymethacrylates and comparable to the gene expression of lipofectamine® (Christiaens et al. 
2005). Conjugation of penetratin with elastin like polypeptides showed maximum reduction in 
growth and proliferation of SKOV-3 and HeLa cells (Massodi et al. 2005). 
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1.3.4. Mastoparan 
Mastoparan is a 14-residue peptide from wasp (vespulalewisii) venom and belongs to a 
class of peptides that are more amphipathic (Yandek et al. 2007; Ha¨llbrink et al. 2001). This 
peptide has been used in the construction of 21 residue peptide transportan 10 (TP10) which has 
been widely investigated in the delivery of cargo like proteins into the cells (Pooga et al. 2001).  
The use of this amphiphilic peptide is restricted due its cytolytic effects (Deshayes et al. 2005; 
Saar et al. 2005; Cardozo et al. 2007). Previous reports have indicated the application of 
mastoparan peptide for mitochondrial delivery causing increased apoptosis of tumor cells 
(Pfeiffer et al. 1995;Hirai et al. 1979). Yamada et al., reported that the peptide caused increased 
permeability of mitochondrial membrane causing leakage of components from the mitochondrial 
matrix eventually leading to apoptosis of tumor cells (Yamada et al. 2008). Another report, 
showed that presence of mastoparan peptide, Transportan 10 (Tp10), significantly increased the 
transfection efficiency of PEI. Also, low concentration (0.6nM)  of Tp10 conjugates with DNA 
showed efficient gene expression in HeLa cells and Murine fibroblast C3H 10T1/2 cells(Kilk et 
al. 2005). 
1.4. Drug delivery to brain 
 The presence of multiple endogenous transporters and tight junctions in brain capillary 
endothelial cells restricts the transport of many essential therapeutic molecules across BBB thus 
posing a great challenge to treatment of CNS related disorders. Passive diffusion of the 
systemically administered therapeutic molecules across the BBB depends on the lipophilicity and 
the molecular weight of the drug (Ren et al. 2012).  However, a large number of drugs that have 
very low molecular weight and high lipophilicity are also pumped back into the blood stream  by 
the efflux pumps like multiple organic anion transporter (MOAT) especially the P-glycoprotein 
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(Pgp) or the multidrug resistance protein (MDR) (Begley 1996). In addition, the tight junctions 
between the endothelial cells of brain capillaries result in a very high electrical resistance across 
the brain endothelial barrier (around 1500-2000 cm2) as compared to the other body tissues 
(approximately 33.3 cm2) (Crone and Cristensen, 1981; Crone and Olesen, 1982).  This has 
necessitated the need for developing efficient drug delivery approaches like targeted 
nanoparticles, liposomes etc. Poly (butyl cyanoacrylate) is one the earliest and efficient, 
biodegradable and biocompatible polymer that has been used in forming nanoparticles for 
improving the delivery of water soluble drugs to brain (Grislain et al. 1983; Couvreur et al. 
1986).  Dalargin, a hexapeptide (Tyr-D-Ala-Gly-Phe-Leu-Arg) with opioid activity was the first 
drug delivery to brain using systemically administered poly (butyl cyanoacrylate) nanoparticles 
(Alyautdin et al. 1995; Kreuter et al. 1995). The dalargin loaded nanoparticles showed improved 
brain delivery and antinociceptive activity, demonstrated by the hot plate and tail flick test, as 
compared to the control groups (Alyautdin et al. 1995; Kreuter et al. 1995; Schroeder et al. 1996; 
Ramge et al. 1999).  Another study compared the development of epileptic spikes after brain 
perfusion of tubocurarine and after intraventricular injection of this drug. No spikes were 
observed after addition of the drug to the perfusate. In contrast adding of polysorbate 80 coated 
poly(butyl cyanoacrylate) nanoparticles loaded with tubocurarine resulted in  the development of 
frequent severe spikes in the EEC comparable to those developed after intraventricular injection 
of the drug (Alyautdin et al. 1998).  
 Certain receptors that are present in high concentrations on the surface of tumor cells can 
be used for delivering the desired therapeutic agents via active targeting of these receptors 
(Gutman et al. 2000). Low density lipoprotein (LDL) receptors are usually overexpressed in 
tumors cells like gliomas and this helps in realizing the therapeutic advantage of the LDL 
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targeted delivery vehicle (Yamamoto et al. 1997). Gutman et al. developed boronated LDL by 
modifying the cholesterol group of the LDL and utilized this molecule for active targeting of 
LDL receptors during boron neutron capture therapy (BNCT) of glioma cells (Gutman et al. 
2000).  The results showed that the boronated LDL not just accumulated around the tumor but 
showed considerable internalization into the tumor. Transferrin is an 80kDa serum glycoprotein 
that facilitates the transport of iron into cells. It is transported across the cell membranes via 
transferrin receptor mediated transcytosis (Yoon et al. 2009). A group of researchers utilized the 
occurrence of transferrin receptors on the surface of brain endothelial cells for active brain 
targeting of the liposomes (Sharma et al. 2013). The liposomes were surface modified with 
transferrin protein for targeting the brain endothelial receptors and were additionally conjugated 
to CPP for improving their internalization into brain by overcoming receptor saturation. The 
results showed about 8 fold higher penetration of the liposomes into brain as compared to the 
unmodified liposomes.  Many metabolic sugars and amino acids are able to cross the BBB via 
specific carrier mediated transport systems that exist on both the luminal (blood side) and 
abluminal (brain side) of the brain endothelial cells (Béduneau et al. 2007).  Glucose transporter 
(GLUT) system is one such transporter of sugars into brain. The GLUT1 isoform exists on the 
luminal surface of the brain endothelial cells and has been reported to possess the potential of 
enhancing the transport of carriers into brain (Tsuji 2005; Pardridge et al. 1990). GLUT1 has 
been reported to facilitate the transport of sugars with structures similar to glucose like 2-
deoxyglucose, galactose and mannose analogs (Pardridge 1995). A recent study reported dual-
modified liposomes surface modified with  a mannose analog,  p-aminophenyl-α-D-manno-
pyranoside (MAN) for targeting GLUT1 receptors and transferrin protein targeted to  transferrin 
receptors on the brain endothelium for improving the delivery of the anticancer drug, 
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daunorubicin,  into brain (Ying et al. 2010). The results showed that the dual-modified 
daunorubicin liposomes were able to improve the therapeutic efficacy of the drug after 
intravenous administration of the daunorbicin encapsulating liposomes. The C6 glioma tumor 
volume was reduced to 54.7% and the median survival time of the tumor bearing rats (22 days) 
was significantly longer than the rats administered with free daunorubicin (17 days, p= 0.001). 
 Effective brain targeting requires high selectivity of the BBB receptors which means that 
ideally the receptor should be expressed preferentially on the BBB. However, most of the 
receptors are nearly non-specific and therefore, limit the highly selective targeting of the delivery 
vectors to brain. More efforts need to be focused on exploring the BBB biology and occurrence 
of receptors that can be utilized for active targeting of therapeutic agents. 
1.5. Gene delivery to brain 
 Gene therapy is an effective tool for providing lasting and notable treatment for genetic 
disorders like cystic fibrosis, combined immunodeficiency syndrome and many cancers that 
result from the presence of defective genes (Cavazzana-Calvo et al., 2000; Cavazzana-Calvo et 
al., 2001; Cavazzana-Calvo et al., 2007). Considering the remarkable progress in the 
development of efficient gene transfer vectors leading to safer transduction and robust transgene 
expression coupled with increased understanding of the molecular mechanisms of neurological 
and other CNS disorders, it is rational to believe that gene therapy can play an inevitable role in 
the treatment of CNS diseases by introducing genes into brain (Manfredsson et al. 2010; 
Costantini et al., 2007). Gene therapy can be used for the treatment of a wide range of CNS 
disorders like neurodegenerative diseases by increasing the expression of growth factors, anti-
apoptotic molecules or antioxidants (Costantini et al., 2007; Bowers  et al., 1997; Raymon et al., 
1997); it can reduce the proliferation of tumor cells by producing anti-angiogenic factors or by 
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down regulating the expression of certain genes using antisense or siRNA (Carter et al., 1999; 
Fueyo et al., 1999; Boviatsis et al., 1994; Haque et al., 1997). However, the major challenge 
faced by the scientific community lies in the safe and efficient delivery of therapeutic genes to 
the brain. The transport of therapeutic agents to brain is largely inhibited by the BBB after 
intravenous administration.  Nucleic acids are commonly administered for gene therapy via 
craniotomy or intracerebral injections which are extremely invasive and are useful only for local 
gene delivery (Schlachetzki et al. 2004; Pardridge et al. 2002). In contrast, the delivery of genes 
via viral and non-viral vectors leads to widespread gene expression throughout the CNS, post 
intravenous administration (Pardridge et al. 2001).  The usefulness of a viral vector is based on 
the ratio of cytopathic effects to beneficial effects of the transgene. Previous reports indicate the 
complexity associated with generation of non-toxic replication defective viral vectors that caused 
neuronal cytotoxicity in vitro (Johnson et al. 1992). Local injection site toxicities were evident as 
necrosis accompanied with inflammation and gliosis during in vivo studies (Isacson 1995). 
In mid 1990s the number of gene therapy clinical trial reached an average of 100 per year, 
however with the death of a patient, enrolled in an experiment for deficiency of ornithine-
transcarbamylase using adenoviral vector, in 1999 and the development of leukemia in two 
pateints with SCID-X1 treated with gamma retroviral vector, the number of such trials declined 
significantly (Marshall 1999 and Buckley 2002).  
Considering the side effects of viral vectors, the efforts for achieving safe and efficient 
gene delivery are focused on developing non-viral vectors. RVG29 is a 29-residue peptide 
derived from the rabies virus glycoprotein (RVG) that has been shown to specifically bind to 
neuronal cells expressing the nicotinic acetylcholine receptor (AchR) (Lentz et al. 1982).  Also, 
the presence of AchRs on brain capillary endothelial cells facilitates the transport of RVG 
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peptide via receptor mediated transcytosis (Liu et al. 2009; Lafon 2005). A previous report 
showed efficient gene expression in neuro2a cells after transfection with pGFPpolyplexed 
RVG29-octarginine polymer (Gong et al. 2012). In addition, the polymer complexed with 
luciferase expressing plasmid (pGL3) showed 3fold higher gene expression in mice brain after 
intravenous administration as compared to the control administered with plasmid alone.  Another 
recent study demonstrated successful delivery of desired gene to mouse brain using RVG peptide 
conjugated bioreduciblepolyethylenimine  polymeric vectors (Son et al. 2011).The complexes 
showed efficient in vitro biocompatibility. Polymeric complexes containing 30µg of pDNA 
expressing red fluorescence protein (CMV-RFP) showed efficient gene expression in brain. 
Furthermore, PEG conjugated RVG tethered complexes showed 1.3 fold higher gene expression 
in mouse brain as compared to the non-RVG tethered Pegylatedpolyplexes. A group of 
researchers showed efficient targeted gene delivery using PEGylatedpoly(2-(dimethylamino) 
ethyl methacrylate)/DNA polyplex micelles surface modified with phage-displayed TGN peptide 
(Qian et al. 2013). The polyplex micelles were non-cytotoxic and demonstrated efficient cell 
uptake and transfection, in vitro as compared to the control polyplexes without the targeting 
peptide. In addition, the TGN peptide conjugated micelles showed 3 fold higher gene expression 
in brain as compared to the control group. Another group of scientists investigated lactoferrin 
modified nanoparticles for gene delivery to brain (Huang et al. 2010). The researchers utilized 
the brain targeting ability of lactoferrin protein for delivery across BBB. The nanoparticles 
loaded with ethidiummonoazide bromide (EMA)-labeled pGL2- control plasmid vector were 
injected into nude mice and the distribution of the nanoparticles was assessed after 4h using Cri 
in vivo imaging. The lactoferrin modified nanoparticles showed lower accumulation in peripheral 
organs like liver and improved transport to brain as compared to the unmodified nanoparticles. 
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Furthermore, the lactoferrin targeted nanoparticles showed higher pGFP (green fluorescent 
protein expressing plasmid) expression in the mid brain sections of balb/c mice as compared to 
the control nanoparticles.  
Gene therapy for disorders of central nervous system is currently under investigation and 
the clinical trials are aimed at slowing of disease progression and safe and effective treatment of 
genetic abnormalities. With the advancement in the understanding of molecular mechanism 
underlying various neurological disorders and development of efficient gene transfer system, the 
success of focal and global delivery of therapeutic genes to brain appears realizable. Limitations, 
such as stability and regulation of transgene expression and safety of both vector and the 
expressed transgene are still evident. Furthermore, the heterogeneity of cell types and the 
existence of post mitotic cells present several challenges in successful delivery of gene to brain. 
Considering these factors, it is highly probable that successful delivery of genes for treatment of 
CNS disorders will require multiple modes of gene delivery and collaborative efforts between 
basic researchers and clinical scientists. 
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Table 2. Drug and gene delivery vectors for transport across BBB 
Nanoparticles for brain 
delivery  
Properties References 
Bolaamphilic cationic 
vesicles 
High serum stability, efficient 
cell uptake and improved brain 
targeting 
Dakwar et al. 
2012;Philosof-Mazor 
et al. 2013  
Poly(lactide-co-
glycolide) (PLGA) 
nanoparticles 
Biocompatible, biodegradable, 
efficient cellular uptake and 
delivery of therapeutic agents 
into cells  
Jalali et al. 201; Seju 
et al. 2011 
Angiopep-conjugated 
nanoparticles 
Internalization by brain capillary 
endothelial cells, efficient cell 
uptake, transport across BBB and 
gene expression. 
Ke et al. 200; Shao et 
al. 2010 
CPP modified Tf-
liposomes 
Biocompatible, efficient cell 
uptake, transfection, transport 
across BBB in vitro and in vivo. 
Sharma et al. 2012; 
Sharma et al. 2013 
RVG peptide conjugated 
nanocarriers 
High serum stability, 
biocompatibility, efficient 
transfection in vitro and in vivo 
Kim et al. 2013; Son 
et al. 2011 
Solid lipid nanoparticles 
Biocompatible, efficient cell 
uptake and drug delivery in vitro, 
efficient brain delivery in vivo 
Martins et al. 
2012;Venishetty et a. 
2013;Madan 2013  
TAT-liposomes 
Efficient cell uptake, low 
cytotoxicity, improved brain 
targeting and penetration  
Wang et al. 2012; Qin 
et al. 2011 
Surfactant coated 
nanoparticles 
Efficient brain penetration and 
improved therapeutic efficacy. 
Borchard et al. 
1983;Kreuter et al.  
1997; Wilson et al. 
2008   
Antibody conjugated 
nanoparticles 
Significantly enhanced brain 
delivery, biocompatible, 
improved therapeutic efficacy 
Pang et al. 2008; 
Fengetal. 2009;Furrer 
et al. 2009 
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1. 6. Statement of problems and research objectives 
 Over the recent years, there has been a considerable progress in the field of neuroscience 
leading to an improved understanding of disorders of central nervous system (CNS). In contrast, 
the development of successful strategies for treating these disorders is limited due to the 
protective function of blood brain barrier (BBB). The formidable challenge of delivering an 
effective therapeutic agent to brain requires collaborative multidisciplinary efforts that take into 
consideration the blood brain barrier (BBB) biology as well as the study of basic transport 
mechanisms for delivery to brain. There are about 100 billion capillaries in the human brain with 
a surface area of approximately 20 m
2
 that constitute the BBB (Sharma et al. 2013; Chen et al. 
2012; Pardridge et al. 2003). The occurrence of specific receptors on the surface of BBB 
facilitates the transport of various essential molecules into the brain. Transferrin receptor 
mediated transcytosis is the most well characterized system for transport of iron to brain 
(Pardridge et al. 2005). In addition, the transferrin receptors on the surface of brain endothelial 
cells have been widely explored for targeting various drug delivery systems to brain (Chena et al. 
2010; Xie et al. 2005; Sharma et al. 2012).  
Liposomes, being functionally versatile, can be engineered for targeting these receptors, 
thereby rendering them as promising carriers for drug and gene delivery (Peer et al. 2007). 
Nevertheless, this receptor facilitated uptake, being disposed to receptor saturation cannot 
provide adequate transport of ligand conjugated liposomes into the cells and lowers the 
therapeutic effect of the encapsulated agent (Huwyler et al. 1996). Therefore, in this study we 
have conjugated the liposomes with two ligands (1) a receptor targeting protein (transferrin) and 
(2) a cell penetrating peptide (Poly-L-arginine, HIV-1 TAT, Penetratin and Mastoparan). We 
hypothesize that a combination of these two ligands on PEGylated liposomes will enhance their 
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ability to penetrate the BBB and transfect the desired cells via receptor targeting and improved 
cell penetration. Our primary aims are: (I) to synthesize and evaluate dual-modified PEGylated 
liposomal delivery system, surface modified with transferrin and cell penetrating peptide (Tf-
CPP-liposomes), in vitro (II) To investigate the bio-distribution, transfection and 
biocompatibility of the dual-modified delivery system in vivo.   
The long term objective of our research is to design a vector for efficient delivery of 
therapeutic agents to brain. Specifically, our research work is focused on designing PEGylated 
liposomes surface modified with transferrin and a cell penetrating peptide for enhancing the 
delivery of desired therapeutic agent to brain. The contribution is significant because this is the 
first step in the continuum of research that is expected to illustrate the influence of grafting the 
targeted liposomal delivery vector to cell penetrating peptide and forming near neutral vesicles 
for improving the delivery of therapeutics across BBB. 
1.6.1. Specific aim 1 
1.6.1.1. To synthesize bi-functional liposomes targeted to brain endothelial cells  
Lipid-based nanocarriers for drugs/genes, e.g., liposomes, can alter the disposition and 
improve the utility of variety of therapeutic agents. Several ligands like transferrin, monoclonal 
antibodies or peptides can be conjugated to PEG moieties on liposomal surface for active 
targeting of desired cells (Huwyler et al. 1996, Oba et al. 2007). In our study, we propose to 
conjugate transferrin-coupled liposomes to a CPP (i.e. short cationic or amphipathic peptides that 
have the ability to transport the associated molecular cargo such as oligonucleotides, liposomes, 
nanoparticles etc. inside the cells) (Bolhassani et al. 2011). The bi-functional liposomes were 
synthesized using post-insertion technique. Transferrin, being negatively charged protein 
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molecule, balanced the positive charge of cell penetrating peptides thereby imparting a near 
neutral charge (zeta potential in the range of 0-15 mV) to the liposomal vector.  
1.6.1.2. To evaluate the biocompatibility, transfection efficiency, cellular uptake and of the 
bi-functional liposomes, in vitro 
The efficiency of the delivery vector lies not only in its ability to carry the encapsulated 
agent into the desired cells but also its biocompatibility at the concentrations used. We evaluated 
the cytotoxic potential of bi-functional liposomes, in various tumor (e.g. Daoy, U87) and brain 
endothelial (bEnd3) cell lines using MTT assay. Hemolysis assay was performed to authenticate 
the biocompatibility of liposomes for in vivo administration. We also investigated the uptake of 
DiR (near infra-red indicarbocyanine) dye labeled and doxorubicin encapsulating liposomes and 
the transfection efficiency of Green fluorescent protein (GFP) plasmid encapsulating liposomes 
in these cell lines. A comprehensive investigation of the mechanism of cell uptake was also 
performed in different cell lines (U87, Daoy and brain endothelial cells) using various inhibitors 
like chlorpromazine, colchicine, methyl-β-cyclodextrin, amiloride and low temperature (4°C).  
1.6.1.3. To design 2 dimensional (2D) BBB model and 3- (3D) in vitro brain tumor model 
and evaluate the transport of liposomes across the barrier layer  
   The transport of DiR labeled liposomes was evaluated across 2D BBB model that will be 
designed by co-culture of brain endothelial and primary glial cells on opposite sides of culture 
inserts. Despite the dubiousness associated with the feasibility of developing an in vivo brain 
tumor model, very little or no research has been done to develop efficient in vitro brain tumor 
models where the transport to the tumor is regulated via the endothelial barrier. Therefore, we 
designed an in vitro brain tumor model using biodegradable chitosan-PLGA scaffolds where the 
transport of liposomes to the 3-dimensional tumor was regulated via the endothelial cells 
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cultured on transwell inserts. We developed the 3D in vitro brain tumor model using PLGA 
based scaffold for culture of tumor cells (glioblastoma). The porous structure of the scaffold 
supports the growth of tumor cells in a 3-dimensional environment (Kim et al. 2005). 
Reportedly, the cells attach to the intertwined scaffold fibers and fill the spaces/pores within the 
scaffold to form 3D tumor (Sourla et al. 1996;  Bell et al. 1995). These 3D tumors, cultured on 
the scaffold, were combined with the 2D BBB model. 
1.6.2. Specific aim 2 
1.6.2.1. To evaluate the in vivo biodistribution of bi-functional liposomes  
    The in vivo evaluation of the delivery vectors is essential for clinical translation. The 
presence of high serum concentrations and non-specific binding to extracellular components can 
interfere with the in vivo performance of the delivery vector.  Therefore, considering the 
complexity of in vivo environment, we investigated the ability of dual-modified liposomes to 
target brain and deliver the desired gene across BBB, in vivo. Biodistrbution of DiR labeled and 
doxorubicin encapsulating liposomes was evaluated in adult Sprague Dawley rats. Additionally, 
we evaluated the in vivo transfection efficiency of β-gal encapsulating liposomes in adult SD rats 
after intravenous administration. The in vivo biocompatibility of the dual-modified liposomes 
was assessed by histological evaluation of the transfected tissue sections from different organs. 
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CHAPTER II. MATERIALS AND METHODS 
2.1. Materials 
The materials used are listed in table 3. 
2.2. Cell culture 
Primary glial cells were isolated from 2 to 3 weeks old rats (details of the method are 
provided in supporting information). Brain endothelial (bEnd.3) cells were obtained from 
American Type Culture Collection (ATCC, Rockville, Maryland). Human medulloblastoma 
(Daoy) and glioblastoma (U87) were obtained from Dr. Erxi Wu’s laboratory (Department of 
Pharmaceutical Sciences, North Dakota State University). All cell types were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% FBS and 1% Psf in an atmosphere of 
5% carbon dioxide (CO2) at 37C. 
2.3. Animals 
All animal experiments were conducted as approved by the Institutional Animal Care and 
Use Committee (IACUC) at North Dakota State University (Protocol #A12024). Adult Sprague-
Dawley (SD) rats were used to evaluate the biodistribution, transfection efficiency, and 
biocompatibility of liposomes. The animals were housed under controlled temperature conditions 
with 12 h light and dark cycles and were allowed free access to food and water. 
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Table 3. List of materials and their sources 
 
Material Company and location 
Alexa-Fluor 594 goat anti-rabbit IgG Abcam Inc. (Cambridge, MA) 
Alexa-Fluor 488 goat anti-mouse IgG Abcam Inc. (Cambridge, MA) 
Amiloride hydrochloride Sigma-Aldrich Co. (St. Louis, MO) 
Anti-transferrin receptor antibody (OX26) Abcam Inc. (Cambridge, MA) 
β-galactosidase assay kit Promega Corp. (Madison, WI) 
Chlorpromazine HCl Enzo Life Sciences (Farmingdale, NY) 
Cholesterol Sigma-Aldrich Co. (St. Louis, MO) 
Colchicine Enzo Life Sciences (Farmingdale, NY) 
Cytoseal 60 
Thermo Fisher Scientific Inc., Barrington, 
IL) 
1,1’-dioctadecyl-3,3,3’3’-
tetramethylindocarbocyanineperchlorate 
(DiI) 
Invitrogen (CA) 
1,1'-dioctadecyl-3,3,3',3'-tetramethyl-
indocarbocyanine iodide (DiR) 
Invitrogen (CA) 
1,2-Dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) 
Avanti Polar Lipids (Birmingham, AL) 
1,2-dioleoyl-3-trimethylammonium-
propane chloride (DOTAP) 
Avanti Polar Lipids (Birmingham, AL) 
1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-
[carboxy(PEG)2000](DSPE–PEG–
COOH) 
Avanti Polar Lipids (Birmingham, AL) 
3-(4,5-dimethylthiazol-2-yl) -2,5-
diphenyltetrazolium bromide (MTT) 
Sigma-Aldrich Co. (St. Louis, MO) 
Dulbecco’s modified Eagle medium 
(DMEM) 
ATCC, Rockville, MD 
Eosin Y Alfa Aesar (Ward Hill, MA) 
1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC·HCl) 
Creosalus Inc. (Louisville, KY) 
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Table 3. List of materials and their sources (continued) 
 
Material Company and location 
Ethylenediaminetetraacetic acid (EDTA) Sigma–Aldrich Co. (St. Louis, MO) 
Fetal bovine serum (FBS) ATCC, Rockville, MD 
gWiz™-GFP (Plasmid encoding green 
fluorescent protein) 
Aldevron LLC (Fargo, ND) 
Harris Hematoxylin solution Sigma-Aldrich Co. (St. Louis, MO) 
HIV-1 TAT peptide Sigma-Aldrich Co. (St. Louis, MO) 
Hoechst 33342 dye Anaspec (Fremont, CA) 
Mastoparan Anaspec (Fremont, CA) 
N-Hydroxysuccinimide (NHS) Alfa Aesar (Ward Hill, MA) 
Penetratin Anaspec, Inc. (Fremont, CA) 
Penicillin-streptomycin-Fungizone (Psf) United Biochemical (Sanborn, NY) 
Phloxine B Spectrum® (New Brunswick, NJ) 
Phosphate buffered saline (PBS) ATCC, Rockville, MD 
Polyethylene terephthalate (PET) 
transwellculture inserts 
BD BioCoat™ ;BD Biosciences (NC) 
Poly-L-arginine hydrochloride (Mwt. 
13,300 Da) 
Sigma–Aldrich Co. (St. Louis, MO) 
Poly (lactic-co-glycolide) (50:50; PLGA) Polyscitech (West Lafayette, IN) 
Tissue lysis/protein extraction buffer Fab Gennix International, Frisco, TX 
Tissue-Tek® OCT™ Compound Sakura Finetek Inc., (Torrance, CA) 
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2.4. Experimental methods 
2.4.1. Preparation of Tf-PR-liposomes 
2.4.1.1. Preparation of PR-coupled liposomes 
 Poly-L-arginine was coupled to DSPE–PEG phospholipid as previously reported and 
coupling was confirmed using 1H NMR technique (Kim et al. 2010). Briefly, the primary amino 
group of poly-L-arginine was coupled to the linker phospholipid, DSPE-PEG-COOH via 
EDC/NHS reaction to form the poly-L-arginine coupled lipid (DSPE-PEG-PR). The PR–PEG–
lipid was then combined with other lipids, in the following molar ratio: DOPE/DOTAP/PR–
PEG–lipid/ cholesterol 45:45:4:2 mol % in chloroform/methanol (2:1) solution and dried on a 
rotavapor to form a thin film of lipids. For preparation of DiI-labeled liposomes, 0.5 mol % of 
the dye was added to the lipid mixture prior to formation of thin lipid film.The lipid film was 
hydrated using 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-buffered saline (pH 
7.3) Plasmid GFP polyplexes (GFP-chitosan) were added to the hydration buffer at N/P ratio of 5 
for encapsulation into liposomes. 
2.4.1.2. Preparation of Tf–PR liposomes 
Bi-functional liposomes were prepared using post-insertion technique (Visser et al. 
2005).Tf was coupled to the phospholipid DSPE–PEG–COOH as reported previously (Li et al. 
2009). Briefly, DSPE–PEG–COOH (remaining 4mol%of the total phospholipid content)was 
suspended in HEPES buffered saline (pH 5.0) to form micelles. The micellar suspension was 
then treated with 360 µl of both EDC (0.5 M in H2O) and NHS (0.5 M in H2O) per 10µmols of 
the phospholipid. Excess EDC was removed by dialysis and pH of the micellar suspension was 
adjusted to 7.3 with 0.1 N sodium hydroxide. Tf (125 µg/µmol of the lipid) was added to the 
resulting suspension and stirred at 25°C for about 8 h. The resulting Tf micelles were stirred 
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overnight with PR liposomes at room temperature and the final liposomal suspension was passed 
through Sephadex G-100 column. 
2.4.2. Preparation of Tf-CPP (Tf-TAT, Tf-Penetratin, Tf-Mastoparan) liposomes 
The dual-functionalized liposomes, conjugated with TAT, Penetratin or Mastoparan, 
were prepared using post insertion technique as described above for preparation of Tf-PR 
liposomes. Briefly, the primary amine group of the CPPs was terminally conjugated to 
EDC/NHS activated DSPE-PEG2000-COOH. The DSPE-PEG-CPP was then mixed with other 
phospholipids DOPE/DOTAP/cholesterol in chloroform: methanol (2:1) and dried to form a thin 
lipid film. The thin film was then hydrated using Hepes buffered saline, pH 7.4 to form 
CPPcoupled liposomes (CPP-liposomes). Transferrin was coupled to the distal end of DSPE-
PEG-COOH via EDC/NHS reaction to form Tf-micelles. The CPP-liposomes were then stirred 
overnight with Tf-micelles at room temperature to form Tf-CPP-liposomes. The free Tf-micelles 
were separated from the Tf-CPP liposomes by passing the liposomes through sepahadex G-100 
column 
2.4.3. Loading of doxorubicin into Tf-CPP-liposomes 
Doxorubicin encapsulating liposomes were generated using pH gradient drug loading. 
The thin phospholipid film was hydrated using citric acid buffer, pH 5.0 (to form CPP-
liposomes) followed by stirring with Tf-micelles in the citric acid buffer. The final liposomes 
were passed through sephadex G-100 column pre-equilibrated with Hepes buffered saline, pH 
7.4 to remove any extra liposomal Tf-PEG-lipid and to exchange the extra liposomal citric acid 
buffer with the Hepes buffered saline. Therefore a pH gradient was generated between the outer 
aqueous buffer at pH 7.4 and the intra liposomal citric acid buffer at pH 5.0. The drug 
doxorubicin was added to the liposomal suspension and incubated at 50°C for 60 min. The drug 
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loaded liposomes were then cooled to room temperature and passed through sephadex columns 
to remove the unencapsulated drug. Encapsulation efficiency of the liposomes was determined 
using high performance liquid chromatography (HPLC). A solution of 10μl of the liposomes, 
before and after passing through the column, was prepared in 380μl of phosphate buffer (pH 5.5) 
with 10μl of 0.1%tritonX-100 and 100μl of methanol. The samples were analyzed using HPLC 
system equipped with UV-visible detector (Yamano et al. 2011). The analysis was performed at 
a wavelength of 234 nm using C18 column and phosphate buffer pH 5.5: Acetonitrile (75:25) 
mixture as mobile phase with a flow rate of 0.5 ml/min. In addition, doxorubicin release studies 
were performed by diluting the liposomal samples in PBS with 10% FBS and incubating the 
samples at 37°C (Supplementary Material Fig. S10). Samples were withdrawn at different time 
points, passed through sephadex columns and analyzed using HPLC. 
2.4.4. Physical characterization of liposomes 
2.4.4.1. Characterization of Tf-PR-liposomes 
We evaluated the morphologic appearance and shape of liposomes with and without Tf 
and PR conjugation using AFM (VeecoDI-3100 Veeco, St Paul, MN) (Anabousi et al. 2000; 
Nakano et al. 2008). Freshly cleaved mica(grade V-4; 15 × 15 × 0.15 mm
3
) was used as a 
substrate for AFM imaging. The liposomal suspensions were diluted with HEPES-buffered 
saline (pH 7.4). Approximately, 10µl of the diluted suspension was placed on the surface of thin 
mica film followed by air drying. Images were recorded in tapping contact mode at scan rate and 
scan size of 1Hz and 1µm, respectively. The average hydrodynamic diameter and zeta potential 
of liposomes were determined using Zetasizer Nano ZS 90 (Malvern Instruments, 
Worcestershire, UK) at 25°C. The Tf content of the liposomes was determined using micro 
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bicinchoninic acid (BCA) assay (PR liposomes were used as control). Pure bovine serum 
albumin was used as a standard.  
Additionally, we determined the pDNA (β-gal plasmid) loading efficiency of liposomes. 
Briefly, 100 μl of the liposomal suspension was diluted (1:3) with HEPES buffered saline, pH 
7.4. The evaluation of pDNA loading was performed under three conditions: after liposome 
preparation, after storage at 4 °C for 30 days and after incubation at 37 °C for 7 days in the 
presence of 10% FBS. Poly aspartic acid was used to maintain free DNA and Hoechst dye 
33342was used for fluorescent staining of released pDNA. The fluorescence intensity of the 
samples was measured at excitation and emission wavelengths of 354 and 450 nm, respectively 
(Spectra Max M5microplate spectrofluorometer (Molecular Devices, Sunnyvale, CA)). The 
percent pDNA encapsulated (EE) and percent pDNA released (RL) were determined using the 
following equations: 
EE (%)= [F(t)-F(0)]/F(t)]x100  (1) 
RL(%)= 1-EE(%) (2) 
where, F(t) is the fluorescence of the sample after lysis of the liposomes using methanol and F(0) 
is the fluorescence intensity of the sample before lysis of liposomes. 
2.4.4.2. Characterization of Tf-CPP liposomes 
The Tf-CPP-liposomes were characterized for size and charge using zetasizer. The 
coupling efficiency of transferrin to the liposomes was determined using microbicinchonic acid 
assay as described earlier (Sharma et al. 2012). The conjugation of CPPs to the DSPE-PEG lipid 
was confirmed using fluorescamine assay (Rea et al. 2008). Stock solution of fluorescamine 
(Fluram®) was prepared in acetone at a concentration of 1 mg/ml. A fixed volume (50μl) of 
fluorescamine stock solution was added to each standard or sample prepared in sodium borate 
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buffer, pH8.5 (Miedel et al. 1989; Yuba et al. 2008). The standard curve was generated using 
varying concentrations of free CPPs. DSPE-PEG-lipid without CPP conjugation was used as a 
control. The fluorescence of the samples and standards was measured at excitation and emission 
wavelengths of 365 and 470 nm, respectively. In addition, doxorubicin release studies were 
performed by diluting the liposomal samples in PBS with 10% FBS and incubating the samples 
at 37°C. Samples were withdrawn at different time points, passed through sephadex columns and 
analyzed using HPLC. 
2.4.5. Qualitative evaluation of Tf-receptor expression in brain 
We confirmed the presence of high density of transferrin receptors in rat brain sections 
using immunohistochemistry. Anti-transferrin receptor antibody (OX26), anti-CD31 antibody, 
Alexa-Fluor 594 goat anti-rabbit IgG (excitation 590 nm and emission 617 nm) and Alexa-Fluor 
488 goat anti-mouse IgG (excitation: 494 nm and emission: 517 nm) were used to confirm the 
presence of transferrin receptors. Rat brain tissue was obtained from the breeding colony which 
originated from Charles River laboratories (Wilmington, MA). The tissue was embedded in 
Tissue-Tek® OCT compound (Ted Pella Inc., CA) and snap frozen in liquid nitrogen. The frozen 
brain tissue was sectioned using cryostat (Leica 1950, Nussioch, Germany) to obtain 10µm 
sections. These tissue sections were then fixed for 15 min with 4% paraformaldehyde in 
phosphate buffered saline (PBS, pH 7.4) containing 0.1% Tween 20 (PBS-Tween). The tissue 
sections were washed twice for 10 min with PBS-Tween and incubated with PBS-Tween 
containing 5% bovine serum albumin (BSA) to block non-specific binding sites. The sections 
were then incubated overnight at 4ºC with rabbit anti-CD31 Ab (1:400, diluted in PBS-Tween 
with 1% BSA) and mouse anti-transferrin receptor Ab (OX26, 1:400, diluted in PBS-Tween with 
1% BSA) followed by washing with PBS-Tween (two washings for 10 min each). On the next 
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day, the sections were counter-stained with secondary antibodies (Alexa-Fluor 594 goat anti-
rabbit IgG, 1:800 and Alexa-Fluor 488 goat anti-mouse IgG, 1:800, diluted with PBS containing 
0.1% tween 20 and 1% BSA) for 1 hour at room temperature. The staining of endothelial cells 
and transferrin receptors was observed under FV300 confocal fluorescence microscope 
(Olympus, NY, USA). Brain capillary endothelial cells were stained with the endothelial marker, 
CD-31 antibody and counter stained with secondary antibody, Alexa fluor 594. Transferrin 
receptors, on the rat brain sections, were similarly stained with transferrin receptor antibody, 
OX26 and counterstained with secondary antibody, Alexa fluor 488.  
2.4.6. Measurement of pDNA encapsulation efficiency 
The pDNA (pGFP or β-gal plasmid) encapsulation efficiency of the liposomes was 
calculated based on the previously reported method (Zhang et al. 2007). Briefly, 100μl of the 
liposomal suspension was diluted (1:3) with HEPES buffered saline, pH 7.4. The evaluation of 
pDNA loading was performed under three conditions: after liposome preparation, after storage at 
4 °C for 30 days and after incubation at 37°C for 7 days in the presence of 10% FBS.DNA 
intercalating dye Hoechst 33342 was used to fluorescently stain the encapsulated DNA. Poly 
aspartic acid was used to maintain free pDNA. The fluorescence was measured using Spectra 
Max M5microplatespectrofluorometer (Molecular Devices, Sunnyvale, CA) at excitation and 
emission wavelengths of 354 and 450 nm, respectively. Percent pDNA encapsulation (EE) was 
calculated by using the following equation: 
EE (%) = [FI(t) - FI(0)]/FI(t)      (3) 
Where, FI(t) is the total fluorescence intensity of the sample after lysis of the liposomes 
using 1% Triton X-100 (St Louis, MO) and FI(0) is the fluorescence intensity of the sample 
before lysis of liposomes. The percent pDNA released (RL) was calculated as follows: 
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   RL(%) = 1-EE(%)       (4) 
2.4.7. Evaluation of cytotoxicity 
MTT assay, apart from being a rapid and reliable method for estimation of cell viability, 
also allows for multiple sample concentrations to be evaluated spectrophotometrically on a single 
96-well plate (Edmondson et al. 1998). Biocompatibility of the formulated liposomes was 
therefore evaluated in both glial and endothelial cells using MTT assay based on previously 
reported method (Lila et al. 2009).Cell viabilities of Tf-PR liposomes were evaluated in bEnd3 
and primary glial cells at varying phospholipid concentrations (100, 200, 400, and 600 nM) 
prepared by serial dilution of liposomes in a serum-free medium, that is, DMEM. Similarly, the 
biocompatibilities of the CPP-liposomes and Tf-CPP liposomes (Tf-TAT, Tf-Penetratin and Tf-
Mastoparan) were evaluated in three different cell lines, Daoy (medulloblastoma), U87 
(glioblastoma), and bEnd.3 (brain endothelial). The cytotoxic potential of the liposomes was 
assessed at 50, 100, 200, 400 and 600 nM concentrations of phospholipids. For evaluation of the 
biocompatibilities of both Tf-PR and TF-CPP liposomes, the cells were plated in 96-well plates 
at a density of 5 × 10
2
 cells/ well 24 h prior to addition of liposomes. Following this, the culture 
medium was replaced with serum free medium containing different concentrations of either 
plain, Tf, PR, CPPs (TAT, Penetratin or Mastoparan), Tf–PR or TF-CPP liposomes. 
Followingincubation for 2 h, the liposomes were removed and fresh DMEM containing 10% 
FBS was added. Thecells were incubated further for a total of 48 h. Themedium was then 
removed and 25 µl of MTT (2mg/ml in PBS, pH 7.4) was added to the wells. After 3 h, the MTT 
solution was removed and the formazan crystals were dissolved in 200 µl of DMSO. The 
absorbance of the cells was measured at 570 nm. Untreated cells (without exposure to liposomes) 
were used as controls. 
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2.4.8. Evaluation of cell uptake 
Cellular uptake of DiI-labeled liposomes (Plain, Tf, Tf-PR and PR) was evaluated in 
bEnd.3 cells, while the uptake of doxorubicin encapsulating (Plain, Tf, Tf-CPP and CPP) 
liposomes was evaluated in Daoy, U87 and bEnd3 cells.Qualitative investigation of liposomal 
uptake was performed using fluorescence microscopy. The cells (6x10
4
/well) were seeded onto 
35 mm culture dishes 24h prior to the uptake analysis. Doxorubicin encapsulating liposomes 
were incubated with the cells at a concentration of 100nM and the uptake of liposomes was 
investigated at different time intervals. Following liposomal uptake, the cells were rinsed with 
PBS, pH 7.4. The nuclei of the cells were stained with 4’,6-diamidino-2-phenylindole (DAPI) 
dye and fluorescence of the cells was evaluated using fluorescence microscope (Olympus, 
Melville, NY).Quantitative estimation of DiI labeled liposome uptake was performed by lysis of 
cells in PBS containing 0.1% Triton X-100 followed by extraction of the fluorescent dye in 
methanol. The fluorescence intensity of samples was measured spectrofluorometrically 
(excitation wavelength: 553 nm and emission wavelength: 570 nm).The uptake of doxorubicin 
carrying liposomes was quantified by lysis of the cells in triton X-100 followed by extraction in 
methanol. The solution was centrifuged at 3000 rpm for 15 min at 4C and the supernatant was 
analyzed using HPLC system equipped with UV-visible detector. The analysis was performed as 
described above for evaluation of doxorubicin loading. 
2.4.9. Measurement of transfection efficiency 
The transfection potential of Tf–PR liposomes was evaluated in primary glial cell 
cultures using GFP plasmid. To protect the gene from acidic pH of the endosome, the gene of 
interest was further complexed with chitosan and subsequently added to the hydration buffer for 
encapsulation into Tf–PR liposomes. Transfection efficiency of bifunctional liposomes was 
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compared with that of plain and Tf liposomes. The cells were seeded onto 35 mm culture dishes 
(6 × 10
6
 cells/dish) precoated with poly-L-lysine and cultured in DMEM containing 10% FBS at 
37°C in 5% CO2 until approximately 80% confluent. Liposomal formulations containing pGFP 
chitosan complexes were then added to these cells in serum-free medium.After 2 h, the medium 
containing liposomes was removedand the cells were further incubated for a totalof 48 h in 
serum-containing medium. The cellswere then analyzed for GFP expression using confocal laser 
scanning microscope, and quantitative evaluation was performed using FACS analysis 
(AccuriC6 flow cytometer (Accuri cytometers, Ann Arbor,MI),laser excitation wavelength: 488 
nm, emission detection wavelength using optical filter: FL1 533/30 nm). 
The transfection efficiency of the Tf-CPP liposomes was assessed using gWiz GFP and 
β-galactosidase expressing plasmids (Aldevron LLC, Fargo, North Dakota). The cells were 
seeded onto poly-L-lysine coated 35 mm dishes and cultured in DMEM containing 10% FBS at 
37C in 5% CO2 until approximately 85% confluent. The cells were then incubated with either 
GFP or β-galactosidase(β-gal) expressing plasmid (pGFP/pβ-gal) encapsulating liposomes in 
serum free media for 1h following which the liposomes were removed and the cells were 
incubated with fresh serum containing media for further 48 h. The cells were then evaluated for 
expression of GFP using fluorescence microscopy. The gene expression was quantified using β-
gal assay kit (Promega, Madison, WI). The β-gal assay was based on the enzymatic hydrolysis of 
the colorless substrate ONPG to the yellow colored product o-nitrophenol by β-gal enzyme. The 
hydrolytic reaction was stopped by the addition of sodium carbonate following which the 
absorbance of the sample was measured at 420 nm. Control samples consisted of the cells 
exposed to naked β-gal pDNA (not encapsulated into liposomes). Cells not exposed to DNA 
were similarly processed to determine the endogenous β-gal activity of different cells. 
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2.4.10. Design of in vitro BBB model 
The in vitro BBB model was constructed using a combination of bEnd.3 and primary 
glial cell cultures. Glial cells (1.5 × 10
4
/cm
2
) were seeded on the bottom side of collagen-coated 
polyethylene terepthalate (PET) membrane (0.4 µm pore size; effective growth area 4.2 cm
2
) of 
Transwell inserts (BD BioCoat
TM
; BD Biosciences, North Carolina) in DMEM with 20% FBS. 
The cells were allowed to adhere firmly to the membrane overnight. Following this, the 
endothelialcells (1.5 × 10
6
/cm
2
 per culture insert) were seeded on the inside of culture inserts 
placed in six-well plates and cultured in DMEM with 20% FBS and 1% Psf. The cell culture 
inserts were kept in six-well plates in the culture medium for 6–7 days to allow the formation of 
tight barrier layer. As a control, models with only bEnd.3 cells on the upper side of the culture 
inserts, without any glial cells on the underside of the membrane, were also constructed and 
maintained similarly. The cells were regularly checked for confluency under the microscope, and 
the cell culture medium was replaced every other day during the incubation period. 
2.4.11. Evaluation of barrier integrity 
The intactness of the barrier layer was calculated by measuring the transendothelial 
electrical resistance (TEER) using patch clamp technique.33 Briefly, the culture inserts were 
filled with 1.5 mL of PBS (with Ca
2+
 and Mg
2+
 ions), and electric pulses with duration of 100 ms 
were applied through cell layer and voltage generated across the layer was recorded. The current 
density between 2.0 and 20 µA/cm
2
 was selected depending on the resistance (greater than or 
less than 1000 cm2). The paracellular transport across the in vitro models was evaluated by 
measuring the flux of sodium–fluorescein (Na–F) across the barrier layer as previously reported 
(Nakagawa et al. 2009; Veszelka et al. 2007).Cell culture inserts with both glial and endothelial 
cells (co-culture)or only endothelial cells (monolayer) were transferred to six-well plates 
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containing 1.5 mL of PBS (pH 7.4) in the lower compartment. In the upper compartment of the 
inserts, the culture medium was replaced with 1 mL of PBS containing 10µg/mL Na–F. The 
culture inserts were transferred to new wells containing buffer at specific time intervals of 5, 15, 
30, and 45 min. The concentrations of the fluorescent molecule in samples from the upper and 
the lower compartments were determined by fluorescence SpectraMax
®
M5 multimode micro 
plate reader (Molecular devices, Sunnyvale, CA)excitation wavelength: 485 nm, emission 
wavelength: 535 nm). Flux was also measured across cell-free inserts and the transendothelial 
permeability coefficients (Pe) were determined for both model types (glial-bEnd.3 and bEnd.3) 
as previously described (Veszelka et al. 2007; Deli et al. 2005).All experiments were performed 
in quadruplicates and each experiment involved a set of four culture inserts(n = 4 × 4). 
2.4.12. Transport across the in vitro BBB model 
The transport of four types of DiI-labeled liposomes (plain, Tf liposomes, PR liposomes, 
and Tf–PR liposomes) was measured across the in vitro BBB model (Qin et al. 2011).To mimic 
the in vivo environment, flux of these liposomes was evaluated in sterile PBS (pH 7.4) 
containing10% FBS. The inserts were transferred to six well plates containing 1.5 mL of PBS in 
the lower compartment. The culture medium inside the inserts was replaced with liposomal 
suspensions (100 nM) in 1mL of fresh serum-containing buffer. The inserts were transferred at 
15, 30, 60 min, 2, 4, and 8 h to new wells with serum–PBS. The concentrations of the liposomes 
in the upper and the lower compartments were determined by measuring the fluorescence 
intensity of the dye molecule in the samples using fluorescence Spectra Max
®
M5 multimode 
microplate reader(excitation wavelength: 553 nm, emission wavelength:570 nm). Apparent 
permeability coefficient (Papp) for each liposomal formulation was calculated, according to 
Gaillard et al. by using the following equation: 
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Paap= dQ/dt1/AC0.60cm/s      (5) 
Where dQ/dt is the amount of liposomes transported per minute (µg/min), A is the 
surface area of the transwell membrane (cm
2
), C0 is the initial concentration of liposomes 
(µg/mL), and 60 is the conversion factor from minute to second. Paap for liposomes wasalso 
evaluated across cell-free inserts. This apparent permeability was termed as Pt for the 
permeability coefficient of the total system (in vitro model) and Pf for the permeability 
coefficient across cell-free inserts. The permeability of the endothelial barrier was then 
calculated using the following equation (Xie et al. 2005; Fenke et al. 2000): 
1/Pe= 1/Pt - 1/Pfcm/s      (6) 
The percent transport, for all four types of liposomes, was also calculated over a period of 8 h. 
2.4.13. Design of 3D in vitro BBB model 
2.4.13.1. Construction of porous scaffold 
The porous scaffold for the growth of tumor cells was generated using emulsion freeze 
drying technique (Fenke et al. 2000). Poly(D,L-lactide-co-glycolide) (PLGA, lactic acid/glycolic 
acid 50:50) was dissolved in dichloromethane at a concentration of 0.2 g/ml. This solution (5 ml) 
was added to a mixture of 500 mg of Chitosan (50 kDa) and 150 mg poly vinyl alcohol (PVA) in 
10 ml of acetic acid buffer, pH 4.5 at 2 ml/min with constant stirring using a glass rod. Five 
hundred microliter solution of collagen in 0.1 M acetic acid (0.1%w/v) was added to the above 
mixture with stirring to form an emulsified paste. The paste was then poured into rod shaped 
moulds and freeze dried to form the chitosan-PLGA scaffold. The scaffolds were sectioned into 
discs of 2 mm thickness which were used for the culture of tumor cells. 
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2.4.13.2. Growth of tumor cells in 3D microenvironment 
The scaffold discs were rinsed with PBS, pH 7.4 and the glioblastoma cells were added to 
the scaffold surface and incubated overnight. Fresh media containing 20–30% serum was added 
the following day and the cells were cultured for approximately 35 days to form 3D tumors on 
scaffold. The cellular biocompatibility was assessed using MTT assay and the cell growth was 
monitored by hematoxylin-eosin stainingof the frozen scaffold sections. The scaffold sections, 
atdifferent time points, were embedded in Tissue Tek OCT™ compound and snap frozen in dry 
ice. The scaffold with tumor cells was sectioned using cryostat, mounted on polylysine coated 
slides and stained using hemotoxylin-eosin (Sharma et al. 2013). The scaffold was assessed for 
continuous pore formationand 3D tumor growth using scanning electron microscopy(SEM). The 
scaffold sections were attached to the sample stubswith carbon paint and were sputter coated 
with gold. Thesesections were evaluated under JEOL JSM-6490LV highperformancevariable 
pressure SEM. The tumor cells growingin 3D environment on the scaffolds were then combined 
with the culture inserts (0.4μm pore size) carrying bEnd.3 cells onthe luminal surface of the 
insert membrane(Sharma et al. 2012) to forma 3Dbrain tumor model. Culture inserts with brain 
endothelialcells were placed above the scaffold and different liposomes(TAT, Penetratin and 
Mastoparan peptides conjugated to Tf-liposomes)were evaluated for transport across the in vitro 
braintumor model. 
2.4.13.3. Evaluation of liposomal transport across 3D brain tumor model 
The culture inserts seeded with mouse brain endothelial cells (bEnd.3) were placed above 
the tumor scaffolds on day 28 of tumor growth and cultured for about 7 days to form a brain 
tumor barrier model. Brain tumor model was designed to simulate in vivo tumor conditions 
where the permeability of the brain endothelial barrier is compromised by the glioblastoma 
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tumor growth. The intactness of the barrier was determined by measuring the transendothelial 
electrical resistance (TEER) and the sodium fluorescein (Na-F)permeability coefficient across 
the endothelial cell layer. The TEER of culture inserts was measured using patch clamp 
technique (Sharma et al. 2012; Erben et al. 1995). However, in this study the TEER values were 
determined across the endothelial cell layer on the culture inserts after removing the inserts from 
the scaffold containing wells and transferring them to the 24-well plates containing PBS (with 
Ca
2+
 and Mg
2+
 ions). The presence of scaffold with the inserts caused physical contact of the 
electrodes with the scaffold and interfered with the measurement of resistance resulting in very 
high resistance values. The Na-F permeability of the barrier was assessed by replacing the media 
inside the culture inserts with 500μl of PBS, pH 7.4 containing 10μg/ml of Na-F. The media in 
the lower compartment of the inserts, for the culture of tumor cells, was also replaced with PBS 
(pH 7.4). The paracellular transport of Na-F was assessed by measuring the fluorescence 
intensity of the samples from the upper and the lower compartment using fluorescence Spectra 
Max®M5multimodal micro plate reader (Molecular devices, Sunnyvale, CA) at 
excitation/emission wavelength: 485/535 nm. Following transport, the scaffolds were rinsed with 
PBS and approximately 50μl of 0.1% w/v Triton X-100 was added to tumor cells on scaffold 
with 500μl of PBS, pH 7.4and incubated for ~1 h at 37°C to lyse the tumor cells. The 
fluorescence of the lysate was measured at different time points to calculate the amount of Na-F 
transported across the endothelial barrier. The flux measured across cell free inserts and across 
the total model system was used to calculate the endothelial permeability coefficients (Pe) using 
equation (4), as described above. The permeability coefficients were assessed across the culture 
inserts with only endothelial cells and across the in vitro brain tumor model and were compared 
with the permeability coefficient values across the in vitro BBB model. The liposomal transport 
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was similarly assessed by adding different liposomes to the culture inserts seeded with brain 
endothelial cells and placed on the 3D tumor scaffolds. The media in surrounding the scaffold in 
the lower compartment was replaced with fresh serum containing PBS (pH 7.4). Also, the media 
inside the culture inserts was replaced with the liposomal suspensions (200nM) in 1 ml of fresh 
serum containing buffer. The doxorubicin containing liposomes were transported across the 
endothelial barrier into the 3Dtumor cell mass growing within the porous scaffold. Following the 
transport of liposomes, the tumor cells were lysed as described above and the lysates were 
analyzed using HPLC system equipped with UV-visible detector. The analysis was performed at 
wavelength of 234 nm using C18 column and phosphate buffer pH 5.5: Acetonitrile (75:25) 
mixture as described earlier for cell uptake analysis. 
2.4.14. Hemolysis assay 
To study the interaction of CPP modified liposomes with the negatively charged 
erythrocytes, we performed the hemolysis assay at increasing phospholipid concentrations. 
Blood was collected from an adult rat into tubes containing EDTA solution and centrifuged at 
2000 rpm for 10 min. The pelleted erythrocytes were washed three times with phosphate 
buffered saline (PBS), pH 7.4. The erythrocyte count was determined using a hemocytometer. 
The liposomes, at different concentrations in PBS, were added to pre-determined number of 
erythrocytes and incubated at 37 °C for 60 min. The samples were centrifuged at 2000 rpm for 
10 min and absorbance (A) of the supernatant was analyzed at 540 nm by spectrophotometric 
analysis. Triton X-100 and PBS treated erythrocytes were used as controls for 100% and 0% 
hemolysis, respectively. The percent hemolysis was calculated as: 
Hemolysis (%) = {[A(experimental group)-A (PBS)]/[A(Triton X-100)]}*100 (7) 
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Less than 10% hemolysis was regarded as non-toxic (Fischer et al. 2003; Lee et al. 2004). 
The microscopic examination of erythrocytes, exposed to varying liposome concentrations, was 
performed to further confirm the results from spectrophotometric measurements. Erythrocytes, 
subjected to different liposomes at increasing concentrations, were observed under light 
microscope (Olympus DP72,Melville, NY) equipped with a 12.8 megapixel digital colored 
camera. The images were captured and analyzed using Olympus Cell Sens Version 1.5 Software. 
All experiments were performed in triplicate and repeated four times to obtain statistically 
relevant results. 
2.4.15. In vivo evaluation of liposomes  
2.4.15.1. Evaluation of Tf and Tf-PR liposomes 
After a seven day acclimation period, the rats were injected via tail vein with either DiR-
labeled liposomes or β-gal plasmid encapsulating liposomes. Animals injected with phosphate 
buffered saline (PBS), pH 7.4, or with β-gal plasmid alone were used as control. 
2.4.15.1.1. Biodistribution of DiR labeled liposomes 
Animals were divided into four groups where each group, consisting of 6 rats, was 
administered with either PBS, plain liposomes, Tf-liposomes or Tf-PR-liposomes. The 
biodistribution profiles of the liposomal formulations were investigated by injecting the animals 
with DiR-labeled liposomes via tail vein at a dose of ~15.2 μmoles phospholipids/kg body 
weight. At time points of 12, 24, 48, and 72 h, different organs such as brain, heart, liver, spleen, 
lungs, and kidneys were excised and rinsed with PBS (n=6 for each time point). Qualitative 
evaluation of liposomal distribution was performed by acquiring ex vivo fluorescent images of 
the organs using NIR imaging. The system was equipped with a halogen lamp (150 W) as the 
excitation light source and the band pass filters were adjusted for excitation and emission at720 
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and 790 nm, respectively. Tissue samples from different organs were weighed, homogenized 
with PBS (200 μl), and the fluorescent dye was extracted in 3 fold excess of chloroform: 
methanol (3:1). The homogenized samples were centrifuged at 4000 rpm for 10 min and 
fluorescence intensity of the supernatant (100 μl) was measured using spectrophotometric 
analysis. Standard curve for the measurement of the dye extracted from each organ was 
generated by vortexing free DiR in methanol with the tissue samples from the corresponding 
organs of the control rat. The organs were homogenized and the dye was extracted as described 
above. All data were normalized in units of percentage of injected dose per gram of the tissue (% 
ID/g). 
2.4.15.1.2. Transfection efficiency of Tf and Tf-PR liposomes 
After a seven day acclimation period, the rats were injected via tail vein with β-gal 
plasmid encapsulating liposomes. Animals injected with β-gal plasmid alone were used as 
control. The transfection efficiencies of Tf-liposomes, Tf-PR-liposomes, and naked DNA were 
assessed by administering the rats with β-gal plasmid encapsulating formulations via tail vein, at 
a dose of 50μg of DNA/rat (n=6). After five days, different organs (i.e., brain, liver, spleen, 
heart, lungs and kidneys) were isolated and snap frozen in liquid nitrogen. Tissue samples from 
different organs were excised, weighed, transferred to 200μl of tissue lysis/protein extraction 
buffer (Fab Gennix International Inc., Frisco, TX), and homogenized using a high speed 
homogenizer (Biospec products, Inc., Bartlesville, OK). The homogenized samples were 
centrifuged at 4000 rpm, 4 °C for 15 min. The supernatant was separated and stored in ice for 
further processing with the β-gal assay kit. The homogenates extracted from the tissue samples 
were diluted with an equal volume of assay buffer containing the substrate, o-nitrophenyl-β-D-
galactopyranoside (ONPG), and incubated at 37 °C for 60 min. The tissue samples transfected 
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with β-gal plasmid express the enzyme β-gal. The β-gal activity of the transfected tissues was 
quantified using the β-gal assay kit (Promega, Madison, WI).The transfection efficiency was 
determined by evaluating the enzymatic hydrolysis of the colorless substrate ONPG to the 
yellow colored product o-nitrophenol by β-gal enzyme. The reaction was terminated by the 
addition of sodium carbonate and the absorbance was measured at 420 nm. Tissue samples 
fromcontrol rats (without administration of DNA or liposomes) were similarly processed to 
quantify the endogenous activity of individual organs. 
2.4.15.1.3. Histological evaluation of tissues 
The biocompatibility of liposomes, in vivo, was evaluated by histological examination of 
tissue sections transfected with β-gal plasmid encapsulating liposomes. The transfected tissue 
sections from different organs were embedded in Tissue-Tek® OCT™ Compound (Sakura 
Finetek USA, Inc., Torrance, CA) and snap frozen in dry ice. The frozen tissues were sectioned 
using cryostat, mounted on poly lysine coated slides and fixed in 4% paraformaldehyde 
(prepared in PBS, pH 7.4). The sections were stained with Harris hematoxylin solution, washed 
in running tap water and differentiated in 1% acid alcohol for 10 seconds. The stained tissue 
section was then rinsed in tap water and blued in 1.36% lithium carbonate solution. The slides 
were then dehydrated in 95% alcohol and counter stained with eosin Y-phloxine B solution for 
5–10 s. The stained tissue sections were cleared in xylene, mounted with Cytoseal 60 (Thermo 
Fisher Scientific Inc., Barrington, IL) and observed under light microscope. Since, the liver and 
spleen were exposed to highest concentration of liposomes, therefore, these tissue were carefully 
examined for any signs of toxicity. The liver sections were observed for ballooning of 
hepatocytes, enlargement of nuclei or kupffer cells, and granulomas (Semete et al. 2010; Tseng 
et al. 2012). Similarly, the splenic tissue was evaluated for necrosis and inflammation (Kanth et 
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al. 2010). Heart and lungs were also examined for signs of necrosis or extravasation of red blood 
cells(Abdelhalim 2011) and thickening of alveoli (Kamata et al. 2011), respectively. Kidneys 
were observed for inflammation and necrosis(Kanth et al. 2010) and brain tissue for any signs of 
lesions (Cole et al. 2011). 
2.4.15.2. Biodistribution of Tf-CPP liposomes 
After 7 days of acclimation period, the rats were intravenously injected with either free 
doxorubicin or doxorubicin loaded liposomes. Animals were divided into 7 groups and each 
group was injected with either free doxorubicin, doxorubicin loaded plain, Tf, Tf-TAT, Tf-
Penetratin, or Tf-Mastoparan liposomes at a dose of 15.2μmols of phospholipids/kg body weight. 
Animals injected with PBS, pH 7.4 were used as control. At time points of 12, 24 and 48h 
various organs including brain, liver, heart, lungs, kidneys and spleen were isolated and blood 
samples were withdrawn. The distribution of drug to various organs was determined by 
homogenization of tissue samples and extraction of the drug in chloroform: methanol (3:1). The 
extracted samples were then dried in a vacuum drier and the residue was reconstituted in 
phosphate buffer pH5.5:methanol(4:1). The reconstituted samples were vortexed to allow 
complete re-suspension of the residue followed by centrifugation of the samples at 10,000 rpm 
and 4°C to remove any unwanted proteins. The supernatant was then analyzed using HPLC 
system equipped with UV-visible detector at 234 nm as described for cell uptake analysis. A 
standard curve for the measurement of the drug extracted from each organ was generated by 
vortexing free doxorubicin in methanol with the tissue samples from different organs of control 
rat. The samples were homogenized and the drug was extracted as illustrated above. All data 
were normalized in units of percentage of injected dose per gram of the tissue (%ID/g). 
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2.4.16. Statistical analysis 
The statistical data were processed using Microsoft Excel 2010 software and presented as 
mean ± standard deviation (S.D.). The treatment and control groups were compared using two 
tailed student’s t-test and analysis of variance (ANOVA). 
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CHAPTER III. RESULTS 
3.1. Characterization of liposomes 
 The liposomes were characterized for hydrodyanamic size and zeta potential values. The 
conjugation of peptides to the surface of liposomes was determined using fluorescamine assay. 
Surface properties of Tf-PR liposomes were characterized using AFM techniques. The amount of 
transferrin protein conjugated with the functional lipid DSPE-PEG-COOH was determined using 
micro BCA assay. Cytotoxic and hemolytic potential of the liposomes was assessed via MTT 
and hemolysis assay, respectively. In vivo biodistribution and transfection of the liposomes was 
evaluated in adult SD rats. 
3.2. Physical properties of liposomes 
The phase image analysis using AFM revealed spherical morphology with uniformly 
dispersed liposomal vesicles as shown in Figure 1. The conjugation of Tf protein and PR did not 
cause any apparent change in the shape or aggregation of liposomes. The overall morphological 
appearance for the two types of liposomes was observed to be same. Because the AFM analysis 
involved drying of the liposomal samples; therefore, this technique was used only for the 
evaluation of shape and morphological appearance. The average hydrodynamic particle size and 
zeta potential of liposomes were evaluated in HEPES-buffered saline (pH 7.4), using Zetasizer 
Nano ZS 90 (Malvern Instruments), at 25C. The overall size of the liposomes was less than 
200nm. The average size for plain unconjugated and Tf–PR liposomes was observed to be in the 
range of 172.3±3.77 and 196.2±9.5 nm, respectively, and zeta potential was in the range of 
6.21±1.2 and 11.19 ± 2.7 mV (mean ± SE), respectively. The results showed that conjugation of 
transferrin protein to the liposomes significantly (p <0.05) increased the particle size of the 
liposomes. The sizes of TAT, Penetratin, and Mastoparan conjugated liposomes did not differ 
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significantly (p >0.05) from each other. Also, the incorporation of Tf decreased the zeta potential 
to a negative value. This negative zeta potential was attributed to the presence of negatively 
charged protein on the surface of the liposomes. This negative charge was balanced by the 
positively charged PR or other CPPs in dual-modified liposomes, thereby imparting a near-
neutral zeta potential to the Tf-CPP liposomes. Table 4 summarizes the size and zeta potential 
values for different liposomes. 
No significant (p >0.05) change in size of Tf-CPP liposomes was observed after 
incubation of the liposomes at 37°C in PBS containing 10% serum. However, the size of CPP-
liposomes increased significantly (p <0.05) after incubation in PBS containing serum (Table 5). 
This was ascribed to the adsorption of negatively charged serum proteins onto CPP-liposomes 
(due to the presence of only cationic CPPs on the liposomal surface leading to higher positive 
zeta potential). The presence of polyethylene glycol on the liposomes prevented their 
aggregation in the presence of serum. However, the presence of serum proteins in the buffer 
resulted in slightly negative zeta potential values. 
Micro BCA assay for Tf content of liposomes revealed that 58±1.6% of the Tf was 
coupled to the Tf–PR liposomes. The coupling efficiency indicated a slight decrease in the 
incorporation of Tf-PEG-lipid micelles to the liposomes in the presence of PEGylated PR. The 
Tf content was approximately 69.82±5.2%, 63.21±5.1%, 60.13±4.9%, and 61±5.8% for Tf-
liposomes, Tf-TAT, Tf-Mastoparan and Tf-Penetratin liposomes, respectively. Fluorescamine 
assay showed a coupling efficiency of approximately 85±4.3%, 82.88± 5.2% and 83.31±4.8% 
for TAT, Penetratin and Mastoparan, respectively. Coupling of PR was to the PEG lipid was 
confirmed using 1H NMR technique. The results indicated that approximately 55.6% of the PR 
was coupled to the PEG–lipid. The pDNA encapsulation efficiencies of plain, Tf, PR, and Tf–PR 
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liposomes were 35±3.8%, 36±5.4%, 42±2.2%, and 39.6±4.2%, respectively. The loading 
efficiencies of different liposomes were not significantly (p>0.05) different. No significant 
difference (p>0.05) was observed in the encapsulation efficiencies of the liposomes. The drug 
encapsulation efficiencies were observed to be 78±5.3%, 74.82±4.6%, 76.33±3.8%, and 
77.98±4.3% for plain, TAT, Penetratin, and Mastoparan liposomes, respectively. The 
doxorubicin encapsulation efficiencies were 68.38±6.3%, 65.81±5.2%, and 66.73±5.8% for Tf-
TAT, Tf-Penetratin and Tf-Mastoparan liposomes, respectively. 
The release of pDNA from the liposomes stored at 4°C was also determined after two 
weeks. The percentage of pDNA released from plain, Tf, PR, and Tf-PR liposomes was 9.3± 
2.8%, 12.4± 4.2%, 7.3±5.4% and 8.5± 5.7%, respectively. The results indicated that ~90% of the 
loaded pDNA remained encapsulated in the liposomes after storage at 4°C for two weeks. The 
pDNA release profile was determined after incubation of the liposomes at 37°C in the presence 
10% FBS for 7 days. The results showed that approximately 70-80% of the pDNA remained 
encapsulated in the liposomes (Figure 2). The percent cumulative release was not significantly 
different (p>0.05) among the different liposomal formulations, however the release was observed 
to be slightly higher from the Tf-liposomes as compared to plain and Tf-PR-liposomes. Also, the 
Tf-CPP liposomes were assessed for doxorubicin encapsulation and leakage. The drug 
encapsulation efficiencies were observed to be 78±5.3%, 74.82±4.6%, 76.33±3.8%, and 
77.98±4.3% for plain, TAT, Penetratin, and Mastoparan liposomes, respectively. The 
doxorubicin encapsulation efficiencies were 68.38±6.3%, 65.81±5.2%, and 66.73±5.8% for Tf-
TAT, Tf-Penetratin and Tf-Mastoparan liposomes, respectively. The liposomes showed less than 
31% of the doxorubicin leakage after 12 h of incubation in PBS (pH 7.4) in the presence of 
serum, at 37°C (Figure 3).  
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Figure 1. Morphological appearance of liposomes observed using atomic force microscope  
(A) Surface view of plain liposomes; (B) surface view of Tf–PR liposomes. Air-dried samples 
of the liposomal suspensions were observed under Veeco DI-3100 atomic force microscope in 
tapping contact mode at a scan size of 1 µm and at a scan rate of about 1 Hz. AFM images 
showed the formation of spherical liposome.  
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Table 4. Particle size and zeta potential measurements for liposomes 
Data are presented as mean ± SD from at least four different preparations. 
*PDI: Poly Dispersity Index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Liposomes 
Physical property  
Particle size 
(nm) 
Zeta Potential (mV) 
PDI* 
Plain-liposomes 172.3±3.77 6.58 ± 3.27 0.258 ± 0.014 
Tf-liposomes 185.6±8.40 -8.151±4.96 0.404 ± 0.037 
PR-liposomes 188.3 ± 10.6 25.25 ± 3.6 0.275 ± 0.014 
TAT-liposomes 176.7±4.70 19.07± 2.82 0.242 ± 0.008 
Mast-liposomes 175.2±3.21 16.83 ± 2.82 0.231 ± 0212 
Pen-liposomes 178.7±7.71 21.20± 2.471 0.218 ± 0.065 
Tf -PR-liposomes 196.2±9.5 11.19 ± 2.7 0.290 ± 0.043 
Tf-TAT-liposomes 183.0±6.41 13.16 ± 3.80 0.319 ± 0.038 
Tf-Mast-liposomes 188.3±8.21 11.28 ± 5.73 0.212 ± 0.042 
Tf-Pen-liposomes 186.82±9.21 15.28 ± 5.31 0.201 ± 0.073 
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Table 5. Particle size of different liposomes in the presence of serum at 37C for 1h 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Data are presented as mean ± S.D, n=4. Polydispersity index (PDI) > 0.5 above 800 nmoles of 
phospholipids for all liposomal formulations. 
  
Type of liposomes 
Particle Size 
(nm) 
Plain 175.5 ± 6.3 
Tf 186.5 ± 7.3 
PR 190 ± 9.9 
Tf-PR 198 ± 7.9 
Tf-TAT 184.2 ± 6.4 
Tf-Pen 188.4 ± 7.2 
Tf-Mast 190.8 ± 8.2 
TAT 185.8 ± 5.9 
Pen 190.6 ±6.8 
Mast 188.2 ± 5.4 
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Figure 2. Graphical representation of the percent cumulative pDNA release profiles for Plain, Tf 
and Tf-PRliposomes. Data are presented as mean±SD from four different preparations. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Graphical representation of the percent cumulative doxorubicin release profiles for 
Plain, Tf and Tf-CPP-liposomes. Data are presented as mean ± SD from at least four different 
preparations. The release studies were performed at 37C in the presence of 10% FBS. 
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3.3. Transferrin receptor expression of brain endothelial cells 
Brain capillary endothelial cells were stained with the endothelial marker, CD-31 
antibody and counter stained with secondary antibody, Alexa fluor 594. Transferrin receptors, on 
the rat brain sections, were similarly stained with transferrin receptor antibody, OX26 and 
counterstained with secondary antibody, Alexa fluor 488. A strong overlap in the fluorescence 
regions of CD31 receptors on brain endothelial cells and transferrin receptors in brain provided a 
qualitative confirmation of the presence of high density of transferrin receptors on the brain 
capillary endothelial cells. The liposomal formulation in this study was designed to target these 
receptors on the brain capillary endothelial cells.  
 
Figure 4. The brain capillary endothelial cells (red) were labeled with primary antibody (rabbit 
anti-CD31) and counterstained with secondary antibody (Alexa-Fluor 594 goat anti-rabbit IgG), 
transferrin receptors (green) were marked with mouse anti-transferrin receptor Ab (OX26) and 
counterstained with (Alexa-Fluor 488 goat anti-mouse IgG). Co-labeling of (A) CD31 and (B) 
transferrin receptors shown in the (C) merged image indicate the presence of high densities of 
transferrin receptors on brain capillary endothelium. Fluorescence images were taken at 10x 
magnification. 
 
3.4. Biocompatibility of liposomes 
3.4.1. Cytotoxicity assay 
The results indicated a cell viability of about 90% in glial cells after exposure to plain 
liposomes (100nM) and about 80% after exposure to Tf-PR-liposomes (100nM) as depicted in 
Figure 5. Also, Figure 6 shows that the endothelial cell viabilities on exposure to plain liposomes 
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were close to the viabilities of unexposed endothelial cells and about 85% after exposure to Tf-
PR-liposomes at the same concentration. The overall viabilities for endothelial cells were higher 
in comparison to the glial cells indicating greater sensitivity of glial cells on exposure to different 
liposomes. The cell viabilities were observed to increase with decreasing concentration of 
phospholipids. Consequently, cell uptake and transfection studies were performed at an 
optimized concentration of 100nM without compromising with cell viabilities (concentrations 
less than 100nM showed low transfection efficiencies).   
The biocompatibilities of CPP and Tf-CPP liposomes were evaluated in bEnd3, U87 and 
Daoy cells. The liposomes, without doxorubicin, were observed to be non-toxic in all three cell 
lines and showed a cell viability of approximately 80–90% upto a phospholipid concentration of 
200nM (Figure 10-12). The cell viabilities were observed to be lower with Tf-Mastoparan 
liposomes at higher concentrations in all three cell lines. The viabilities at 600 nM concentration 
were observed to be approximately 71.6%, 59.8% and 56.8% in Daoy, U87 and bEnd.3 cells, 
respectively. Furthermore, the viabilities were higher in the tumor cell lines (Daoy and U87) as 
compared to the brain endothelial (bEnd.3) cells. Also, U87 cells were found to be more 
sensitive to liposomal exposure as compared to the Daoy cells. In contrast, the negatively 
charged Tf-liposomes showed higher cell viabilities (approximately 90.23–95.48%), irrespective 
of the type of cells. The cell viabilities were observed to decrease significantly (p <0.05) after 
encapsulation of doxorubicin (Figure 7-9). The cytotoxicity of Tf-TAT liposomes was least 
while Tf-Mastoparan liposomes showed maximum cytotoxic potential. In addition, a significant 
(p <0.05) decrease in cell viability was observed at higher concentrations with all liposomes. Tf-
Mastoparan liposomes showed a cell viability of approximately 13–18% at 600nMconcentration 
in all three cell lines. The cell viability of Tf-TAT liposomes decreased from approximately 
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75.7–35.6% with an increase in phospholipid concentration from 50nM to 600nM concentration 
in Daoy cells. The cell viabilities of the single ligand CPP-liposomes were lower as compared to 
the dual-functionalized, Tf-CPP or plain liposomes. 
 
 
Figure 5. Bar graph representation of the viabilities of glial cells after exposure to varying 
concentrations of liposomes (plain, transferrin (Tf) coupled, poly-L-arginine (PR) coupled, and 
Tf–PR coupled). Results are expressed as mean ± SE (n = 4). ∗p < 0.05, ∗∗p <0.01 against plain 
liposomes at 100 nM concentration.  
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Figure 6. Bar graph representation of the viabilities of bEnd.3 cells after exposure to varying 
concentrations of liposomes (plain, transferrin (Tf) coupled, poly-L-arginine (PR) coupled, and 
Tf–PR coupled). Results are expressed as mean ± SE (n = 4). ∗p < 0.05, ∗∗p <0.01 against plain 
liposomes at 100 nM concentration. 
 
Figure 7. Bar graph depiction of the viabilities of Daoy cells after exposure to doxorubicin 
encapsulating plain and dual-functionalized liposomes. The data are presented as mean ± S.D. 
(n=4); Statistically significant (p<0.05) differences are indicated in comparison with (*) plain 
and (#) Tf-liposomes at the respective concentrations. 
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Figure 8. Bar graph depiction of the viabilities of U87cells after exposure to doxorubicin 
encapsulating plain and dual-functionalized liposomes. The data are presented as mean ± S.D. 
(n=4); Statistically significant (p<0.05) differences are indicated in comparison with (*) plain 
and (#) Tf-liposomes at the respective concentrations. 
 
 
Figure 9. Bar graph depiction of the viabilities of bEnd3 cells after exposure to doxorubicin 
encapsulating plain and dual-functionalized liposomes. The data are presented as mean ± S.D. 
(n=4); Statistically significant (p<0.05) differences are indicated in comparison with (*) plain 
and (#) Tf-liposomes at the respective concentrations. 
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Figure 10. Graphical representation of the viabilities of Daoy cells after exposure to dual 
modified liposomes (without doxorubicin), at varying phospholipid concentrations. The results 
are expressed as mean ± S.D. (n=4); *p<0.05 against plain liposomes at respective 
concentrations. 
 
Figure 11. Graphical representation of the viabilities of U87 cells after exposure to dual 
modified liposomes (without doxorubicin), at varying phospholipid concentrations. The results 
are expressed as mean ± S.D. (n=4); *p<0.05 against plain liposomes at respective 
concentrations. 
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Figure 12. Graphical representation of the viabilities of bEnd3 after exposure to dual modified 
liposomes, at varying phospholipid concentrations. The results are expressed as mean ± S.D. 
(n=4); *p<0.05 against plain liposomes at respective concentration. 
3.4.2. Hemolysis assay 
The interaction of cationic polymers with the negatively charged membrane of the 
erythrocytes can cause cell lysis and release of hemoglobin (Antohi et al. 1984). Since the 
liposomes were designed to be injected intravenously into adult SD rats, we evaluated their 
interaction with the erythrocytes in vitro prior to the in vivo biodistribution analysis. Hemolysis 
assay of the liposomes demonstrated that the dual-modified liposomes did not show any 
significant (p>0.05)increase in the hemoglobin release up to 600 nmoles of 
phospholipids/1.4x10
7
 erythrocytes (Figure 13-14) and were therefore, considered non-toxic. 
Slight hemolysis was observed with the Tf-PR-liposomes at 800 nmoles of phospholipids 
exposed to the same number of erythrocytes. The light microscopic observation of the 
erythrocytes did not reveal any disruption of cellular membrane or aggregation of the red blood 
cells with either Tf or Tf-PR-liposomes up to concentrations of 600 nmoles of phospholipids 
(Figure 15). Microscopic examination revealed changes in the structure of erythrocyte membrane 
and morphological appearance accompanied with slight aggregation after exposure to Tf-PR-
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liposomes at 800 nmoles of phospholipids. PBS, pH 7.4, was used as a negative control and did 
not show any damage to erythrocyte membrane under microscopic examination or release of 
hemoglobin on spectrophotometric measurement. Triton X-100, used as a positive control, 
demonstrated maximum lysis of erythrocytes, as observed under the light microscope, and 
release of hemoglobin on spectrophotometric analysis. 
Similar results were observed upon analyzing the hemolytic activity of Tf-CPP 
liposomes. The release of hemoglobin increased with increasing concentration of phospholipids 
(Figure 16). Lessthan 10% hemolysis was considered non-toxic (Sharma et al. 2013). Plain, Tf- 
Penetratin, and Tf-TAT liposomes were observed to be nontoxic upto a concentration of 600 
nmol of phospholipids/1.5×10
7
 erythrocytes. Slight hemolysis was observed withTf-Penetratin 
liposomes at concentration of 800 nmol ofphospholipids. However, Tf-Mastoparan liposomes 
showed a significantly higher (p<0.05) cytotoxicity at a concentration of 200 nmoles of 
phospholipids. 
 
 
 
 
 
 
Figure 13. Photo images of ependorf-tubes containing supernatant from RBCs exposed to 
different liposomes at varying concentrations. PBS, pH 7.4 and triton X-100 were used as 
negative and positive controls, respectively.   
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Figure 14. Graphical representation of percent hemolysis by different liposomes. Less than 10% 
hemolysis was considered non-toxic. *p<0.05 versus plain liposomes; #p<0.05 versus Tf-
liposomes. 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Microscopic images of RBCs exposed to (A) Plain (B) Tf (C) Tf-PR liposomes at 
600 nmoles of lipids (D) PBS (E) Tf-PR-liposomes at 800 nmoles of lipids (F) Triton X 100. 
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Figure 16. Graph showing the hemolytic activity (%) of various liposomal formulations. Red 
blood cells were exposed to PBS and triton X-100 for negative and positive controls, 
respectively. Less than 10% hemolysis was considered non-toxic. Statistically significant 
(p<0.05) differences are reported in comparison to free drug (a) and plain liposomes (b). Data are 
presented as mean ± S.D. (n=5). 
3.5. Cellular uptake studies 
3.5.1. Cell uptake of Tf-PR liposomes 
The uptake of DiI labeled liposomes was investigated in bEnd.3 cells using confocal 
fluorescence microscopy.  Figure 17 shows that the uptake of plain liposomes was lowest in the 
target cells while Tf-PR liposomes exhibited a clear and strong pattern of fluorescence 
throughout the cytoplasm and overlapping with the nuclei of the cells. The fluorescence of the 
cells was found to intensify with increase in the incubation time of cells with liposomes. The 
uptake of PR liposomes, facilitated by improved cellular binding and penetration alone, was 
lesser in comparison to the uptake of Tf-liposomes governed by receptor mediated endocytosis, 
indicating a higher uptake by receptor targeting mechanism in contrast to cell penetration. A 
combination of these two techniques resulted in substantial improvement in the uptake of 
fluorescently labeled liposomes by cells. Quantitative estimation of liposomal uptake was 
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performed by lysis of cells in PBS containing 0.1% triton X-100 followed by extraction of the 
fluorescent dye in methanol. Figure 18 shows that the fluorescence intensity of the samples 
increased with time. The uptake of Tf-liposomes was observed to increase from 35.9 ± 4.4% 
after 5 minutes to 82 ± 3.4% after 30 minutes. The increase in percent liposomal uptake was 
lowest for plain liposomes (from 18.4 ± 2.1% after 5 minutes to about 38.6 ± 5.8% after 30 
minutes) followed by the  uptake of PR-liposomes (from 29.2 ± 3.5% after 5 minutes to 58.9 ± 
4.1% after 30 minutes). The extent of uptake was highest for Tf-PR-liposomes with an increase 
in percent liposomal uptake from 47.2 ± 4.2% after 5 minutes to 94.8± 3.4% after 30 minutes. 
Further, adding excess of free transferrin reduced the uptake of Tf-liposomes to 35.62± 6.4% 
(observed after 30 minutes) due to inhibition of transferrin receptors. Transport of Tf-PR-
liposomes also decreased to 54.2 ± 5.8% after 30 minutes, however no significant alteration in 
the uptake behavior of plain and PR-liposomes was observed. Hence, the study demonstrated 
that uptake was mainly governed by receptor facilitated mechanism however, cell penetration 
significantly (p<0.05) improved the extent of liposomal delivery to cells. 
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Figure 17. Confocal microscopic images of bEnd.3 cells after uptake of DiI (excitation 553 nm 
and emission 570 nm) labeled liposomes at different time intervals. The nuclei of the cells were 
stained with DAPI (excitation330-385 emission 420nm). The image shows an overlap of the 
nuclei (blue) and liposomes (red) after uptake of liposomes by the endothelial cells (bEnd3). (B) 
Quantitative assessment of liposomal uptake in bEnd.3 cells at different time intervals. The 
percent cellular uptake is expressed as mean ± S.E. (n=4). Statistically significant (p<0.05)  in 
comparison to plain-lip (a), PR-lip (b), Tf-lip (c). 
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Figure 18. Quantitative assessment of liposomal uptake in bEnd.3 cells at different time 
intervals. The percent cellular uptake is expressed as mean ± S.E. (n=4). Statistically significant 
(p<0.05) differences are indicated in comparison to plain-lip (a), PR-lip (b), Tf-lip (c). 
 
3.5.2. Cell uptake of Tf-CPP liposomes 
We exploited the presence of transferrin receptors on the three cell lines (Daoy, U87 and 
bEnd.3) for delivery of Tf-CPP liposomes. Figures 19 and 20 illustrates the transport of different 
liposomes in the three cell lines following 1h of incubation. Free drug demonstrated negligible 
uptake after incubation with the cells (Figures 21 and 22). Plain liposomes, in the absence of any 
surface modification, showed the lowest transport in all types of cells while the dual-
functionalized Tf-CPP liposomes showed maximum uptake and therefore, the strongest 
fluorescence pattern in all cells (Figure 19).  Also, the uptake of Tf-liposomes was more than 
plain and CPP-liposomes. The uptake of liposomes was observed to increase with time (Figure 
20, 23 and 24).   
Quantitative estimation of liposomal uptake further confirmed the efficacy of dual-
functionalized liposomes over single ligand and plain liposomes (Figure 20). Tf-TAT liposomes 
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showed an uptake of about 90%, 82% and 77% in U87, Daoy, and bEnd.3 cells, respectively. 
The uptake of Tf-Penetratin liposomes was about 98%, 96%, and 89% while the uptake of Tf-
Mastoparan liposomes was about 97%, 90% and 87% in U87, Daoy, and bEnd.3 cells, 
respectively. The order of increasing fluorescence intensity for dual-functionalized liposomes 
was Tf-TAT<Tf-Mastoparan<Tf-Penetratin.  The results emphasized the significance of dual-
mechanism of uptake over receptor targeting or cell penetration alone. 
 
Figure 19. Fluorescence microscopic images (10x magnification) of different cells after uptake 
of doxorubicin encapsulating liposomes (excitation/emission wavelengths: 470/585 nm). The 
nuclei of the cells were stained with DAPI (excitation/emission: 330–385/420 nm). The image 
shows an overlap of the cells after uptake of doxorubicin liposomes (red) and the nuclei of the 
cells (blue). 
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Figure 20. Bar graph representation of the uptake of doxorubicin liposomes after 1h of 
incubation with either Daoy, U87, or bEnd3 cells. Following uptake, the cells were lysed and the 
uptake of liposomes was determined using high performance liquid chromatography (HPLC) 
equipped with UV visible detector at 234nm. The results are expressed as mean ± S.D 
(n=5).Statistically significant (p < 0.05) differences are indicated versus plain liposomes (*) and 
Tf liposomes (#). 
 
 
 
 
 
 
Figure 21. Fluorescence microscopic images (10x magnification) of bEnd.3, Daoy and U87 cells 
after exposure of these cells to free doxorubicin (1mg/ml in Hepes buffered saline, pH 7.4) 
(excitation/emission wavelengths: 470/585 nm) for 1h. 
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Figure 22. Bar graph representation of the quantitative assessment of the uptake of free 
doxorubicin in different cell lines after exposure of cells to the drug for 1h. The percent cell 
uptake is expressed as mean± S.D (n=4). 
Figure 23. Quantitative assessment of the uptake of doxorubicin encapsulating liposomes after 
15 minutes of incubation with the three cell lines. Following uptake, the cells were lysed and the 
uptake of liposomes was determined using high performance liquid chromatography (HPLC) 
equipped with UV-visible detector at 234nm. The results are expressed as mean ± S.D (n=5). 
 
91 
 
 
Figure 24. Quantitative assessment of the uptake of doxorubicin encapsulating liposomes after 
30 minutes of incubation with the three cell lines. Following uptake, the cells were lysed and the 
uptake of liposomes was determined using high performance liquid chromatography (HPLC) 
equipped with UV-visible detector at 234nm. The results are expressed as mean ± S.D (n=5). 
3.6. Mechanism of uptake 
The uptake of all types of liposomes was almost completely inhibited at 4C thus 
indicating an energy dependent uptake of the liposomes in all three cell lines (Figure 25-27). 
Colchicine, an inhibitor of caveolae formation, did not inhibit the uptake of plain, Tf, or Tf-CPP 
liposomes. Also, macropincytosis inhibitor amiloride did not significantly (p>0.5) inhibit the 
uptake of Tf-TAT, Tf-Penetratin, Tf, or plain liposomes. However, a significant (p<0.05) 
reduction in the uptake of Tf-Mastoparan liposomes was observed using amiloride, thereby 
indicating the contribution of Mastoparan in the macropinocytic uptake of the liposomes into all 
three cell lines. Some inhibition (non-significant) of other Tf-CPP liposomes was also observed 
in the presence of amiloride. However, plain and Tf-liposomes were not affected by the 
macropinocytic inhibitor thus eliminating macropinocytosis as the uptake pathway for these 
liposomes. In contrast, the uptake of single ligand CPP-liposomes was considerably affected by 
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the presence of amiloride and chlorpromazine (Figure 28-30). In addition, chlorpromazine 
reduced the uptake of all types of liposomes to approximately 30%-50% in all cell lines thereby 
illustrating clathrin-mediated uptake as the major pathway for uptake of liposomes. M-β-CD 
(methyl-β-cyclodextrin) depletes cholesterol, which is involved in the formation of invaginations 
leading to the development of clathrin-coated vesicles during the uptake of extracellular 
components (Rodal et al. 1999). A significant (p<0.05) reduction in the uptake of liposomes was 
observed using m-β-CD, thus re-confirming the participation of clathrin-coated vesicles in the 
uptake of liposomes.  The results indicated clathrin-mediated uptake as the major pathway for 
the transport of plain, Tf and Tf-CPP liposomes. The uptake of free drug was only slightly 
inhibited at 4C, thus indicating a non-energy dependent uptake as the major pathway for 
transport of free doxorubicin. 
 
Figure 25. Graphical representation of effect of various inhibitors on the uptake of doxorubicin 
encapsulating Tf-CPP-liposomes in Daoy cells. The uptake of doxorubicin liposomes was 
quantified by lysis of the cells and measurement of the drug using HPLC system equipped with 
UV visible detector at 234 nm. The results are expressed as mean±S.D. (n=4).  
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Figure 26. Effect of various inhibitors on the uptake of doxorubicin encapsulating Tf-CPP-
liposomes in U87 cells. 
 
Figure 27. Effect of various inhibitors on the uptake of doxorubicin encapsulating Tf-CPP-
liposomes in bEnd3 cells.  
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Figure 28. Effect of various inhibitors on the uptake of doxorubicin encapsulating CPP-
liposomes in Daoy cells. 
 
 
 
 
 
 
 
Figure 29. Effect of various inhibitors on the uptake of doxorubicin encapsulating CPP-
liposomes in U87.  
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Figure 30. Effect of various inhibitors on the uptake of doxorubicin encapsulating CPP-
liposomes in bEnd3.  
3.7. In vitro transfection potential of liposomes 
The designed liposomes were intended to target transferrin receptors, therefore, 
transfection efficiencies of only transferrin coupled (Tf and Tf-PR) liposomes were compared 
while plain liposomes were used as passive control. Confocal microscopic imaging showed the 
highest expression of green fluorescent protein in primary glial cells transfected with Tf-PR-
liposomes (Figure 31a). Flow cytometeric evaluation indicated a transfection efficiency of 39.9% 
for Tf-PR-liposomes, as shown in Figure 31b, which was significantly (p<0.05) higher than the 
transfection efficiency of Tf- liposomes (5.89 %). The plain liposomes demonstrated higher 
transfection efficiency (11.9%) than Tf-liposomes in primary glial cells which can be explained 
by the higher zeta potential of plain liposomes in comparison to the Tf-liposomes. 
In addition, the dual-functionalized liposomes also showed efficient gene expression in 
Daoy, U87, and bEnd.3 cells after transfection with liposomes encapsulating either green 
fluorescent protein or β-galactosidase expressing plasmid (Figure 32 and 33). Maximum 
transfection levels were obtained using Tf-Penetratin liposomes. The single ligand CPP 
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liposomes demonstrated lower transfection levels as compared to the Tf-CPP liposomes. Dual-
modification increased the cellular translocation of plasmid carrying liposomes and therefore 
improved the cellular delivery of pDNA. The higher transfection levels of penetratin conjugated 
Tf-liposomes as compared to other CPP conjugated Tf-liposomes were attributed to the cationic 
charge and amphiphilicity of Penetratin as compared to the other CPPs.  
Figure 31. (A) Confocal microscopic images (10x magnification) of primary glial cells 
transfected with Tf-PR-liposomes encapsulating chitosan-GFP plasmid polyplexes (B) 
Quantitative evaluation performed using FACS analysis. 
 
 
 
 
Figure 32. Fluorescence microscopic images of different cells transfected with either TAT, 
TAT-Tf, Penetratin, Penetratin-Tf, Mastoparan or Mastoparan-Tf liposomes encapsulating 
gWiz®GFP plasmid. 
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Figure 33. Transfection efficiencies of dual-modified, plain and single-ligand CPP-liposomes in 
three different cell lines; #p<0.05 versus plain liposomes. 
 
3.8. Evaluation of in vitro BBB model 
3.8.1. 2D in vitro BBB model 
3.8.1.1. In vitro BBB integrity  
The TEER of the both monolayer and co-culture models, was gauged every other day 
during the incubation period and was observed to increase with increase in the cell densities on 
the membrane. The TEER value for the co-culture model, as observed on the seventh day of 
incubation period, was found to be 315 ± 18  cm2 which was significantly (p<0.05) higher than 
the TEER of 198± 15  cm2 for the monolayer model. The paracellular permeability for both the 
models was also monitored correspondingly and the Pe value was found to be significantly (p< 
0.05) less for the co-culture model as compared to the monolayer model for BBB as shown in 
Figure 34.  
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3.8.1.2. Transport of liposomes across in vitro BBB 
 Tf-liposomes and Tf-PR-liposomes showed significantly (p<0.05) higher permeability 
across the barrier layer in comparison to the plain unconjugated and PR-liposomes as shown in 
Figure 35. Also, permeability of Tf-PR-liposomes (Pe 4.79) was observed to be higher as 
compared to the Tf-liposomes, thereby validating the incorporation of poly-L-arginine to the 
liposomes. Assessment of the percent liposomal transport across in vitro BBB model, illustrated 
a similar pattern as observed with the permeability data. The percentage of liposomes transported 
increased from about 5.4% for plain unconjugated liposomes to approximately 18.9% for Tf-PR-
liposomes. Also, transport of Tf-liposomes and PR-liposomes was lesser as compared to Tf-PR-
liposomes as shown in Figure 36. Therefore, maximum transport across the barrier layer was 
achieved using liposomal delivery vector conjugated to both poly-L-arginine and transferrin. 
3.8.2. 3D in vitro BBB model 
3.8.2.1. Evaluation of barrier properties 
The scanning electron microscopic (SEM) images confirmed the formation of a porous 
scaffold and the growth of tumor spheroids inside the pores after approximately 35 days of 
culture in high serum containing media (Figure 37). The scaffold showed excellent cellular 
biocompatibility and a considerable improvement in cell growth with time as observed with 
hematoxylin-eosin staining. Dense growth of overlapping tumor cells was observed on 20µm 
thick sections of the scaffold on day 35 (Figure 38). The 3D tumor culture was combined with 
the inserts (0.4µm pore size) carrying brain endothelial cells cultured on the luminal side of the 
membrane. For 2D BBB model (described above), we observed a significantly lower (p<0.05) 
paracellular transport of Na-F across the in vitro BBB model constructed using both bEnd.3 cells 
and primary glial cells as compared to the model without glial cells. In this study, we observed a 
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significant reduction in the paracellular transport of Na-F across the bEnd.3 cells on culture 
inserts combined with glioblastoma tumor scaffolds (Pe = 3.96 x 10
-6
) as compared to the 
transport of the fluorescent molecule across the inserts with bEnd.3 cells alone (Pe= 7.93 x 10
-6
) 
(Figure 39). However, the paracellular transport across the in vitro 3D tumor model was greater 
than the in vitro BBB model with primary glial cells on the underside of the membrane (Pe = 
1.98 x 10
-6
). In addition, the TEER value of the endothelial cell layer cultured with the 3D tumor 
(226 ± 14 cm2) was higher than the TEER across the endothelial cell layer cultured alone (192 
± 23 cm2) but was lower than the TEER across the in vitro BBB model with endothelial cells 
on the upper side and the glial cells on the underside of the membrane (323 ± 16 cm2).  
3.8.2.2. Transport of liposomes across 3D brain tumor model 
The transport of dual-functionalized Tf-CPP liposomes was observed to be significantly 
(p<0.05) higher in comparison to the single ligand Tf or CPP liposomes. The transport of plain 
liposomes was the lowest and was comparable to that of the free drug. Tf-Penetratin liposomes 
showed the highest endothelial permeability coefficient (Pe = 5.52 x 10
-6
) which was not 
significantly different (p>0.05) from the Tf-Mastoparan liposomes (Pe= 4.89 x 10
-6
) (Fig 40). 
The percentage of liposomes transported increased from approximately 4.2% for TAT to 10.6 % 
for Tf-TAT liposomes, from 5.4% for Mastoparan to 13.9% of Tf-Mastoparan liposomes, and 
from 6.5% for Penetratin to 14.9 % for Tf-Penetratin liposomes (Figure 41). Therefore, dual 
modification considerably improved the transport across the in vitro brain tumor model. 
Additionally, the scaffolds were embedded into Tissue Tek OCT compound (Sakura Finetek 
USA, Inc., Torrance, CA) and sectioned on a cryostat to evaluate the uptake of doxorubicin 
liposomes by tumor cells growing in a 3D microenvironment (Figure 42). Maximum 
fluorescence was observed in tumor scaffolds exposed to Tf-Penetratin liposomes. The results 
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further justified the incorporation of CPP to Tf liposomes and triggering of the dual mechanism 
of transport via both receptor-mediated transcytosis and improved cell penetration. 
 
Figure 34. Endothelial permeability coefficient for sodium fluorescein (Na-F Pe, expressed in 
10
-6
 cm/s) of blood-brain barrier models. 
 
 
 
 
 
 
 
 
Figure 35. Endothelial cell permeability (Pe, expressed in 10
-6
 cm/s) coefficient for different 
liposomal formulations; p<0.05 versus (a) plain liposomes (b) PR liposomes (c) and Tf-
liposomes. 
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Figure 36. Flux of different liposomes evaluated across in vitro BBB model, over 8h; p<0.05 
versus (a) plain liposomes (b) PR liposomes and (c) Tf-liposome. 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. SEM images showing (A) porous structure chitosan-PLGA scaffold and (B) tumor 
cells growing in a 3 dimensional environment within the pores of the scaffold.  
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Figure 38. Hematoxylin-eosin staining of 20µm thick sections of scaffolds with tumor cells 
growing in 3 dimensional environment in the porous scaffold.  
 
Figure 39. Endothelial cell permeability coefficient for sodium fluorescein (Na–F Pe, expressed 
in 10
−6
 cm/s) for brain tumor model; p < 0.05 versus (*) only bEnd.3 cells and (#) bEnd3/tumor 
cells on 3D scaffolds. 
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Figure 40. Endothelial cell permeability (Pe, expressed in 1x10
−6
 cm/s) coefficient for different 
liposomal formulations; p<0.05 versus free doxorubicin (*) and plain liposomes (#).  
 
 
Figure 41. Percent transport of different doxorubicin encapsulating liposomes across in vitro 
brain tumor model, over a period of 8 h; p<0.05 versus (a) free drug, (b) plain, (c) Tf. 
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Figure 42. The images show 20µm thick sections of the scaffolds with tumor cells after 8h of 
liposomal transport 
 
3.9. In vivo evaluation of liposomes 
3.9.1. Evaluation of Tf-PR-liposomes 
3.9.1.1. Biodistribution  
 The biodistribution of DiR-labeled liposomes was tracked using NIR imaging of various 
organs at different time points.  Considering the previous report demonstrating poor transport of 
PR-liposomes across in vitro BBB model (Sharma et al. 2012) and due to the absence of the 
targeting ligand, transferrin, PR-liposomes were not evaluated for distribution in vivo. Plain 
liposomes were used as passive control for evaluating the biodistribution of DiR-labeled 
phospholipid liposomes. Quantitative estimation of liposomal distribution (Figure 43a-f) showed 
maximum accumulation of fluorescently labeled liposomes in the spleen and liver, 12h post 
intravenous injection. The amount of liposomes (%ID/ gram of tissue) in different organs 
decreased at increasing time intervals. A more rapid decrease in fluorescence intensity of plain 
liposomes was observed, in different tissues, with time as compared to the Tf and dual-modified 
liposomes thus indicating a higher clearance of plain liposomes from circulation. The decrease in 
the concentration of Tf-liposomes was less in liver, spleen and kidneys as compared to the plain 
and dual-modified liposomes thus indicating increased circulation and lower elimination of Tf-
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liposomes by the macrophage system. The dual-modified liposomes accumulated more in lungs 
and heart as compared to other liposomes. The liposomes were transported to lungs and were 
gradually eliminated with time. Presumably, the cationic charge of Tf-PR-liposomes also 
increased their penetration in the highly perfused heart. Also, the occurrence of a cell penetrating 
peptide on the transferrin receptor targeted liposomes resulted in eight fold greater penetration of 
Tf-PR-liposomes into brain in comparison to plain liposomes and two fold greater than the Tf-
liposomes. The results from ex vivo imaging of organs (Figure 44) showed that the fluorescence 
intensity of dual modified liposomes in the brain was stronger as compared to either plain or Tf-
liposomes and maximum fluorescence was observed after 24h of liposomal administration. Also, 
the fluorescence decreased 72h post intravenous injection. The decrease in fluorescence in 
various organs with time might be explained by increased elimination of liposomes from the 
body with time (MacKaya et al. 2005). 
 
 
 
 
 
 
 
Figure 43. Distribution of liposomes in liver at different time points, expressed as percent 
injected dose (ID)/gram body weight; *p<0.05 versus plain liposomes. 
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Figure 44. Distribution of liposomes in spleen at different time points, expressed as percent 
injected dose (ID)/gram body weight; *p<0.05 versus plain liposomes. 
 
 
 
 
 
 
 
 
Figure 45. Distribution of liposomes in lungs at different time points, expressed as percent 
injected dose (ID)/gram body weight; p<0.05 versus (*) plain and (#) Tf-liposomes. 
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Figure 46. Ddistribution of liposomes in heart at different time points, expressed as percent 
injected dose (ID)/gram body weight; p<0.05 versus (*) plain and (#) Tf-liposomes. 
 
 
 
 
 
 
 
 
 
 
 
Figure 47. Distribution of liposomes in kidneys at different time points, expressed as percent 
injected dose (ID)/gram body weight; *p<0.05 versus plain liposomes. 
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Figure 48. Distribution Distribution of liposomes in brain at different time points, expressed as 
percent injected dose (ID)/gram body weight; p<0.05 versus (*) plain and (#) Tf-liposomes. 
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Figure 49. (A) Ex vivo imaging of different organs isolated from rats at 24h post intravenous 
injection (exposure time 2 min). (B) ex vivo imaging of brains isolated from rats at 24h time 
point (exposure time 8 minutes). 
3.9.1.2. Transfection potential  
The β-gal activity of the tissues was determined using the β-gal assay kit. The dual-
modified liposomes demonstrated significantly (p<0.05) higher levels of enzyme activity in brain 
(1.49± 0.22mU/mg of protein) as compared to the single-ligand liposomes (0.90± 0.21mU/mg of 
protein) or naked DNA (0.65 ± 0.13 mU/mg of protein) (Figure 45). The Tf-PR-liposomes also 
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showed higher levels of enzyme activity in different organs (Figure 46) e.g. liver and spleen. The 
enzymatic activity varied from 23.38 ± 2.58 mU/mg of protein in spleen, 12.67±2.98 mU/mg of 
protein in liver, 9.73±1.9 mU/mg of protein in lungs, 6.43± 1.91 mU/mg of protein in kidneys to 
4.54 ±1.3 mU/mg of protein in heart using the dual-modified liposomes. The levels of enzyme 
activity in these organs were observed to be comparatively low with the Tf-liposomes varying 
from 16.9 ± 1.98 mU/mg of protein in spleen, 9.29 ±2.33 mU/mg of protein in liver, 4.43 ±1.99 
mU/mg of protein in lungs, 4.48 ± 1.76 mU/mg of protein in kidneys to 2.32 ± 0.81 mU/mg of 
protein in heart. In addition, the enzyme activity induced by naked DNA in different tissues was 
close to the endogenous activity of the corresponding tissue thereby indicating practically no 
transfection with plasmid DNA alone.   
 
 
 
 
 
 
 
 
 
 
 
Figure 50. Comparison of transfection efficiencies of dual-modified and conventional Tf-
liposomes in brain after intravenous injection of β-gal plasmid encapsulating liposomes; p<0.05 
versus (*) naked DNA, (#) Tf-liposomes. 
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Figure 51. Comparison of transfection efficiencies of dual-modified and conventional Tf-
liposomes, in different organs after intravenous injection of β-gal plasmid encapsulating 
liposomes; p<0.05 versus (*) naked DNA, (#) Tf-liposomes. 
 
3.9.1.3. Tissue biocompatibility 
Cell penetrating peptides have been reported to cause toxicity in highly perfused organs 
like lungs, heart, kidneys and liver due to their non-specific interaction and higher penetration in 
tissues (Ramana et al. 2010).The histological examination of transfected tissues facilitated the 
evaluation of in vivo biocompatibility of liposomal formulations. The tissue sections from the 
animals administered with PBS were used as control. Hematoxylin-eosin staining of the 
transfected tissue sections revealed no alterations in the morphological appearance of the tissues. 
Tissue sections from different organs did not show any necrosis, inflammation or enlargement of 
nuclei (Figure 47) and were comparable to the tissue sections obtained from control animals. 
Since the biodistribution studies demonstrated higher accumulation of liposomes in liver and 
spleen, these organs were carefully examined for any histological changes. No ballooning of 
hepatocytes or signs of inflammation were observed in the liver sections and no signs of necrosis 
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were evident in the tissue sections obtained from spleen at the administered dose of liposomes 
(15.2 µmoles of phospholipids/kg body weight). There were no signs of toxicity in the tissue 
sections up to a dose of 20 µmoles of phospholipids/kg body weight. Also, in our pilot studies, 
we evaluated the transfection efficiency and tissue histology after 48 h (based on in vitro 
transfection studies) of the intravenous administration of liposomes. No inflammation or tissue 
necrosis was observed at this time point or later. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52. Histological examination of different tissues after transfection with β-gal plasmid 
encapsulating liposomes.  
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3.9.2. Biodistribution of Tf-CPP liposomes 
 Considering the poor transport of CPP-liposomes across the in vitro brain tumor model, 
these liposomes were not evaluated for in vivo transport to brain.  Doxorubicin loaded plain 
liposomes were used as a passive control. HPLC analysis of tissue samples indicated maximum 
accumulation of Tf conjugated liposomes in the spleen and liver 12h post intravenous 
administration (Figure 48a-g). The %ID (percent injected dose) of the liposomes per gram of 
tissue decreased with increasing time intervals in all organs. Free doxorubicin and plain 
liposomes were eliminated more rapidly from the liver and spleen as compared to the Tf-CPP 
liposomes. Tf-Mastoparan liposomes showed a higher elimination from the major macrophage 
organs including the liver and spleen as compared to Tf-TAT or Tf-Penetratin liposomes. Tf-
Penetratin liposomes were transported more to the heart and their elimination from heart was 
slower as compared to the other liposomes. The transport of Tf-Mastoparan liposomes to the 
lungs was slightly higher as compared to the Tf-Penetratin liposomes, nevertheless, the 
elimination of Tf-Mastoparan liposomes was more rapid than the Tf-Penetratin liposomes. 
Previous studies reported greater interaction of cationic polymers and CPPs with the blood cells 
and their subsequent accumulation in lungs (Sharma et al. 2013; Kibria et al. 2011). In this study, 
approximately 10-15% of the dual-functionalized liposomes were transported to the lungs after 
24h. The elimination of negatively charged Tf-liposomes was slower from liver, spleen and 
kidneys as compared to plain or dual-functionalized liposomes. The dual-functionalized, Tf-
Penetratin liposomes showed maximum brain penetration after 24h (~3.67% ID/gram of tissue) 
followed by the Tf-TAT liposomes (~2.89% ID/gram of tissue). The accumulation of Tf-
Mastoparan liposomes was lower as compared to the other Tf-CPP liposomes in brain. 
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Figure 53. Distribution of doxorubicin containing liposomes in liver at various time points; 
p<0.05 versus (†) free doxorubicin, (*) plain and (#) Tf liposomes. 
 
 
 
 
 
 
 
Figure 54. Distribution of doxorubicin containing liposomes in kidneys at various time points; 
p<0.05 versus (†) free doxorubicin, (*) plain and (#) Tf-liposomes. 
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Figure 55. Distribution of doxorubicin containing liposomes in spleen at various time points; 
p<0.05 versus (†) free doxorubicin, (*) plain and (#) Tf-liposomes. 
 
 
 
 
 
 
 
 
 
 
 
Figure 56. Distribution of doxorubicin containing liposomes in heart at various time points; 
p<0.05 versus (†) free doxorubicin, (*) plain and (#) Tf-liposomes. 
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Figure 57. Distribution of doxorubicin containing liposomes in lungs at various time points; 
p<0.05 versus (†) free doxorubicin, (*) plain and (#) Tf-liposomes. 
 
 
 
 
 
 
 
Figure 58. Distribution of doxorubicin containing liposomes in brain at various time points; 
p<0.05 versus (†) free doxorubicin, (*) plain and (#) Tf-liposomes. 
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Figure 59. Distribution of doxorubicin containing liposomes in blood at various time points; 
p<0.05 versus (†) free doxorubicin, (*) plain and (#) Tf-liposomes. 
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CHAPTER IV. DISCUSSION 
Targeted delivery vectors can be administered systemically without causing physiological 
disruption of the BBB (Huwyler et al. 1996; Pardridge et al. 1985). The application of sterically 
stabilized Tf receptor targeted nanoparticles, for delivery to the brain, after parenteral 
administration has become well established over the past years (Sharma et al. 2013; Zhong et al. 
2002; Cheng et al. 2004).However, receptor saturation has been identified as the major 
challenging factor that limits the transport of molecules via receptor targeted systems (Sharma et 
al. 2012; Kibria et al. 2011). In addition, the endocytic uptake of these nanoparticulate drug 
carriers eventually leads to lysosomal degradation (Varga et al. 2000; Gupta et al. 2005). This 
research work is focused on developing novel dual-modified delivery systems for therapeutic 
agents (small molecule drugs and genes). The liposomes were conjugated to transferrin protein 
for targeting the transferrin receptors on BBB. In addition, the liposomes were conjugated to 
various cell penetrating peptides to improve the penetration of molecules into the targeted tissue.  
Surface modification of liposomes with CPPs facilitates endosomal escape and increases their 
cellular delivery (Bolhassani 2011). The mechanism of internalization of these peptides is greatly 
dependent on the CPP used, the concentration, the type of cell line, and cargo carried. Although 
it is now known that the uptake of CPPs is mediated both via endocytic and non-endocytic 
pathways, the exact mechanism of cellular uptake still remains controversial. We investigated the 
influence of various cell penetrating peptides on internalization of transferrin receptor targeted 
liposomes and their mechanism of uptake by different cell lines. The rationale for using these 
peptides was based on the difference in proportion of hydrophilic, amphiphilic, and hydrophobic 
amino acid residues in these three CPPs. Poly-L-arginine consists of all hydrophilic arginine acid 
residues, TAT peptide consists of more hydrophilic amino acids as compared to hydrophobic 
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amino acids, Penetratin has almost an equal proportion of hydrophilic and hydrophobic amino 
acids while Mastoparan consists of more hydrophobic amino acid residues. 
4.1. Physical characterization of liposomes 
We designed novel liposomal vectors combining the effects of receptor targeting and 
improved cell penetration. Using the AFM technique, we visualized the spherical shape of 
evenly dispersed nanosized liposomes clearly, both with and without conjugation of Tf and PR. 
The existence of PEG chains on the surface of the liposomes inhibited aggregation of the 
vesicles in spite of the near-neutral zeta potential values. Tf was conjugated to the liposomes via 
post-insertion technique. This simple, effective, and flexible method for preparing ligand-
conjugated liposomes allows insertion of biologically active ligand proteins into preformed drug 
or gene-loaded liposomes (Iden and Allen 2001). The conventional method of incorporating a 
functional lipid to the liposomal bilayer followed by coupling of a protein is accompanied with 
the possibility of leaving untreated functional groups or traces of coupling reagents on the inside 
of the bilayer, thus exposing the encapsulated agent to chemical reagents (Moreira 2002). In this 
study, PEG–lipid–Tf was inserted into preformed PR liposomes encapsulating the desired gene 
using simple stirring at room temperature. The coupling efficiency of Tf with PR or CPP 
liposomes was observed to be slightly (non-significantly) less than with the plain liposomes. This 
was attributed to the presence of PEG-conjugated PR/CPPs in the preformed liposomes that 
resulted in a decrease in the equilibrium shift of PEGylated Tf from the micellar phase to the 
liposomal bilayer. 
 Liposomes, being uniformly dispersed nano-sized vesicles, can be classified as colloidal 
suspensions. The size and charge of a colloidal suspension are important factors controlling its 
stability during storage. Large sized colloidal suspensions with neutral charge tend to become 
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unstable and gradually agglomerate (duPlessis et al. 1996). As previously discussed, the 
liposomal vesicles were synthesized to possess near neutral charge (Sharma et al. 2012)which 
emphasizes the significance of monitoring the stability of liposomes during storage and under 
simulated in vivo conditions. The stability of the liposomes was examined at 4C for 30 days and 
in the presence of serum (10% FBS) at 37°C for 60 min. The occurrence of a stearic stabilizer, 
polyethylene glycol (PEG), reduced aggregation and improved the stability of near neutral 
liposomes during prolonged storage and in the presence of serum at 37°C. In addition, the 
presence of a negatively charged protein, transferrin balanced the cationic charge of CPP and 
further reduced the destabilization of liposomes by decreasing the non-specific binding of serum 
proteins with the cationic peptide. The liposomes were observed to be stable and showed no 
significant change (p>0.05) in size and zeta potential values under the tested conditions (Table 
5). Since the liposomes were intended to deliver the desired gene to the target tissue, therefore 
we evaluated the pDNA encapsulation and release profile of the liposomes under storage at 4°C 
and under biologically relevant conditions, in the presence of 10% serum at 37°C. The liposomes 
demonstrated stable encapsulation of the pDNA at 4 °C for 30 days. Also, approximately 20% of 
the DNA was released from the dual-modified and plain liposomes after incubation at 37 °C for 
7 days in the presence of serum. The release of pDNA from Tf-liposomes was about 30% and 
was not significantly different (p>0.05) from the percent DNA release from plain and Tf-PR 
liposomes. However, since the encapsulation efficiencies were not significantly different for 
different liposomes, therefore the slight increase in the release of pDNA from the negatively 
charged Tf-liposomes can be attributed to greater displacement of the released DNA from Tf-
liposomes by serum proteins (Xu et al. 1996). The PR-liposomes showed a release of about 18% 
after incubation at 37°C for 7 days. No significant (p>0.05) difference in the Doxorubicin 
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encapsulation efficiencies of dual-functionalized liposomes was observed, however, the loading 
of plain and CPP modified liposomes was slightly higher (non-significantly) than the dual-
functionalized liposomes. This might be due to the interference in the transport of drug 
molecules into preformed liposomes, via pH gradient loading, due to the presence of transferrin 
protein on the surface. In addition, the Tf-CPP liposomes showed less than 31% of the drug 
leakage after 12 h of incubation in PBS (pH 7.4) in the presence of serum, at 37°C (Figure 3). 
The percent cumulative release of the drug was greater with plain liposomes as compared to the 
Tf and Tf-CPP liposomes. This was due to the presence of negatively charged protein, 
transferrin, which reduced the interaction of the Tf and Tf-CPP liposomes with serum proteins. 
Also, the higher positive charge of Penetratin contributed to greater interactions of the Tf-
Penetratin liposomes with the serum proteins and therefore, a greater release (non-significant) of 
the encapsulated drug as compared to the other Tf-CPP liposomes. 
4.2. In vitro biocompatibility of liposomes 
The efficiency of the delivery vector lies not only in its ability to carry the encapsulated 
agent intothe desired cells but also in its biocompatibility atthe concentrations used. The 
cytotoxic potential of liposomes, at varying concentrations, was evaluated in vitro. BBB is 
composed of tightly packed endothelial cells supported by the surrounding glial cells that aid in 
the induction and maintenance of tight junction barrier (Malina et al. 2009; Tontsch et al. 1991). 
Since, the liposomes were intended for delivery across BBB; hence, we initially evaluated the 
biocompatibility of Tf-PR-liposomes in both glial and brain endothelial cells for finding an 
optimized concentration for further assessment of cellular uptake and transfection efficiency. In 
addition, we assessed the cytotoxicity of Tf-CPP-liposomes, using MTT assay in Daoy, U87, and 
bEnd.3 cells. The rationale for selecting these tumor cell lines was based on the incidence and 
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severity of these tumors in the human population which directly relates to the need for 
establishing a successful treatment strategy for these tumors. Glioblastoma multiforme is the 
highest grade of astrocytic tumors and is associated with very low survival rates (Krex et al. 
2007). Also, medulloblastoma is a rapidly growing high grade tumor and is the most common 
type of embryonal tumors (McNeil et al. 2002). 
Tf-PR liposomes showed a cell viability of about 84% in endothelial cells and 81%in 
primary glial cells (Figures 5 and 6). The PR liposomes demonstrated lowest biocompatibility, 
which was attributed to the positive charge of PR. A decrease in the viability was observed with 
increasing concentration of phospholipids, which was ascribed to the presence of cationic lipids 
forming liposomes and positively charged peptide on the liposomal surface. An acceptable 
balance between transfection efficiency and biocompatibility of bifunctional liposomes was 
achieved at a concentration of 100 nM. The liposomes showed low transfection efficiencies at 
concentration below 100 nM. The liposomes were, therefore, used at 100 nM concentration for 
further in vitro studies. Also, the dual-functionalized Tf-CPP-liposomes were highly 
biocompatible, however, the liposomes considerably increased the cytotoxic potential of the 
anticancer drug, doxorubicin. The Tf-PR liposomes showed efficient biocompatibility in bEnd.3 
and glial cells up to 100nMphospholipid concentration.  
However, the short chain CPPs (TAT, Penetratin and Mastoparan) demonstrated an 
improved cellular biocompatibility up to 200nM phospholipid concentration. The Tf-TAT and 
Tf-Penetratin liposomes showed higher cell viability as compared to the Tf-Mastoparan 
liposomes. The cell viabilities of the dual-functionalized liposomes without doxorubicin were 
approximately 85–98%, however, incorporation of the drug reduced the viability of tumor cells 
to approximately 30–40%indicating efficient translocation of the anticancer drug intothe tumor 
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cells. The greater cytotoxic effect of Tf-Mastoparan liposomes could be partially attributed to the 
membrane disruptive potential of Mastoparan via binding to intracellular targets (Saar et al. 
2005). The single ligand CPP-liposomes were observed be more cytotoxic as compared to the 
dual modified Tf-CPP liposomes. The greater cytotoxicity of the CPPliposomes was due to the 
higher cationic charge of the CPP modified liposomes as compared to the dual functionalized 
(Tf-CPP) or plain liposomes. In contrast, the negative charge of transferrin protein resulted in 
greater cell viabilities of Tf-liposomes as compared to the Tf-CPP liposomes. 
 The Dual-modified liposomes were intended for delivery into systemic circulation. 
Cationic macromolecules have been reported to trigger thrombosis, embolization and hemolysis, 
in vivo (Antohi and Brumfeld 1984; Zhu et al. 2007). The presence of cationic peptides on the 
liposomal surface can therefore, induce interactions with the erythrocyte membrane causing cell 
lysis and release of hemoglobin. Therefore, we performed a hemolysis assay to afford additional 
information regarding in vivo biocompatibility of the proposed liposomes. Both dual-modified 
and Tf-liposomes were biocompatible at elevated phospholipid concentrations. However, at 
extremely high concentrations of liposomes (~800 nmoles of phospholipids/1.4×10
6
 
erythrocytes), hemolysis was evident. This can be explained by the increasing interactions of the 
liposomes at higher phospholipid concentrations, with the same number of erythrocytes. The in 
vitro assay for hemolysis was performed by exposing ~10
7
 erythrocytes to varying phospholipid 
concentrations. Both Tf and Tf-PR-liposomes were observed to be safe up to 600nmoles of 
phospholipids in a volume of 0.5 ml of PBS. Therefore, the concentration of the phospholipids 
was 1.2 mM. We can estimate the total blood volume of an adult SD rat using Lee and Blaufox 
equation (Lee and Blaufox 1985): BV=0.06 X BW+0.77. Therefore, the blood volume will range 
from 15.7 to 21.7 ml for adult rats (250–350 g).The dose of liposomes injected was 15.2 
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μmoles/kg body weight i.e.~3.8–5.32 μmoles for rats weighing 250–350g blood volume~20 ml). 
Therefore, the concentration of phospholipids used is ~228μM, which is much below the 
hemolytic concentration of phospholipids. The dose of the liposomes (15.2μmoles of 
phospholipids/kg body weight) was obtained by initial optimization during the preliminary pilot 
studies. The hemolytic activity of the plain liposomes was observed to be significantly (p<0.05) 
lower than Tf-PR-liposomes. This can be explained by absence of cationic poly-L-arginine and 
the shielding effect of the PEG molecules on the surface of plain liposomes. Tf-liposomes 
demonstrated minimal hemolytic activity at low phospholipid concentrations which can be 
attributed to the presence of negatively charged proteins molecules on the liposomal surface, 
thereby reducing interactions with the erythrocyte membrane. However, at higher concentrations 
the Tf-liposomes demonstrated greater hemolysis as compared to the plain liposomes. This can 
be attributed to the aggregation of protein conjugated Tf-liposomes at elevated concentrations, 
thus initiating non-specific interactions and destabilization of erythrocyte membrane. To confirm 
the aggregation of Tf-liposomes, we performed additional studies relating the effect of 
phospholipid concentrations to the particle size and zeta potential values of the liposomes 
(Sharma et al. 2013). Tf-liposomes showed significant (p<0.05) increase in size above 500 
nmoles of phospholipids/40 μl of suspension, exposed to erythrocytes. The Tf-PR-liposomes did 
not shown any significant aggregation up to 750 nmoles of phospholipids, nonetheless, the 
cationic charge of CPP caused greater interactions with the erythrocyte membrane as compared 
to the Tf-liposomes. The shielding effect of PEG on the plain liposomes averted any significant 
changes in particle size distribution of these liposomes. Nevertheless, such high amounts of 
phospholipids in small buffer volumes, exposed to a fixed number of erythrocytes, were not 
125 
 
physiologically relevant and were only evaluated to study the interaction behavior of liposomes 
with erythrocytes at higher lipid concentrations.  
The interaction of Tf-CPP liposomes with the erythrocytes showed that the liposomes 
with short chain CPPs were more biocompatible as compared to Tf-PR liposomes. Both Tf-TAT 
and Tf-penetratin were observed to be non-toxic up to concentrations as high as 800 nmoles of 
phospholipids. However, Tf-Mastoparan liposomes demonstrated significantly higher (p <0.05) 
hemolytic activity as compared to other Tf-CPP liposomes. This could be due to the cytolytic 
nature of the Mastoparan peptide (Cardozo et al. 2007). In addition, we anticipate that the 
presence of more hydrophobic amino acids in Mastoparan might increase the interaction of this 
peptide with the lipophilic erythrocyte membrane. 
4.3. Cellular uptake and transfection studies for liposomes 
The presence of high concentrations of protein, caveolin-1, in brain capillary endothelial 
cells assists transcytosis of essential nutrients from blood to brain (Frank et al. 2009). An 
efficient transport to brain would require effectual uptake of nutrients by brain capillary 
endothelial cells followed by transfer to other brain cells, for example, astrocytes, pericytes, and 
neurons. Cellular uptake of DiI-labeled Tf-PR liposomes was, therefore, evaluated in brain 
endothelial cells. The uptake of dual-modified liposomes was significantly (p<0.05) higher than 
the plain and single-ligand liposomes (Figure 17). The binding and internalization of PR 
liposomes was facilitated by the cationic charge of the peptide. Previous studies report the initial 
electrostatic binding of CPPs to heparan sulfate proetoglycans on the cell surface that promote 
subsequent interactions responsible for internalization of the peptides via endocytic mechanisms 
(Trabulo et al. 2010). Cell uptake of PR liposomes facilitated by these electrostatic interactions 
was observed to be lesser in comparison with the uptake of Tf liposomes mediated by receptor 
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uptake, indicating that receptor-mediated uptake leads to greater internalization of the associated 
vector. A combination of cell penetration and receptor targeting, however, involved both initial 
binding of the liposome followed by receptor-mediated endocytosis, leading to considerable 
improvement in the uptake of liposomes. The dual functionalized liposomes were transported 
across the cell membranes more efficiently as compared to the single ligand, Tf or CPP-
liposomes.  
The celluptake of Tf-CPP (TAT, Penetratin or Mastoparan) liposomes (approximately 
77–89% in bEnd.3 cells and approximately 90–98% in tumor cells after 1 h) was slower in 
comparison to the previously reported Tf-PR-liposomes (approximately 95% in bEnd.3 cells 
after 30 min) (Sharma et al. 2012). This was ascribed to the presence of greater number of basic 
arginine residues in long chain poly-L-arginine as compared to the short chain CPPs used in this 
study. However, as mentioned above, the lower cationic charge of the CPPs used in this study 
considerably improved the biocompatibility of the liposomes. Binding and internalization of 
CPP-liposomes were driven by the cationic charge of CPPs and interaction of CPP-liposomes 
with heparan sulfate proteoglycans (Sharma et al. 2012). In comparison, the translocation of 
dual-modified Tf-CPP liposomes was facilitated via specific receptor targeting and improved 
penetration effect of CPPs. Since doxorubicin, acts by nuclear localization, the uptake of 
doxorubicin encapsulating liposomes resulted in an intense overlap in the fluorescence regions of 
the drug and nuclei. Furthermore, the rate of liposomal uptake was dependent on the type of 
cells. A more rapid and greater uptake was observed in the tumor cell lines, Daoy and U87, while 
the bEnd.3 cells showed less and slower uptake. In entirety, the results emphasized the 
significance of dual-mechanism of uptake over receptor targeting or cell penetration alone. The 
analysis of the uptake pathways performed using various inhibitors indicated that the transferrin 
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conjugated (Tf and Tf-CPP) liposomes were primarily transported into the cells via clathrin 
mediated endocyotis, irrespective of the type of cells, while the uptake of CPP-liposomes was 
controlled by both macropinocytosis and clathrin coated vesicles (Figures 28-30). 
We also evaluated the ability of Tf–CPP liposomes to efficiently deliver the desired gene 
to the primary culture of glial cells, bEnd3, Daoy and U87 cells and compared the transfection 
efficiency of CPP modified Tf-liposomes with single ligand, Tf liposomes. Single-ligand 
modification with only Tf was not able to produce efficient transfection. The incorporation of 
cell-penetrating cationic peptide to the Tf-conjugated liposomes significantly (p<0.05) increased 
their transfection efficiency. The increase can be explained by the positive charge of Tf–CPP 
liposomes due to incorporation of CPPs, whereas the zeta potential of Tf liposomes was 
observed to be negative. Also, Tf liposomes showed lower transfection in vitro as compared with 
plain liposomes; however, the transport of plain liposomes across the endothelial barrier was 
observed to be significantly (p<0.05) less than the Tf liposomes, thereby delivering less 
liposomes for transfection of cells. 
4.4. 2D and 3D in vitro BBB models 
The results cannot directly predict in vivo performance of liposomes, which depends on 
their transport across the BBB. The studies were, therefore, scaled to the evaluation of liposomal 
transport across the in vitro BBB model. We initially designed an in vitro BBB model to evaluate 
the ability of liposomes to cross the barrier layer. Glial cells were seeded on the bottom side of 
PET membrane of transwell inserts, and endothelial cells were seeded on the upper side of these 
inserts. The lower density of glial cells in comparison with endothelial cells was maintained to 
simulate in vivo barrier conditions and to avoid any redundant entrapment of liposomes in the 
glial cell layer. In vitro models, both with glial and endothelial and only endothelial cells, were 
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assessed for barrier tightness by measuring the TEER and flux of Na–F across the barrier layer. 
The TEER of the coculture model with both glial and endothelial cells was significantly (p<0.05) 
higher than that of the monolayer model with only endothelial cells. Also, the permeability of 
Na-F across the co culture barrier layer was lesser as compared with the monolayer. Decreased 
permeability in the presence of glial cells could be ascribed to the improvement of junctional 
properties along with the additional physical barrier provided by the glial cell layer. These 
findings were in accordance with previous studies reporting the significance of glial cells in 
induction and maintenance of BBB composed of closely packed endothelial cells (Deli et al. 
2005; Arthur et al. 1987; Janzer and Raff 1987); therefore, a co-culture of glial and endothelial 
cells was used to establish the 2D in vitro model for evaluating the transport of liposomes. 
Further, we followed an innovative approach in designing a simple and robust 3D in vitro 
brain tumor model. The model was constructed by culturing the glioblastoma cells in the porous 
chitosan-PLGA scaffolds and combining it with the tightly packed endothelial cell layer to 
simulate the in vivo tumor environment. The porous structure of the scaffold supported the 
growth of tumor cells in 3-dimensional milieu (Kim 2005). Reportedly, the cells attach to the 
intertwined scaffold fibers and fill the spaces/pores within the scaffold to forma 3D tumor 
(Sourla et al. 1996; Bell 1995). The tightness of the tumor associated endothelial barrier was 
compared with the intactness of the endothelial barrier without the tumor scaffold and with glial 
cells on the abluminal side of the membrane. The lower transport of sodium fluorescein across 
the tumor associated endothelium versus the endothelial cells alone was partially ascribed to the 
physical contact of endothelial cells with scaffold in the in vitro brain tumor model versus the 
presence of only endothelial cells on the luminal surface of culture inserts (bEnd.3 model). Also, 
since the transport was based on the lysis of cells and release of fluorescent molecule, incomplete 
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lysis of the tumor could also contribute to lower fluorescence intensity. However, significant 
reduction (p<0.05) in the transport of Na-F was observed across the in vitro BBB model, where 
primary glial cells were grown on the abluminal surface of the membrane with the endothelial 
cells inside the culture inserts (Sharma et al. 2012). This was similar to the in vivo condition 
where the occurrence of tumor is associated with the increased permeability of the BBB 
(Provenzale et al. 2005). The paracellular transport of Na-F increased (non-significantly) after 
the transport of liposomes which could be due to the increased permeability of the barrier after 
interaction with the cationic peptide conjugated liposomes. However, the tightness of the 
endothelial barrier (decreased permeability of Na-F) was restored after incubation of the 
endothelial cell culture inserts with the 3D tumor in the presence of 20–30% serum. The TEER 
across the endothelial cell layer of the BBB model with bEnd.3 cells and glial cells was 
considerably higher as compared to the TEER across the endothelial cell layer of the tumor 
model and across the endothelial cell layer cultured alone. This was ascribed to the down 
regulation of tight junction proteins like occludin and claudin in the tumor associated endothelial 
barrier (Ishihara et al. 2008). Also, the absence of any glial cells, in the model with the 
endothelial cell culture alone, contributed to the formation of leakier barrier due to the lack of the 
induction and maintenance of barrier properties (Janzer and Raff 1987). The dual-functionalized 
liposomes showed higher transport across the barrier layer with Tf-Penetratin liposomes 
demonstrating the maximum permeability. The cationic charge of penetratin and the presence of 
amphiphilic amino acids contributed to increased interaction of Tf-Penetratin liposomes with the 
endothelial membrane as compared to the Tf-TAT liposomes. The presence of transferrin 
triggered receptor mediated transcytosis across the endothelial membrane. In contrast, the lower 
cationic charge of the mastoparan peptide reduced the endothelial transcytosis of Tf-Mastoparan 
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liposomes (non-significantly) as compared to the Tf-Penetratin liposomes. In addition, the 
transport of CPP and plain liposomes was lower in comparison to the Tf-CPP liposomes which 
could be attributed to the absence of dual-mechanism of cell uptake and greater entrapment of 
these liposomes in the endothelial cell layer. 
4.5. In vivo evaluation of liposomes 
4.5.1. In vivo evaluation of Tf-PR-liposomes 
Considering the complexity of in vivo environment, we examined the ability of Tf-PR-
liposomes to target brain after administration into systemic circulation. The distribution of the 
liposomes in vivo was tracked by fluorescent labeling of the liposomes with DiR followed by 
NIR imaging of different organs (spleen, liver, heart, kidneys, lungs and brain) at specific time 
points. The preliminary results from whole animal imaging indicated significant accumulation of 
the DiR labeled liposomes in brain after 24 h. Very less fluorescence was observed in the brain at 
6 h time point. As expected, a strong fluorescence signal was observed in the liver immediately 
after injection and the signal intensity decreased gradually with time resulting in very low 
fluorescence after 48 h. Individual organs were therefore isolated and examined by NIR imaging 
at 12, 24, 48, and 72 h time points (Figure 44). Considering the lower accumulation of DiR 
labeled liposomes in brain as compared to other organs, the exposure time was adjusted to 8 min 
for brain while 2 min for other organs (i.e., liver, spleen, kidneys, heart and lungs) to avoid a 
large background signal while imaging the brain. This was followed by quantification of 
liposomal accumulation using organ homogenization and extraction of the fluorescent dye in 
chloroform: methanol. The results showed that incorporation of cell penetrating peptide, poly-L-
arginine, significantly increased (p<0.05) liposomal accumulation in lungs, heart, and brain 24 h 
post intravenous injection. This indicates that the dual-modified liposomes pass into circulation, 
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penetrate the highly perfused organs and reach brain more rapidly than other liposomal 
formulations. Previous studies have reported a large uptake of intravenously administered 
liposomes by the highly perfused organs like heart, lungs, liver and spleen and very low transport 
of the liposomes to brain (Awasthi et al. 2003; Afergan et al. 2008). The presence of transferrin 
receptors in liver, spleen and kidneys can trigger the non-specific uptake of transferrin receptor 
targeted liposomes by these organs (Deaglio et al. 2002, Jefferies et al. 1984). Also, Liver and 
spleen are the major macrophage organs and therefore, a large portion of the intravenously 
administered liposomes is eliminated by these organs. In addition, it has been previously 
reported the poly-arginine modified liposomes can interact with blood cells and are transported 
to the lung capillaries (Awasthi et al. 2003, Audouyet al. 2002). Nano particulate systems have 
also been reported to passively accumulate in heart (Ishiwata et al. 2000). In this study, about 
20% and 10% of the injected dose was transported to the lungs and heart, respectively. The 
liposomes were eliminated from these organs with time. The transport of liposomes to brain was 
~4% of the injected dose. The percentage of liposomes transported to brain versus those 
transported to other organs is comparatively higher than the percent transport of liposomes to 
brain in previous reports (Awasthi et al. 2003; Afergan et al. 2008). Presumably, the combination 
of a targeting ligand and CPP improved the transport of liposomes to brain. Plain liposomes 
accumulated largely in liver and spleen and exhibited very low transport across BBB. Also, plain 
liposomes showed a more rapid elimination from the organs as compared to the Tf- or dual-
modified liposomes. In contrast, the initial uptake of Tf-liposomes was lower in liver and spleen 
and their accumulation in these organs continued at 72 h indicating longer circulation time of Tf-
liposomes as compared to other liposomes (Figure 43). Also, the transport of Tf-liposomes to 
kidneys was more as compared to other liposomes, however the elimination of Tf-liposomes 
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from kidneys was slower. The presence of negatively charged transferrin molecules, on the 
surface of Tf-liposomes, reduced their non-specific interactions in circulation thereby, decreasing 
their elimination by macrophage system as compared to the plain or Tf-PR-liposomes. The 
accumulation of all liposomal formulations was observed to be least in heart as compared to 
other highly perfused organs. However, comparison of the distribution of different liposomal 
formulations indicates that the Tf-PR-liposomes showed higher penetration in heart and lungs as 
compared to other liposomes which can be ascribed to the occurrence of cell penetrating peptide 
on dual-modified liposomes (Mudhakir et al. 2005; Hayashi et al. 2011). Furthermore, the cell 
penetrating peptide conjugated liposomes showed the highest penetration across BBB. 
Approximately 4% of the injected dose of Tf-PR-liposomes/gram of tissue was transported to 
brain, 24 h post intravenous injection. The accumulation of Tf-PR-liposomes in brain was 
significantly (p<0.05) higher than the accumulation of Tf-liposomes. The cell penetrating 
property of the dual-modified liposomes, in combination with the receptor targeting effect of 
transferrin protein resulted in higher accumulation of Tf-PR-liposomes in the brain as compared 
to the single-ligand transferrin receptor targeted, Tf-liposomes. 
Therapeutically active genes can be delivered to brain via receptor mediated transcytosis 
(Qian et al. 2002). In vivo evaluation of transfection potential is important from the standpoint of 
generating preliminary data for clinical translation. The β-gal expressing plasmid has been 
previously used for evaluating the transfection efficiency of polymeric delivery vectors, in vivo 
(Kim et al. 2007; Guliyeva et al. 2006).With the aim of evaluating the transfection potential of 
dual-modified liposomes in vivo, we encapsulated β-gal plasmid polyplexes in the aqueous core 
of the liposomes, followed by intravenous injection of the formulation via tail vein at a dose of 
50 μg of DNA/rat. The results illustrated significantly higher potential of dual-modified 
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liposomes to cross the BBB (~4% of the ID/gram) and deliver the desired gene to brain as 
compared to plain or Tf-liposomes. However, the expression of transferrin receptors in 
peripheral organs can result in non-specific gene expression in organs other than brain (Deaglio 
et al. 2002; Zhao et al. 2010; Shi et al. 2001). Maximum gene expression was observed in spleen 
which corresponds to greater transport of liposomes to this organ. The gene expression of Tf-PR-
liposomes in lungs, heart and kidneys was also higher as compared to other liposomes. Also, the 
transport of Tf-PR liposomes to liver was lower as compared to Tf or plain liposomes, however, 
the gene expression in liver and lungs was observed to be comparable. This can be explained by 
the higher positive charge of Tf-PR-liposomes which increased their transfection efficiency over 
Tf or plain liposomes. The non-specific gene expression in the peripheral organs can be reduced 
by incorporating an organ specific promoter to allow the expression of the therapeutic gene in 
specific tissues (Zhao et al. 2010) Measurably improved brain-specific gene expression can be 
achieved by incorporating a brain specific promoter (e.g. GFAP promoter) with the desired 
therapeutic gene (Lee et al. 2008). The results from in vivo transfection studies further 
emphasized the significance of dual-mechanism of liposomal transport that resulted in a higher 
penetration across BBB and improved the expression of the encapsulated gene in brain 
(Prabhakara et al. 2011, Bolhassani 2011). The liposomes were primarily transported across the 
BBB via receptor mediated transcytosis, nevertheless the presence of poly-L-arginine on the 
surface of receptor targeted liposomes further improved their penetration into brain. In addition, 
the cationic charge of CPP improved gene expression in the targeted cells and tissues. 
The cationic charge of CPP conjugates can induce tissue necrosis and inflammation 
(Jones et al. 2005).The biocompatibility of the liposomes was therefore, evaluated by 
histological examination of the transfected tissues (Guo et al. 2011). The transfected tissues from 
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different organs were sectioned and stained with hematoxylin-eosin followed by examination 
under light microscope. Liver and spleen were exposed to highest load of the liposomes and were 
therefore, considered as primary organs for evaluation of toxicity. The histological examination 
confirmed absence of inflammation, ballooning of hepatocytes or enlargement of nuclei in liver 
and necrosis in spleen. Other organs such as brain, kidneys, heart and lungs were also examined 
for tissue necrosis or lesions. No toxicity was observed in any of the tissues isolated from the 
animals that were administered with liposomes at dose of 15.2 μmoles of phospholipids/kg body 
weight. The poly-ethylene-glycol chains and transferrin protein counterbalanced the cationic 
charge of poly-L-arginine peptides and reduced the negative effects of this cell penetrating 
peptide. 
4.5.2. In vivo evaluation of Tf-CPP-liposomes 
The evaluation of in vivo biodistribution of doxorubicin encapsulating Tf-CPP liposomes 
(Tf-TAT, Tf-Penetratin and Tf-Mastoparan) showed more rapid uptake of doxorubicin 
encapsulating Tf-Mastoparan liposomes in liver and spleen as compared to the Tf and the other 
Tf-CPP liposomes. The greater hydrophobicity of the mastoparan peptide and its potential to 
trigger non-specific interactions was considered to affect its uptake by the major macrophage 
organs. Also, the decrease in the concentration of the drug transported to the macrophage organs 
via Tf- Mastoparan liposomes was greater as compared to that transported via Tf-Penetratin and 
Tf-TAT liposomes, thus, indicating a more rapid clearance of Tf-Mastoparan  liposomes from 
the system. Tf-Penetratin liposomes showed maximum transport of doxorubicin into brain 
(approximately 4% ID/g) in vivo followed by Tf-TAT liposomes (approximately 2.9% ID/g). 
The lower transport using Tf-Mastoparan liposomes, into brain, was attributed to the greater 
uptake of these liposomes by liver, spleen and lungs and therefore, lesser availability for 
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transport to brain. The drug encapsulated in the negatively charged Tf-liposomes remained in 
circulation for long however, the penetration of drug into brain using Tf-liposomes was lesser as 
compared to the Tf-CPP liposomes. Apparently, the combination of Tf and CPP in dual-modified 
liposomes increased their penetration into brain. Plain liposomes were transported largely to liver 
and spleen and showed negligible transport of drug across BBB. The occurrence of Tf receptors 
in the major macrophage organs (liver, spleen and kidneys) can result in non-specific uptake of 
the transferrin conjugated liposomes by these organs (Deaglio et al. 2002, Jefferies et al. 1984). 
Also, a major portion of the intravenously administered delivery systems is eliminated via liver 
and spleen therefore, a large portion of these liposomes was transported to these organs. In 
addition, previous studies indicate increased interaction of cationic polymers and CPPs with the 
blood cells and their subsequent accumulation in lungs (Fueyo et al. 1999, Audouy et al. 2002). 
The transport of drug encapsulated in the Tf-Mastoparan was more to the lungs than Tf-
Penetratin or Tf-TAT liposomes. This was due to the greater interaction of these liposomes with 
the erythrocytes (Figure 48). Since, the transport of drug encapsulated into the non-targeted CPP-
liposomes, across the in vitro brain tumor model, was lower as compared to the transferrin 
receptor targeted Tf and Tf-CPP liposomes, these liposomes were not considered for in vivo 
evaluation of biodistribution. Evaluation of biodistribution of the water soluble drug 
encapsulated in the Tf-CPP liposomes, provides an insight into the in vivo fate and brain 
transport of the encapsulated agent in these liposomes. The enhanced permeability of the tumor 
associated brain endothelial barrier is anticipated to further increase the translocation of the 
targeted Tf-CPP liposomes into brain, in vivo. 
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CHAPTER V. SUMMARY AND CONCLUSION 
In view of the compelling need for the development of an efficient delivery vehicle that 
can transport the desired therapeutic agents (small molecules, genes etc.) across the formidable 
BBB, we focused our efforts in designing a novel vector that can overcome the limitations of 
conventional delivery agents like receptor targeted polymeric and lipid based carriers. In our 
study, we developed and evaluated dual-modified liposomes that possessed the ability to serve as 
promising vectors for site-specific delivery of desired therapeutic molecules. The liposomes were 
surface conjugated with transferrin protein to achieve targeting of desired receptors on brain 
endothelial cells. In addition, these liposomes were conferred with enhanced permeation 
properties of various cell penetrating peptides. The contribution is significant because this is the 
first step in the continuum of research that is expected to illustrate the influence of grafting the 
targeted liposomal delivery vector to cell penetrating peptide and forming near neutral vesicles 
for improving the delivery of therapeutics across BBB.  
We illustrated the influence of different CPPs on the cell uptake, in vitro tumor 
penetration, cytotoxic potential of Tf-receptor targeted liposomes and in vivo distribution and 
biocompatibility. The dual-modified liposomes showed significantly (p<0.05) higher 
accumulation in vitro in different cell lines (brain endothelial, Daoy, U87) and in vivo rat brain as 
compared to transferrin-liposomes. The results indicated that the incorporation of amphiphilic 
CPPs, TAT and Penetratin, on the surface of Tf-liposomes resulted in biocompatible 
formulations leading to efficient translocation of doxorubicin and genes (pβ-gal and pGFP) 
across cellular and brain endothelial barriers both in vitro and in vivo. The conjugation of 
hydrophobic CPP, Mastoparan, also resulted in improved cellular uptake of Tf-liposomes, 
however, the higher cytotoxicity and hemolytic activity of this peptide provided a strong 
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evidence for restricting its use in vivo. The Tf-Penetratin liposomes showed maximum cell 
uptake and transport of the encapsulated drug, across the in vitro endothelial barrier, followed by 
the transport of Tf- Mastoparan liposomes. However, increased hemolytic activity of Tf-
Mastoparan liposomes resulted in greater clearance of these liposomes by the macrophage 
system and therefore, less availability for penetration into the brain, in vivo. Also, the β-gal 
activity of brain tissue transfected using dual-modified liposomes was higher than the single 
ligand, Tf-liposomes or naked DNA. Also, Histological examination of the transfected tissue 
demonstrated excellent biocompatibility of dual-modified liposomes. The single-ligand 
liposomes showed lower uptake by liver and spleen and greater uptake by kidneys, whereas, the 
Tf-CPP liposomes showed higher penetration in highly perfused tissues like lungs and heart 
along with greater transport across the targeted BBB.  Incorporation of CPP to the Tf-receptor-
targeted liposomes caused a considerable improvement in cellular uptake, transfection, transport 
across in vitro BBB models and in vivo in adult SD rats, as compared with the plain and single 
ligand, Tf liposomes. 
In conclusion, this work demonstrates the development and characterization of dual-
modified liposomes for delivery of small molecule drugs and genes to brain. The dual-modified 
liposomes bear the potential to serve as safe and efficient non-viral gene delivery vectors for the 
transport of desired therapeutic molecules across the BBB. We anticipate that this research work 
will contribute towards the development of high efficiency and low toxicity delivery systems and 
subsequently help to find new treatment strategies for CNS diseases (e.g., tumors, Alzheimer’s 
disease and certain neuropsychiatric disorders). 
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5.1. Future directions 
The study illustrates that the dual-modified liposomes can serve as promising platform 
for the design of novel drug and gene delivery vectors involving the combination of targeting 
ligand and cell penetrating peptide into single delivery system. In this study we combined the 
receptor targeting properties of transferrin protein with various CPPs and illustrated improved 
penetration into the targeted organ. It would be interesting to employ different targeting ligands, 
specifically the receptor binding amino acid sequences of antibodies and proteins, in the 
liposomal formulations, for delivery to desired cells. These specific receptor binding sequences, 
in combination with short chain CPP sequences, are anticipated to augment the targeting and 
cellular delivery of lipid based nanocarriers across different cellular barriers. This approach 
could therefore, be used to target numerous receptors like insulin, neuronal nicotinic Acetyl 
choline, vascular endothelial growth factor receptors etc. for the treatment of diseases like 
diabetes, Alzheimer’s disease, schizophrenia and tumors. Also, this work involved the 
investigation of 3D in vitro BBB model, where the porous structure of polymeric scaffold 
supported the 3-dimensional growth of tumor cells. The process involved construction of 
scaffold using the polymers PLGA and chitosan. It would be valuable to explore other polymers 
like poly ethylinimine (PEI) or poly-L-lysine in combination with PLGA for improving the 
cellular adherence on scaffolds. Both PEI and poly-L-lysine are cationic polymers with basic 
amine groups (pKa 10-11) and stronger bases as compared to chitosan (pKa 6.8). Replacing 
chitosan with these cationic polymers might further improve the interaction of negatively 
charged cell membranes with the polymer coated scaffold, thus increasing the cellular adherence 
and facilitating tumor growth on scaffold. Additionally, the influence of cross linking these 
polymers (using reagents like EDC/NHS) on the stability and rigidity of the scaffold would be 
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another interesting aspect to investigate. Further, since the scaffolds have demonstrated the 
efficient tumor growth, various anticancer drugs and drug delivery vehicles can be evaluated, 
using this model, by monitoring the growth or regression of tumor spheroids in the porous 
structure.  
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